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Molecular Mechanism of Tumor Suppression Carcinogenesis 
THESIS 
ancer is one of the most dreaded diseases of manl<ind that causes alarming 
mortality and morbidity in humans. Through innumerable research efforts, now it is well 
established that causes of the cancer are vast and diverse, but changes in life style 
and dietary habits can reduce the risk of this deadly disease. Thus, utilization of 
complementary and alternative medicines (CAM) becomes an important and promising 
strategy for the prevention as well as treatment of cancer. With the growing awareness 
about the potential role of CAM in preventing cancer and other chronic diseases, most 
of the researches are now focused on validating many of the ancient remedies. Both 
epidemiological and experimental studies suggest that enormous benefit can be 
derived at community level from dietary manipulation or supplementation because of 
their relatively low cost and little or virtually non-toxic effects. Cancer chemoprevention 
using dietary constituents has received growing consideration as a means of cancer 
control in the last few decades. It can be defined as 'the prevention of cancer by the 
administration of one or more chemical entities either as individual drugs or naturally 
occurring constituents of the diet. The appropriate use of a chemopreventive agent 
ultimately depends on the understanding of its mechanism of action at all levels, 
namely at the molecular, cellular, tissue and organ level. The present need in the 
chemoprevention has therefore been to identify/develop new molecules/agents based 
on their mechanism of action or to elucidate the mode of action of well-known agents. 
The most promising area included here is the study at molecular level as molecular 
targeting approaches retain (or enhance) preventive effects while reducing known 
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mutagenic/ carcinogenic effects. These molecular targeting approaches include 
identification and validation of certain biomarkers namely mutations in specific genes, 
abnormalities in cell proliferation and alteration in gene expression, as early or 
intermediate end points in chemopreventive strategies. 
Human diet contains a variety of naturally occurring compound having 
antimutagenic and anticarcinogenic properties. Garlic (Allium sativum) is known since 
ancient times for its therapeutic properties and is probably the most widely studied 
medicinal plant. The beneficial health effects of garlic have been attributed to its 
organosulfur compounds such as S-allyl cysteine, allicin, ajoene, diallyl sulfide (DAS), 
diallyl disulfide, and diallyl trisulfide. DAS, a lipid soluble organosulfur volatile 
compound from garlic, with its characteristic pungent odor is a potent antioxidant with 
anti-inflammatory, antimutagenic and cancer preventive properties. In vitro as well as 
in vivo studies from our lab and elsewhere have shown that DAS imparts 
chemopreventive effects against cancer in a variety of target organs such as skin, 
lung, esophagus, colon and liver. However, the mechanism by which DAS might exert 
its anticarcinogenic effects is still not fully understood. DAS has been shown to 
modulate the metabolism of carcinogens through various phase I and phase II 
detoxifying enzymes and by scavenging free radicals and blocking carcinogen 
bioactivation. It has also been shown to possess inhibitory effects on the proliferation 
of tumor cells associated with induction of apoptosis by modulating the expression of 
antiapoptotic {bcl-2), proapoptotic genes {bax) and the tumor suppressor gene. 
Therefore, present study was designed and executed to provide insight into the 
molecular mechanism of DAS induced tumor suppression using induction of apoptosis, 
induction of tumor suppressor gene expression, inhibition of oncogene expression as 
biomarkers in chemoprevention studies as weW as \is role in chemoprophylactic studies 
by investigating its multiple drug resistance reversal properties. 
Cancer Chemopreventive and Apoptosis Inducing Potential of 
Diallyl Sulfide in Mouse Skin Carcinogenesis 
During the past few decades, cancer chemoprevention by dietary constituents 
has received a great deal of attention as a means of effective cancer control. Studies 
on the tumor inhibitory compounds of plant origin have yielded an impressive array of 
novel structures. Growing evidences from both in vitro and in vivo studies showed that 
suppression of apoptosis is involved in tumor promotion. Therefore, inhibition of 
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apoptosis is one mechanism of tumor formation and many chemopreventive agents 
may act tlirougln the induction of apoptosis by eliminating the defective cells, to block 
the carcinogenic process. Thus, induction of apoptosis is appreciated as an ideal way 
for the elimination of cancer cells and apoptosis inducing agents are viewed as 
potential agents for the prevention and/or treatment of cancer. We therefore studied 
the apoptosis inducing potential of DAS in DMBA induced mouse skin tumors in order 
to study its cancer chemopreventive mechanism. 
The results of the present set of investigations revealed that DAS treatment 
could effectively reduce the cumulative and average number of tumors per mouse and 
effectively prolonged the tumor induction time of DMBA induced tumors. The animal 
bioassay revealed a significant delay in the onset of skin tumorigenesis in DAS 
supplemented Swiss mice by more than three weeks in comparison to the animals 
exposed to DMBA alone. The average number of tumor per mouse was found to be 
inhibited in groups where DAS was given one-hour prior or after the DMBA treatment, 
in comparison to DMBA exposed animals. An important feature of the study was that a 
significant percentage of animals remained tumor free in DAS supplemented groups. 
Further, present investigation revealed the apoptosis inducing potential of DAS in 
DMBA induced tumors. Flow cytometric analysis revealed appearance of sub G1 peak 
indicative of apoptotic population in solid tumors. Quantitation of apoptosis evaluated 
by the percentage of cells in the sub G1 phase revealed about 15.4% apoptotic 
population in DMBA treated group which was increased significantly in tumor cells of 
DAS+ DMBA (42.8%) and DMBA+DAS (34.6%) groups. Analysis of skin tumors 
revealed other characteristic features of apoptosis including the formation of DNA 
ladders on agarose gel, compaction of nuclear DNA and the formation of apoptotic 
bodies. Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling 
(TUNEL) assay of skin tumors of DAS supplemented animals showed a significant 
Increase in the number of apoptotic bodies in comparison to the animals exposed to 
DMBA. Examination of nonmalignant tumors viz. focal epidermal hyperplasia, 
squamous cell papillomas, keratoacanthoma and malignant squamous cell carcinoma 
revealed a significant increase in the TUNEL positive cells in DAS supplemented 
tumor over positive controls (DMBA alone). These observations thus suggest that 
induction of apoptosis may be the major contributing factor for antitumorigenic 
properties of DAS. 
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Role of p53 and p21/waf1 in Diallyl Sulfide IVIediated Tumor 
Suppression in Mouse Skin 
The p53 tumor suppressor gene contributes to the maintenance of genomic 
stability by controlling cell cycle and facilitating DNA repair in response to DNA 
damage. Therefore, alterations in the p53 function are critical events in 
carcinogenesis. Thus, modulation of p53 and its effecter molecules p21/waf1 levels 
are thought to be an effective way of intervention against cancer. The results of the 
this set of study showed a modulatory effect of DAS on the expression of tumor 
suppressor gene p53 (both wild and mutant type) and its effecter molecule p21/waf11 
in mouse skin tumors. Western blot analysis and immunohistochemical localization of 
the protein combined with multi-parameter flow cytometry demonstrated that DAS 
administration induces the expression of the wtp53 and decreases the expression of 
mutp53 in DMBA induced tumors. Western blotting showed enhanced levels of wtp53 
in DMBA induced tumors, which were found to be significantly elevated with DAS 
supplementation. The densitometric analysis of blots showed an increase of 132% in 
wtp53 in the tumor tissue of DMBA exposed animals over untreated controls. A further 
increase of 40% and 31% in the wtp53 protein expression was observed in DAS 
supplemented and DMBA induced tumors. The quantitative analysis of immunostained 
tumor sections using image analysis showed significant increase of 66.55 & 54.21% in 
the levels wtp53 in DAS pre treated and post treated animals. Similarly, flow cytometric 
analysis showed increase in the mean fluorescence intensity (MFI) for DMBA induced 
tumors (5.31) over normal mouse skin (1.68). A further increase in the fluorescence 
was recorded in the DAS supplemented groups suggesting increase in the levels of 
wtp53 by DAS. The MFI was 15.41 and 10.21 respectively in DAS pre and post 
supplemented groups. 
In case of mutp53, the DMBA induced levels were found to reduce to near 
normal levels with DAS supplementation as evident by western blotting. The 
densitometry of the blots showed that in DAS pretreated tumors the expression of the 
mutp53 decreased by 44.9 % whereas in DAS post treated tumors the expression of 
the protein was decreased by 41.7% over DMBA induced tumors. The quantitative 
analysis of immunostained sections using image analysis showed about 53.41 and 
44.26 % decrease in the mutp53 levels in DAS pre treated and post treated animals 
respectively. Flow cytometric analysis further confirmed these observations. The 
normal skin showed low expression levels of mutp53 with MFI 1.06. In DMBA induced 
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tumors a significant increase in tlie fluorescence was recorded witli MFI 16.41 
indicating over expression of mutp53. The FITC fluorescence was found to decrease in 
DAS supplemented groups with MFI 3.76 in DAS+ DMBA and 8.13 in DMBA +DAS 
groups, suggesting down regulation of mutp53 by DAS. The DAS exposed skin 
showed levels of mutp53 close to normal levels with MFI 1.65. The DMBA induced 
tumor showed significantly elevated levels of p21/waf1 as evident by western blotting. 
The DMBA induced levels of p21/waf1 were further increased in DAS supplemented 
groups. The quantitation of the band intensity by densitometry showed an increase of 
72% in the p21/waf1 level in DMBA induced tumors. In the DAS pretreated tumors, the 
expression of p21/waf1 was significantly (74%) induced as compared with DMBA 
alone. Similarly, in the DAS post treated group, the p21/waf1 expression was 65% high 
over DMBA exposed group. The immunohistochemical staining of p21/waf1 levels in 
skin/tumor sections showed 72.86 & 61.22% percent increase in the expression of the 
protein in DAS pre and post treated groups over DMBA treated animals. Furthermore, 
flow cytometric analysis revealed a shift in the MFI from 6.34 for untreated to 22.42 for 
DMBA induced tumors. This shift in the MFI was further enhanced to 53.35 and 44.24 
in tumors where DAS was given before and after DMBA exposure respectively. In 
animals were given DAS only, the fluorescence was recorded at 8.07 channel value 
indicating normal levels of p21/waf1 expression. These results thus demonstrate that 
the chemopreventive property of DAS seems to be through the p53 dependent 
mechanism mediated through its effecter molecule p21/waf1. 
Modulatory Effect of Diallyl Sulfide on p21/ras in Skin 
Carcinogenesis 
The ras gene family members were smong the first oncogenes identified and 
shown to have decisive roles in cell cycle and in neoplastic development. A feature of 
the ras coded proteins is that they must be anchored in the cell membranes to 
function. Specific inhibitors of this step as a means of inhibiting activity of the 
transforming ras protein may serve as a biomarker of the probability of tumor 
formation. Thus detection of mutations or altered expression of these genes could help 
to identify individuals at increased risk of cancer and could be utilized as a effective 
chemopreventive intervention strategy. The results of the present set of investigations 
showed a modulatory effect of DAS on the expression H-ras protein product p21/ras 
following single topical exposure of DMBA after 24hrs. The decrease in the levels of 
the protein was significant at 48 & 72 hrs of DMBA exposure. Furthermore, the 
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modulatory effects of DAS were also evident in DMBA induced tumors. The normal 
mouse skin showed levels of both cytosolic and membrane bound p21/ras within the 
detectable limits as evident by western blot analysis. In DMBA induced tumors high 
levels of p21/ras were found in both the fractions in comparison to controls. However, 
the levels of cytosolic p21/ras in DAS supplemented groups were comparable to the 
levels of the protein in DMBA induced tumors. Whereas, an opposite trend was evident 
for the levels of membrane bound p21/Ras. A significantly diminished level of the 
protein was observed in the membrane fractions from DAS supplemented groups as 
compared to that of DMBA alone. The quantitation of p21/ras levels by densitometric 
analysis of blots showed 11 and 15 % increase in cytosolic p21/ras in DAS pre and 
post-treated group respectively in comparison to DMBA induced tumors. Whereas, a 
significant decrease in the levels of the membrane bound protein was evident in DAS 
supplemented groups as compared to DMBA. This decrease was 34 and 26% in 
tumors where DAS was given before or after the DMBA exposure respectively. The 
levels of both cytosolic and membrane bound p21/ras in DAS exposed skin were found 
to be normal. The results of the immunohistochemical staining of the skin/tumor 
sections further iended support to observation that DAS pre and post supplementation 
decreased the p21/ras expression by 55.82 & 46.86% respectively, thus checking the 
growth of neoplastic cells. The results of the flow cytometric analysis further Iended 
support to the findings of western blotting and immunohistochemistry. A significant 
shift towards higher fluorescence was observed in MFI 1.21 (control) to 13.77 (DMBA) 
induced tumors. This shift in the fluorescence was decreased to 5.42 and 8.76 in 
tumors where DAS was given before and after the DMBA exposure. In DAS exposed 
skin, the fluorescence was recorded at 1.72 channel value indicating normal levels of 
p21/ras expression. These results thus provide clear evidence that the membrane 
association o\ p21/ras is significantly inhibited with a concomitant increase in cytosolic 
p21/ras by DAS administration in DMBA induced mouse skin tumors. Thus, one 
mechanism of the growth inhibitory properties of DAS is through the suppression of 
development of tumors that harbor ras mutations by inhibiting the membrane 
association of oncogenic p21/ras. 
In Vitro and In Vivo Multiple Drug Reversing Potential of Dialiyi 
Sulfide 
Multidrug resistance (MDR) mediated by the over-expression of drug efflux 
protein P-glycoprotein (P-gp) is one of the major obstacles to successful cancer 
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chemotherapy. P-gp acts as an energy dependent drug efflux pump, reducing the 
intracellular concentration of structurally unrelated drugs. Modulators of P-gp function 
have been shown to restore the sensitivity of MDR to such cytotoxic drugs. 
Unfortunately, most of these compounds are not useful to tackle the problem of drug 
resistance at a clinically sustainable level because of unacceptable side effects or 
toxicity at doses required for effectiveness. Therefore, these limitations have spurred 
efforts to search for new compounds with low toxicity and high efficacy with due 
attention to dietary agents. An advantage of using newly identified dietary agents, as a 
modulator of MDR is that they enhance antitumor activity and exhibit little or no 
virtually no side effects. 
The present study revealed the in vitro and in-vivo P-gp modulatory potential of 
DAS in Leukemic K562 cells and mouse liver. K562 leukemic cells were made 
resistant (K562/R10) towards the cytotoxicity of vinblastine (VBL) by progressive 
adaptation of the parental sensitive K562 cells to VBL. Cross-resistance of K562/R 
was found between vincristine (VCR), doxorubicin and other antineoplastic agents. A 
non-toxic concentration of DAS (8.75 x 10'^ M) enhanced the cytotoxic effects of VBL 
and another vinca alkaloid, VCR, time dependently In VBL resistant human leukemia 
(K562/R10) cells but had no effect on the parent (K562/S) cells. The results showed 
that DAS decreased the induced levels of P-gp in resistant cells back to the normal 
levels as analyzed both qualitatively and quantitatively by western blotting and 
immunocytochemistry. Quantitation of immunocytochemical staining showed that this 
inhibition of P-gp expression by DAS was 23, 54 & 79% for 24, 48 & 72 hrs 
respectively in K562/R10 cells. DAS had no effect on P-gp expression in parental 
K562/S cells. Furthermore, in-vivo combination studies showed that DAS effectively 
inhibited the vinca alkaloid induced P-gp over expression in mouse hepatocytes as 
evident by western blotting. Quantitation of immunostained tissue sections with image 
analysis showed that reduction in P-gp levels was up to the extent of 73% for VBL and 
65% for VCR induced drug resistance. The above features thus indicate that DAS can 
serve as a novel, non-toxic modulator of P-gp expression and can be used as a dietary 
adjuvant for the reversal of MDR^ , _ 
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Introduction & Review of Literature 
Cancer 
About thirty years ago, when US President Richard Nixon declared the "war on 
cancer" m 1974, there was hope and anticipation that the deaths from cancer might be 
greatly reduced by the end of last century. Inspite of immense progress in bio-medical 
research to improve treatment and find cures for advanced disease, cancer still 
remains a major global health issue. In 2000, cancer accounted for over 7 million 
deaths (13% of the total mortality) and there were more than 10 million new cancer 
cases worldwide by the end of new millennium (Shibuya et at, 2002). According to a 
report of American Cancer Society on Cancer Statistics, cancers of the lung, prostrate, 
colon and rectum in men and cancers of the lung, breast, colon and rectum in women 
continue to be the most common cause of cancer deaths (Jemal et al, 2002). These 
four types of cancers account for more than half of the total cancer deaths among men 
and women. In USA, lung cancer has surpassed breast cancer as the leading cause of 
cancer death in women since 1987 and is expected to account for about 25 percent of 
all female cancer deaths in 2003 (Jemal et al, 2002). 
Rapid advances in the field of cancer research have generated a rich and 
complex body of knowledge with the realization that cancer is not a single disease 
rather it is a bio-medically complex group of diseases resulting partly from the 
interactions between these genetic changes and the cellular stresses from specific 
environmental and behavioral factors including lifestyle choices such as diet, 
occupation etc. (Perera, 1996). Development of cancer is the process of cancer/tumor 
formation resulting from exposure to chemical, physical and biological agents alone or 
in combination. According to a famous British pathologist, R. A. Willis (1960), tumors 
can been defined as "An abnormal mass of tissue the growth of which is in excess and 
uncoordinated with the normal tissues and persists in the same excessive manner, 
even after the cessation of the stimuli that evoked the change". The vast catalog of 
cancer cell genotypes is a manifestation of six essential alterations in cell physiology 
that collectively dictate malignant growth (Hanahan & Weinberg, 2000). These include: 
Self-sufficiency in growth signals, 
Insensitivity to growth inhibitory signals (antigrowth). 
Evasion of programmed cell death (apoptosis), 
Limitless replicative potential. 
Sustained angiogenesis and adjoining tissue invasion, 
Metastasis 
Introduction & Review of Literature 
Each of these physiological changes acquired during tumor developnnent 
represents the successful breaching of an anticancer defense mechanism. These six 
capabilities are shared in common by most and perhaps all types of human and animal 
tumors. 
Causative Factors: 
Cancer is one of the most alarming disease of mankind, and various type of 
cancer account for million of deaths every year all the world. It may be caused by a 
variety of causative factors, usually over a period of many years (-10-20 yrs.). Many 
specific causes of cancer are now known, the most important being difference in 
lifestyle, occupational exposure and exposure to oncogenic viruses, but a large 
proportion of global variation for common cancers remains still unexplained. The 
known risk factors for cancer can be broadly divided into 'environmental' and 'host 
factors'. Environmental factors can be further subdivided into 'chemical', 'physical' and 
'biological' factors. 
In this era of modernization and technology, large number of chemicals enters 
into our environment through occupational exposure contamination, food, water, 
automobile exhausts, pesticides, industrial wastes and through the items of day-to-day 
utility. These chemicals exist in the environment in a relatively stable condition until 
taken in/by an exposed individual and activated. Thus, these chemicals appear to pose 
a great concern and threat to man. Polycyclic aromatic hydrocarbons (PAH), 
nitrosamines, mycotoxins, pesticide residues and metallic contaminants such as 
arsenic and cadmium are some of the xenobiotics that can enter our food chain during 
processing, storage preservation and cooking. Depending upon the evaluation of 
International Agency Research for Research on Cancer (lARC), now there are about 
88 chemicals, with sufficient evidences of carcinogenic potential in humans (lARC, 
1994). 
Physical agents such as ultra-violet (UV) and the ionizing radiations (X-rays, y-
rays) are known to be hazardous in nearly all tissues or organs of human or 
experimental animals depending upon the radiation dose and exposure schedule 
(lARC, 1992). The scenario is becoming alarming with the application of nuclear 
technology in science, medicine and industries and the expanding use of these 
radiations in diagnosis and therapy of the disease itself (Trichopoulos et al, 1996). 
Introduction & Review of Literature 
Biological agents, Includes certain retroviruses, bacteria and parasitic 
infections. The oncogenic viruses such as papillomas-viruses, feline-leukemia viruses 
and bovine-leukosis virus are linked with increased incidence of neoplasia. The 
Epstein-Barr virus has shown to be implicated with the occurrence of Burkitt's 
lymphoma, Hodgkin and Non-Hodgkin lymphoma and pharyngeal carcinoma (Cordova 
Perez et al, 2003; Young & Murray, 2003). Certain bacteria like Helicobacter pyroli are 
also implicated in the development of cervical, esophagus, head, neck and stomach 
cancer (Peto, 2001). 
Host (Internal) factors comprise of hormonal disturbances, immune functions 
and inherited predisposition to certain cancers. The genetic manipulations such as 
activation of cellular proto-oncogenes and alterations in tumor suppressor genes also 
result in aberrant proliferation of cells (Ames et al, 1995; Peto, 2001). Many cancer 
chemotherapeutic drugs, particularly vinca alkaloids, alkylating agents, 
immunosuppressive agents and certain cyclosporins are also reported to increase the 
cancer risk (Ames et al, 1995; Trichopoulos et al, 1996;Chauvenet et al, 2003). 
Besides, the choice of lifestyle such as tobacco smoking, high alcohol intake, 
high fat diet and dietary habits, are also thought to initiate or promote various cancers 
(lARC, 1993). About 40-60% of all cancers are related to our food choices and about 
one third of all cancer deaths may be related to what we eat. Diets high in fat, low in 
fiber, vitamins, fruits and vegetables, overweight and obesity, lack of physical activity 
etc have been associated with increased incidence of cancer. Thus most of the 
prevalent human cancers can to a significant extent be prevented and many could be 
avoided by a suitable choice of lifestyle, diet and environment. 
Chemical Carcinogens 
'Carcinogens' are the compounds, which can induce the development of 
neoplastic changes in the cells. There are number of compounds which can not cause 
development of tumors on their own but if applied with some other compound can 
potentiate the neoplastic conversion and termed as 'Cocarcinogens'. Carcinogens 
may vary in their efficacy and structure. A number of compounds have been found to 
be carcinogens and cocarcinogens in various epidemiological and experimental 
studies. Based upon these studies, at present lARC (1994) has categorized them into 
different categories: 
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• With sufficient evidence for carcinogenicity in humans, 
• With limited evidence for carcinogenic potential in tiumans and more evidences 
are required with scientifically performed epidemiological studies, 
• With sufficient evidence for carcinogenicity in animals, 
• With limited evidence of carcinogenesis in animals, 
• Suspected carcinogens and 
• Non carcinogens 
The carcinogens can further be divided on the basis of their metabolic fate into 
'procarcinogens' or 'proximate carcinogens' {direct acting carcinogens). 
'Procarcinogens' are active only after their metabolic conversion by the host. The 
'proximate carcinogens' do not require the participation of the enzyme(s) from the host 
organism to generate the key reactive intermediates or the 'ultimate carcinogens', 
which eventually binds to cellular macromolecules and causes mutations or initiate the 
process of carcinogenesis (Miller & Miller, 1976). Most of the direct acting carcinogens 
are synthetic chemicals developed as laboratory tools for research or used in 
industries and because of their high reactivity they do not generally present in the 
environment. In contrast, procarcinogens are comparatively stable and exist in 
environment until reaches their target site and get activated. Some procarcinogens 
are chemically or spontaneously converted to ultimate carcinogens by hydrolytic 
reactions and often exhibit a broad spectrum of activity in many species and target 
organs (Clayson & Garner, 1976; Miller & Miller, 1976). Other procarcinogens, which 
require host controlled biochemical activation, dependent on specific enzymes 
systems (Grover et al, 1974) may exhibit more specific and/or restricted 
carcinogenicity (Falk, 1976). The procarcinogens may also be subjected to 
deactivation reactions, which can lead to the formation of products with either no or 
less carcinogenic potential than the parent molecule (Miller & Miller, 1976). The 
ultimate reactive metabolites are "electron deficient" reactants. They are the 
compounds, which reacts with "electron rich" sites in nucleic acids and proteins 
causing mutagenic effects, frequently paralleled by the onset of DNA repair processes 
(Miller & Miller, 1976). Figure 1, illustrates the generalized scheme of the metabolic 
activation of chemical carcinogens and their possible mechanisms of action. 
Chemical Carcinogenesis 
'Chemical carcinogenesis' is an operational process during which a normal cell 
and its progeny are converted over a period of time into cancer cells i.e. cells, which 
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fail to respond to the normal growth controlling factors in the environment. Despite the 
diversity in chemical structures of known carcinogens and mutagens such as alkylating 
agents, N-nitrosamines and N-nitrosamides, nitroaryl and furan derivatives, aromatic 
heterocyclic amines and azo dyes, PAH, chlorinated hydrocarbons and some naturally 
occurring compounds (e.g. aflatoxins, pyrolizidine, alkaloids etc.), their basic mode of 
action is almost the same. These agents are capable of accomplishing mutations and 
ultimately lead to the development of cancer. Initially these chemical carcinogens are 
not electrophilic in nature and metabolically activated to initiate process of cancer 
development. 
During cancer development the transformation of a normal somatic cell into a 
malignant tumor cell occur via a complex multistage process involving various 
biochemical and genetic changes in the cell (Slaga et al, 1995; Greenwald, 1996) The 
whole process of cancer development consists of three distinct sequences. In the first 
step the normal cell gets converted into a neoplastic cell is called 'initiation', whereas 
second and third, where the initiated cell develops into an overt neoplasm are called 
'promotion' and 'progression' stages respectively (Fig. 2) (Marks & Furstenberger, 
1984; DiGiovanni, 1992). 
Initiation: The initial sequence of events in carcinogenesis consists of the 
transformation of a normal cell into a neoplastic cell through development of genetic 
defects, which are required for the expression of transformation (Elenbaas etal, 2001). 
Initiation in somatic cells is generally brought about by a single, topical/ intragastric 
(Boutwell, 1964) or transplacental (Shukia & Arora, 2001) application of a chemical 
carcinogen at a very low "subtliresholcf' (sub carcinogenic) dose (Fig. 2). Since 
successful induction of tumor growth can be accomplished at almost any time after 
initiation (from few days to life long), the alterations caused by the initiating agent in 
the tissue are thus regarded as irreversible (Boutwell et al, 1982). The target cells for 
initiation stage of chemically induced skin carcinogenesis appear to be stem cells, 
since these cells undergo 'differentiation' and 'dedifferentiation', which is a prerequisite 
for genetic alteration (Perez-Losada & Balmain, 2003). 
The genetic alterations, leading to tumor initiation, appear to be the result of 
one or more simple mutations such as transitions, transversions or small deletions 
(Devereux ef al, 1999). Other modifications, such as alteration of the normal pattern of 
cytosine methylation (Baylin et al, 1998) occur in growth control genes, 
protooncogenes, tumor suppressor genes and their regulatory genes (Bos & vanKreijI, 
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1992; Vogelstein & Kinzler, 1993; Weinberg, 1995; Hussain & Harris, 1998), resulting 
in loss of genetic control in the cell (Sherr, 1996; Weinstein etal, 1997). 
Promotion: Promotion can be characterized by the "phenotypic clonal expansion of 
the initiated cell, which eventually leads to the development of a neoplasm" (Slaga et 
al, 1980). Tumor promotion is comparatively a long event (Fig. 2) and promoting 
agents includes a variety of chemicals such as polypeptides, steroid hormones, growth 
factors and numerous synthetic and naturally occurring chemicals. These promoters 
usually exhibit the properties of the alteration of genetic expression, stimulation of cell 
replication and inhibition of apoptosis etc. (Morse & Stoner, 1993). At the molecular 
level, tumor promotion is characterized by the changes in the expression of the 
genome rather than the structural alterations in DNA (Pitot, 1997). Virtually, all known 
promoting agents like 12-o-tetradeconyl phorbol-13-acetate (TPA), 2,3,7,8-tetrachloro-
dibenzo-p-dioxin (TCDD), phenobarbital etc. mediate their effects through receptor 
mechanisms. These agents interact directly with their plasma membrane receptors, 
causing an activation of the tyrosine protein kinase component of the receptor, which 
in turn phosphorylates critical proteins, leading ultimately to altered expression of 
genes. The other biochemical responses to tumor promoters include increased 
synthesis of DNA, RNA, protein, phosholipids, histidine decarboxylase, and protease, 
and decreased activities of superoxide dismutase and catalase (Pitot, 1997). Other 
events in the course of hyperplastic transformation include an expression of the proto-
oncogenes c-fos and c-myc (Rose-John et al, 1988; Angel & DiGiovanni, 1999), 
desensitization of epidermal cells for antiproliferative endogenous signals (such as 
catecholamine and chalcone), and an impairment of intercellular communication 
(Nishizuka, 1992). 
Progression: 'Progression' or 'conversion' in chemical carcinogenesis refers to the 
rapid cell division and ultimately conversion into a malignant neoplasm from existing 
benign tumor (Fig. 2). Progression is probably the most complex of multistage 
carcinogenesis, because acquired genetic and phenotypic changes occur and cellular 
expansion is rapid. It includes changes in histopathologic type from well differentiated, 
poorly differentiated to anaplastic, biochemical changes such as increased or 
inappropriate expression of metabolic enzymes and chromosomal changes. 
Progression appears to be the consequence of a mutator phenotype, which introduces 
further mutations in replicating neoplastic cells endowing growth advantage (Loeb, 
1991; Loeb & Loeb, 2000). Early in progression the karyotype of neoplastic cells may 
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be diploid but with very subtle structural alterations. Mechanisms that can lead to 
karyotypic instability are numerous and include disruption of the mitotic apparatus, 
alteration in telomere function (Blackburn, 1994), DNA hypomethylation, 
recombination, gene amplification and gene transposition (Cheng & Loeb, 1993). Many 
malignant neoplasms exhibit one or more of these events, which very likely play a role 
in the evolution of process (Pearson & Vogeistein, 1990). Thus, clastogenesis and 
karyotypic instability result from a number of mechanisms, any one, many or all of 
which may be involved in the initial transition from the stage of promotion to that of 
progression, as well as the evolution of the final stage of neoplastic conversion. 
Cellular and molecular basis of multistage carcinogenesis 
The development of several types of cancer involves the progressive 
acquisition of mutations in multiple genes, including activating mutations in dominant 
acting oncogenes and inactivating mutations in recessive tumor suppressor genes 
(Pearson & Vogeistein, 1990; Weinstein e^ al, 1995). The occurrence of these 
mutations involves repetitive cycles of cell proliferation, selection and clonal 
expansion. The targeted genes play highly diverse biochemical and biological roles 
(Mendlsohn et al, 1995; Weinstein et al, 1995, 1997) and can be divided into two broad 
functional categories: (a) genes that control intracellular regulatory circuitry; and (b) 
genes that influence cell surface and extracellular functions. 
The first category includes several subcategories: (i) genes that play a role in 
the responses of cells to external growth factors, i.e., they encode growth factors, 
cellular receptors, coupling proteins, and protein kinases that transduce information 
across the cytoplasm to the nucleus, and nuclear transcription factors that increase or 
repress the expression of other genes; (ii) genes involved in DNA replication and 
repair; (iii) genes involved in cell cycle control; and (iv) genes that determine cell fate, 
i.e., cellular differentiation, senescence, or apoptosis. 
The second category involves genes that influence cell interactions with the 
extracellular matrix and/ or neighboring cells. This category includes various cell 
surface proteins, cell adhesion molecules, extracellular proteases and angiogenic 
factors. Alterations in these genes are especially relevant to tumor cell invasion and 
metastasis. Some of these genes perform multiple functions and the biological effects 
of some of these genes are dependent upon the type of cell in which they are 
expressed. 
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Mouse Skin Carcinogenesis 
Murine skin is the oldest and nnost favorable model for the studies on the 
understanding of development of cancer and for evaluating carcinogenic and 
anticarcinogenic potential of test chemicals (Shukia et al, 1992; Slaga et al, 1995; 
Singh & Shukia, 1998 a& b; Marks & Furstenberger, 2000). The first evidence that 
tumors can be induced in experimental animals was provided by Yamagiwa & 
Ichikawa (1917), when they induced skin tumors by local application of coal tar on 
skin. Later on Rous & Kidd (1941) and Mottram (1944) further explored the inroads in 
skin carcinogenesis. Since then, mouse skin carcinogenesis has been a model of 
choice for scientists because the tumor development can be monitored easily and 
accurately by the naked eyes with certain degree of accuracy, without sacrificing the 
animals. 
Mouse skin model further provided an excellent model system to study the 
multistep nature of cancer development. Skin carcinogenesis involves two stage 
process was reported by Rous & Kidd (1941). Evidence for chemical promotion or 
carcinogenesis was first produced by Berenblum (1941) who reported that a regimen 
of croton oil (weak or noncarcinogenic) applied alternatively with small doses of 
benzo(a)pyrene (BaP) to mouse skin induced a large number of tumors than BaP 
alone. Subsequently, Mottram (1944) found that a single sub carcinogenic dose of 
7,12 dimethylbez(a)anthracene (DMBA) followed by multiple application of croton oil 
could induce a large number of skin tumors. These investigators, as well as others 
including Boutwell (1964, 1974), Van Duuren (1969), and Hecker (1978) defined many 
important aspects of the initiation and promotion of two-stage carcinogenesis. Today, 
mouse skin model of carcinogenesis is considered as the most advanced method for 
artificial generation of benign and malignant tumors. 
Experimentally, tumors can be induced either by using the 'complete 
carcinogenic' protocol or by two-stage, 'initiation-promotion' protocol. In the complete 
carcinogenic protocol either a single large dose or repeated small doses of a complete 
carcinogen (DMBA, BaP, 3-methylcholanthrene) are required for the tumor induction. 
However, in initiation-promotion protocol, usually single sub-carcinogenic doses of a 
carcinogen followed by repeated application of tumor promoter (mainly mitogen) in a 
sequential manner are required for the onset of tumorigenesis. The tumor induction by 
this protocol is comparatively rapid and the number of tumors formed is quite high. But 
the tumors induced by initiation-promotion are benign in nature whereas high 
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incidences of malignant tumors are encountered in complete carcinogenesis protocol. 
In general mice are more sensitive to skin carcinogenesis by either the complete 
carcinogenesis protocol or by the initiation-promotion protocol than in rats and 
hamsters (Slaga etal, 1978). 
Cancer Chemoprevention 
The use of natural products for medicinal purposes as traditional or alternative 
medicine has increased substantially during last few decades. The traditional system 
of medicine has been known since ancient Vedic times. In Hindu mythological books 
there are several examples for the use of various herbs and shrubs as an effective 
medicine for the treatment of human beings. A well-known example of this is quoted by 
'Rishi Valmiki" in 'Ramayana'where the use of 'Sanjivanf has been described for the 
treatment of 'Lakshmana'. Apart from this Chinese, Egyptian, Greek, Roman and 
Syrian texts of civilization, describes the uses of various plants and plant products for 
the treatment of a number of diseases. The Chinese system of traditional medicine has 
its unique methods of treatment, which contains more than seven thousand species of 
medicinal plants into clinical practice (Shen, 1996). 
It has been estimated that nearly 80% of the world's population still rely on 
Complementary and Alternative Medicine (CAM) as their primary form of health care 
(Kamboj, 2000). These alternative medicines include naturopathy, biopathy, 
homeopathy, home remedies, wheat grass therapy, hydrotherapy, acupuncture, 
osteopathy and vipasana (Gupta et al, 1997). The use of CAM throughout the world 
exceeds that of the conventional drugs by two or three times, which is quite popular in 
certain parts of Europe, Australia, China and Israel (Pal, 2002). India, being a rich 
source of various medicinal plants, is having a broad base for the use of alternative 
medicines or herbal remedies due to their cost effectiveness and vast faith in 
Ayurveda. The popular alternative medicines used in India for cancer treatment include 
Ayurveda and herbal, natural, tribal and folk medicines. The Ayurvedic medicines, 
Valipani, Navjeevan and Kamdudha have shown efficacy in some leukemia patients 
(Treleaven e^ a/, 1993). 
With the growing awareness about the potential role of CAM in preventing 
cancer and other chronic diseases, immense research efforts are now being carried 
out for validating many of the ancient remedies. The efforts are also going on for 
determining the identity of the active components, establishing their mechanism of 
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action, exploring interactions with other active agents from foods and plants and 
finding ways to improve bioavailability under normal conditions. 
According to a time worn adage, 'prevention of disease is better than cure'. 
Therefore, an approach to reducing cancer risk that either prevents cancer or reduces 
the risk of cancer development in its early stage is a logical and perhaps the best 
strategy to reduce the overall cancer burden. Thus, the above mentioned notion 
provides a strong rationale for a preventive approach to the control of this disease and 
leads one to consider the possibility of active pharmacological intervention to arrest or 
reverse the process of carcinogenesis before invasion and metastasis occur. This 
forms the basis of 'cancer chemoprevention'. 
The research aimed towards the prevention of cancer development started as 
early as in 1950s, the time almost parallel when the researchers were busy to 
understand the process of carcinogenesis. However, it was in late 1960's when the 
field of cancer chemoprevention became more prominent and focused, when L. W. 
Wattenberg, one of the founders of the field, conceptualized this strategy and 
suggested a mechanistic framework to the diverse array of agents identified 
(Wattenberg, 1966, 1985, 1992). He initially named the concept of cancer 
chemoprevention as 'chemopropiiylaxis of carcinogenesis'. The term 
'chemoprevention' was coined by M. B. Sporn in an article in federation proceedings 
when writing about the work his group was doing with vitamin A analogues (Sporn ef 
a/, 1976). The cancer chemoprevention can be defined as 'tlie prevention of 
occurrence of cancer by administration of one or more compound, as ctiemical entity 
or dietary constituents'. The significance of chemopreventive approach first got the 
recognition when National Cancer Institute (NCI) established the laboratory of 
chemoprevention in 1970's. In early 1980's, NCI initiated a cancer chemoprevention 
program, which developed into a major effort in which more than 400 potential 
chemopreventive agents are being studied (Greenwald, 2002). 
Cancer chemoprevention is principally distinct from cancer chemotherapy. In 
chemotherapy the prime objective is to arrest the growth and to ultimately kill 
cancerous cells to check further neoplastic progression. Whereas, chemoprevention 
involves the increased intake of certain compounds to otherwise healthy individuals 
who may be at increased risk for cancer. At present the primary goal of 
chemoprevention research is to identify effective agents and/or develop efficient 
strategies for clinical trials and ultimately application to humans. Chemoprevention 
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uses a stepwise, systematic research strategy that includes: identification of the 
potential new agents that have higher efficacy in preventing carcinogenesis in aninnal 
nnodels, based on epidemiological observations of preventing human cancer, 
preclinical drug development, and phases I, (I and \\\ clinical intervention trials 
(Greenwald, 2002). The concept of using chemopreventive agents to reduce cancer 
risk is firmly based on epidemiologic and experimental evidence from the last two 
decades that indicates specific compounds may influence carcinogenesis at various 
sites, including the oral cavity, esophagus, stomach, colon, rectum, lung, breast and 
prostate (Kelloff et al, 1997). The investigative scope of cancer chemoprevention is 
vast. At present more than 2000 agents from 20 chemical structural and 
pharmacological activity classes showing preclinical chemopreventive activity are 
available. Some promising and commonly used diet derived agents with 
chemopreventive properties are listed in Table 1. Also of interest is the development of 
combinations of chemopreventive agents that may be more effective, less expensive 
and less toxic than agents used singly. For instance simultaneous or sequential 
administration of two agents with different mechanisms of action may result in additive 
or synergistic chemopreventive activities (Moon e^ al, 1992, Kelloff et al, 1994a). 
Clinical trials for chemoprevention 
Inspite of innumerable number of researches conducted in the past on 
thousands of compounds for their chemopreventive efficacies, very few of them were 
found to be active in in vitro and animal studies. However, to develop these active 
compounds into drugs more studies (clinical trials) are required. In the clinical trials 
very few are being translated as an effective drug and still a number of the compounds 
are under the various stages of clinical trials. At present. Division of Cancer Prevention 
at NCI, is conducting more than 65, phase I, II & III chemoprevention trials for more 
than 32 chemopreventive agents (Greenwald, 2002). The phase II & III trials are 
directed at various cancer targets including breast, colon, prostate, esophagus, mouth, 
lung, cervix, ovary, liver, bladder and skin (Table 2). 
Certain chemopreventive agents such as green tea compounds 
(epigallocatechin-3-gallate (EGCG), polyphenon E), soy isoflavones, curcumin, perillyl 
alcohol etc. have been shown to be effective in phase I trials and are currently 
undergoing phase II chemopreventive trials. Agents found to have efficacy and low 
toxicity in phase II clinical trials are investigated further in large-scale phase III 
intervention trials. Compounds such as celecoxib, 2-difluoromethylornithine, N-(4 
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Table 2: Phytochemicals under Cancer Prevention Trials by the National 
Cancer Institute (USA) 
Target organ Agents 
Phase 1 trials 
Breast 
Colon 
Lung 
Prostate 
Skin 
L- Perillyl alcohol 
Selective oestrogen receptor mociulators-3 (2 trials) 
Soy isoflavones 
Curcumin 
Ursodiol 
Phenethyl isothiocyanate 
L-Selenomethionine and vitamin E 
Lycopene (3 trials) 
Soy isoflavones 
Epigallocatechin gallate and polyphenon E 
Phase II trials 
Anogenital warts, HPV, 
HIV 
Barrett's oesophagus 
Bladder 
Breast 
Cen/ix 
Colon 
Endometrium 
Liver 
Lung 
Mouth 
Ovary 
Prostate 
lndole-3-carbinol 
Celecoxib 
2-Difluoromethylornithine 
Celecoxib 
2-Difluoromethylornithine (2 trials) 
Exemestane 
L-Perillyl alcohol 
Selective oestrogen receptor modulators-3 (2 trials) 
Tamoxifen (2 trials) 
Tamoxifen and /V-(4-hydroxyphenyl)retinamide (2 trials) 
Targretin 
9-c/s-Retinoic acid 
2-Dfluoromethylorinithine 
A/-(4-hydroxyphenyl)retinamide 
Celecoxib (2 trials) 
Celecoxib and 2-difluoromethylornithine 
2-Difluoromethylorinithine and sulindac 
Folic acid 
Vitamin D and calcium 
Medroxyprogesterone v depo-provera 
Oltipraz 
Anetholetrithione 
Budesonide 
Celecoxib 
A/-(4-hydroxyphenyl)retinamide 
/V-(4-hydroxyphenyl)retinamide and oral contraceptive 
Celecoxib 
2-Difluoromethylorinithine 
2-Difluoromethylorinithine and casodex 
Flutamide 
Flutamide and luprolide 
Flutamide and toremifene 
13 
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Skin 
N-(4-hyclroxyphenyl)retinamicle 
Selenised yeast 
Soy (dietary) 
Soy isoflavones 
Vitamin D analogue 
Celecoxib 
Polyphenon E (wartheal) 
Sulindac 
Phase III trials 
Bladder 
Breast 
Colon 
Oesophagus 
Prostate 
Skin 
2-Difluoromethylornithine 
A/-(4-hydroxyplienyl)retinamide 
Raloxifene and tamoxifen 
Celecoxib 
L-Selenomethionine and celecoxib 
Finasteride 
Selenomethionine 
Selenium and vitamin E 
2-Difluoromethylorinithine 
/\/-(4-hydroxyphenyl)retinamide 
[Source: Greenwald, 2002] 
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hydroyphenyl) retinamide are being evaluated in pinase II and phase III clinical studies. 
In an ongoing phase III clinical trial, selenium and vitamin E are under consideration, 
individually and in combination against prostrate cancer (Greenwald & Lieberman, 
2000). In a much-publicized breast cancer prevention trial of tamoxifen in women with 
early breast cancer revealed a significant decrease (40%-50%) of contralateral breast 
cancer (Early breast cancer trialist's collaborative group, 1998). In another clinical trial 
with tamoxifen, conducted with more than 13000 women at increased risk of breast 
cancer was completed in 1998 and it was found that women who took tamoxifen daily 
for five years had a 49% reduced risk of breast cancer compared with those taking 
placebo (Fisher et al, 1998). Another study of tamoxifen and raloxifene showed that 
raloxifene therapy reduces the risk of breast cancer in postmenopausal women 
(Lippman ef a/, 2001). 
Classes Of Chemopreventive Agents 
The chemopreventive compounds belong to different chemical structures, 
origin, and activities. The chemopreventive agents were first classified by Wattenberg 
(1985), on the basis of intervention stages of cancer development. He classified 
chemopreventive agents broadly into two major categories: 
A. Blocking Agents: 'Blocking agents' are the compounds, which can inhibit initial 
steps (initiation) of carcinogenesis, either by blocking the formation of ultimate 
carcinogen from precursor molecule or reactive metabolites from the parent 
carcinogens or by enhancing detoxification system or by trapping reactive electrophilic 
and carcinogenic species before they reach critical target sites (Wattenberg, 1997) 
(Table 3). Inducers of cytochrome P450 also fall in this category as they can increase 
the production of activated metabolites at resistant non-target tissues or by enhancing 
oxidative detoxification. Similarly, certain blocking agents (e.g. vanillin), induces O -^
alkylguanine-DNA-alkyl transferase activity, which repairs 0^-alkylguanine lesions, 
thus enhancing fidelity of DNA repair. Blocking agents, which enhance the 
detoxification of carcinogenic moiety, are of special interest in terms of cancer 
chemoprevention as many of these phase II enzyme-inducing compounds are present 
in fruits and vegetables (Wattenberg, 1992,1997). 
B. Suppressing Agents: The 'suppressing agents' are mainly the compounds which 
either modulate or completely prevents otherwise benign tumor towards malignancy 
(Table 3). Wattenberg (1993) has further subdivided suppressing agents into four 
15 
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Table 3: Blocking/ Suppressing Agents and their Mode of Action 
Mechanism Examples 
Blocking Agents 
Induction of DNA repair 
Scavenging electrophiles 
Inhibition of cytochrome P450 
Induction of cytochrome P450 
Induction of phase II enzymes 
Vanillin 
Ellagic acid, N-acetylcysteine, Sodium 
thiosulfate 
Dithiocarbamates, Isothiocyanates, 
Diallyl sulfide, Ellagic acid 
lndole-3-carbinol, p-naphthoflavone 
Tea polyphenols 
Isothiocyanates, Polyphenols, 
Dithioethiones 
Suppressing Agents 
Inhibition of polyamine metabolism 
Inhibition of arachidonic acid 
metabolism 
Protease inhibition 
Induction of differentiation 
Inhibition of oncogene expression 
• Inhibition of product post-
translational modification 
• Inhibition of transcription or 
translation 
• Inhibition of protein kinase C 
• Inhibition of oxidative DNA 
damage 
a-difluromethyl ornithine. Substituted 
putrescines 
Piroxicam, Indomethacin, Aspirin, 
Quercetin, Curcumin 
tosyl phenylalanine chloromethyl ketone, 
Antipain, Bowman-Birk protease inhibitor 
Retinoids, Calcium, Vitamin D 
Lovastatin, Limonene 
Antisense oligonucleotides Staurosporine, 
Threo-dihydroshingosine, Sarcophytol A, 
Epigatlocatechin galtate. Selenium 
[Source: Morse & Stoner, 1993] 
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classes: a) Agents act to induce differentiation, a characteristic of vitannin A and its 
analogs (retinoids) and other vitamin D analogs (deltanoids); b) Agents act to reduce 
cellular proliferation by disrupting exogenous signals for proliferation and include non-
steroidal anti-inflammatory agents (aspirin), polyamine synthesis inhibitors 
(difluoromethyl ornithine), hormone receptor antagonists (tamoxifen) and inhibitors of 
hormone synthesis (finasteride); c) Agents preventing the consequences of a 
genotoxic insult that resulted in the activation of an oncogene or deactivation of a 
tumor suppressor gene; d) Agents with unknown mechanism of action, however many 
of them have the capacity to inhibit components of the arachidonic acid cascade. 
A substantial number of the suppressing agents are being considered for their 
chemopreventive activities and now viewed as potential candidates to be used in the 
chemopreventive strategies for humans. These include protease inhibitors like 
Bowman-Burke protease inhibitor (Kennedy, 1994; Kennedy et al, 1996), inositols 
(Shamsuddin & Sakamoto, 1992) and glucocorticoids (Wattenberg & Estensen, 1996) 
etc. 
Swan & Ford (1997) suggested following qualities of an ideal chemopreventive 
agent. 
a) Little or no untoward or toxic effects, as in any chemopreventive dosing 
regimen, drug is administered chronically to healthy individuals and only 
certain high-risk populations (survivors of a primary tumor) can be 
reasonably expected to endure mild toxicity or discomfort; 
b) High efficacy in both in-vivo animal models and in clinical trials; 
c) Capability of oral administration which allows self-medication and enhances 
subject compliance; 
d) A known mechanism of action to decrease the possibility of untoward 
interactions with other administered drugs or dietary constituents finals and 
e) Low cost since the agent(s) is chronically administered. 
Mechanism of Action of Chemopreventive Agents 
A great strength of chemoprevention is that a large number of compounds can 
prevent the occurrence of cancer through a number of mechanisms. A potential 
chemotherapeutic agent needs to posses a variety of mechanistically distinct but 
complementary properties. These pathways regulate cell growth, differentiation and 
17 
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survival in order to combat effectively a disease as complicated and multi-factorial as 
cancer (Fig. 3). 
Multiple genetic changes have been known to occur along all stages of 
carcinogenesis (Pearson & Volgstein, 1990) and have been viewed as a continuum of 
mutagenic and mitogenic events. Since the modifiers of carcinogenesis are known to 
act by more then one mechanism therefore, it was difficult to classify them according 
to their mode of action. However, Kelloff et al (1996a) broadly classified these 
compounds into three major categories: 
i) Blocking activities, which encompasses inhibition of carcinogen formation 
or activation, deactivation or detoxification of carcinogens, prevention of 
carcinogen binding to DNA, and enhancement of the level or fidelity of DNA 
repair, 
ii) Antioxidant/anti-inflammatory activities, which may be either blocking or 
suppressing, and include free radical and electrophile scavenging and 
inhibition of arachidonic acid metabolism, 
ill) Antiproliferative/ Antiprogression activities, which do not directly affect 
carcinogens rather inhibit cellular processes involved in the proliferation or 
progression of genetic and other lesions induced by carcinogens. 
Later on, De Flora (1998) proposed another classification based upon mode of 
action of inhibitors of carcinogenesis (Table 4), considering the concept that the 
sequence of events occurring during the carcinogenic processes should not be 
oversimplified by any rigid classification into definite steps. This classification analyzes 
both the inhibition of cancer initiation, either extracellularly or inside cells, and the 
mechanisms interfering with later stages of carcinogenesis i.e. promotion and 
progression. 
Use of Dietary Agents for Chemoprevention Studies 
Even after the decades of developments in the field of medicine a famous 
quote "food should be your medicine and your medicine should be your food' still has 
its importance. Therefore, use of alternatives to the medicines in the form of food and 
food products is an effective approach for the treatment of chronic diseases. Food is 
now being viewed not only as a source of calories, vitamins and minerals but as 
having potential effects well beyond. Terms such as "functional foods" and 
18 
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Table 4: Mechanisms involved in Cancer Chemoprevention 
Meciianism Processes Involved 
Extracellular Mechanisms 
a Inhibition of uptake of mutagens/ 
carcinogens 
• Inhibition of the endogenous 
formation of mutagens and 
carcinogens 
a Complexation, dilution and / or 
deactivation mutagens / carcinogens 
• Favoring absorption of protective 
agents 
Inhibition of penetration 
Removal from the organism 
Inhibition of nitrosation 
Modification of the intestinal microbial flora 
By physical or mechanical means 
By chemical or enzyme-catalyzed reaction 
Intracellular Mechanisms 
a Stimulation of trapping and 
detoxification in non target cells 
• Modification of transmembrane 
transport 
• Modulation of metabolism 
• Blocking or competition 
a Inhibition of cell replication 
a Modulation of DNA metabolism and 
repair 
a Control of gene expression 
Inhibition of cellular uptake 
Stimulation of extrusion outside cells 
Inhibition of activation of promutagens/ 
procarcinogens by Phase I enzymes 
Induction of phase I detoxification and Phase II 
conjugation pathways 
Stimulation of activation with detoxification and 
trapping of reactive metabolites 
• Trapping of electrophiles by chemical or 
enzyme catalyzed conjugation 
• Antioxidant activity and scavenging of reactive 
oxygen species 
• Protection of DNA nucleophilic sites 
Increase of fidelity of DNA replication and repair 
Stimulation of repair and / or reversion of DNA 
damage 
Inhibition of error prone repair 
Correction of hypomethylation 
Inhibition of oncogene expression 
Inhibition oncogene sequences 
Neutralization of oncogene products 
Replacement of deleted tumor suppressor 
genes 
Killing of cells lacking tumor suppressor genes 
19 
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Inhibition of tumor promotion 
Inhibition of tumor progression 
Inhibition of invasion and metastasis 
• inhibition of genotoxic effects 
• Antioxidant activity and scavenging of free 
radicals 
• Inhibition of proteases 
• Inhibition of cell proliferation 
• Induction of cell differentiation 
• Induction of cell apoptosis 
• Protection of intercellular communications 
• Signal transduction modulation 
• Inhibition of genotoxic effects 
• Antioxidant activity and scavenging of free 
radicals 
• Inhibition of proteases 
• Signal transduction modulation 
• Effects on the hormonal status 
• Effects on the immune system 
• Inhibition of angiogenesis 
• Physical, chemical or biological antineoplastic 
activity 
• Inhibition of proteases involved in basement 
membrane degradation and modulation of the 
interaction with the extracellular matrix 
• Induction of cell differentiation 
• Inhibition of neovascularization 
• Effect on cell- adhesion molecules 
• Antioxidant activity 
• Signal transduction modulation 
• Activation of antimetastasis genes 
[Adapted from: DeFlora, 1998] 
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"nutraceuticals" have been introduced to convey this additional efficacy of dietary 
constituents. 
In recent years, there has been an increased emphasis on dietary modulation 
of carcinogenesis because of their safety and the fact that they are not perceived as 
"medicine", in case of other agents mainly synthetic compounds, characterization of 
efficacy and safety, biomarkers of risk, and suitable cohorts for clinical intervention are 
critical to monitor the progress in chemoprevention. Now considerable epidemiological 
and experimental evidences are available, indicating that modifications in life styles, 
including diet, can have a major effect on the risk for cancer (Martinez & Giovanucci, 
1997; World Cancer Research Fund, 1997). The cancer inhibitory action of plant 
derived constituents has been confirmed in different in vitro studies and animal tumor 
models, which has led to an increased attention on cancer prevention strategies in 
which these dietary factors are utilized (Wargovich, 1997; Gescher e^ al, 1998, 
Pezzuto, 1996). The consistent cancer protective effects are reported for individuals 
consuming increased fruits and vegetables including dietary fibre, micronutrients, and 
various phytochemicals. Thus, many nutritive and non-nutritive plants based dietary 
factors are known to inhibit the process of carcinogenesis effectively (Singletary, 
2000;Greenwald etal, 2001). 
There have been two major diet related prevention strategies that have evolved 
to combat cancer i.e. cancer chemoprevention and dietary cancer prevention, with 
appreciable overlap existing between them. Generally cancer chemoprevention is 
recognized as the pharmacological intervention with synthetic or naturally occurring 
chemicals to prevent/inhibit the development of invasive cancer (Kelloff et al, 1997). 
On the other hand, dietary prevention is recognized as the changes in food 
consumption patterns necessary to decrease cancer development (Schatzkin & Kelloff, 
1995; Goodman, 1997). 
Dietary epidemiological studies have provided initial leads for the identification 
of numerous naturally occurring chemopreventive agents (El-Bayoumy ef al, 1997; 
Gescher etal, 1998; Greenwald etal, 2001). An inverse association has been reported 
between intake of fruits and vegetables and cancer risk, reviewing more than 250 case 
control and cohort studies (Negri et al, 1991; Block et al, 1992). In another study, 
Oliveria et al (1997) have shown that, by eating five or more portions of vegetables 
and fruits everyday overall cancer rates can be reduced upto 20% in humans. A 
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cancer protective relationship for food with antioxidant contents such as vitamin C, p-
carotene, vitamin E and selenium as well as the micronutrients vitamin A, calcium and 
folate has been well established (Byers & Guerrero, 1995; van Poppel & Goldbohm, 
1995; Lipkin & Newmark, 1995; Dorgan & Schatzkin, 1991). These studies have 
provided consistent support for the protective effects of foods containing vitamin C for 
cancers of the stomach, esophagus and oral cavity and moderate protective effects for 
cancers of the cervix, rectum, breast and lung. Some promising diet derived 
chemopreventive agents are listed in Table 1. 
Several diet-derived agents are included among the 32 promising agents 
(Table 2) and combinations that are being evaluated clinically as chemopreventive 
agents for major cancer targets (Greenwald, 2002). The clinical trial data support a 
possible protective effect for vitamin E for colorectal and prostate cancer (Alpha-
Tocophenol Beta Carotene cancer prevention study group, 1994) and a link between 
increased intakes of dietary calcium with a decreased risk of colon cancer (Lipkin & 
Newmark, 1995). 
A further advantage of using diet-derived products for cancer prevention is that 
they also have apparent benefit in other chronic diseases such as coronary heart 
diseases, immunodeficiency diseases. Tea and tea polyphenols are known to cause 
lowering of plasma cholesterol and triglyceride levels, as well as reduction of blood 
pressure and platelet aggregation (Kelloff et al, 1996b). Tea polyphenols especially 
EGCG and epicatechin gallate (ECG) are reported to be strong inhibitors of influenza 
virus, human immunodeficiency virus (HIV) reverse transcriptase and cellular 
deoxyribonucleic and ribonucleic acid polymerase (Nakane & Ono, 1990). Increased 
Flavonoids intake was associated with decreased risk of cardiovascular disease and 
carcinogenesis (Hollman et al, 1996). Similarly, lycopene (Gann et al, 1999, 
Giovannucci et al, 1995), soy isoflavones (Kelloff et al, 1996c), curcumin (Kelloff et al, 
1996d), phenethyl isothiocyanate (Kelloff et al, 1996e); indole-3-carbinol (ISC) (Kelloff 
et al, 1996f), perillyl alcohol (Kelloff et al, 1996g) and flavonoids (Hertog et al, 1995) 
have also shown to be protective against several other chronic diseases. 
Use of Intermediate Biomarkers in Chemoprevention Studies 
The ultimate goal of chemoprevention is to reduce the incidence of cancer by 
reducing the probability of disease through active intervention. Agents, which inhibit 
tumor development at the stage of promotion, in particular, are of potential value 
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because of its longer duration. Therefore, the approach to more efficient testing of 
these intervention agents is to use and validate biomarkers that can detect early, 
specific changes exhibiting reversal of neoplastic changes and repair of the damage 
through such intervention. 
Tumor formation and progression are complex processes, involving alterations 
in many molecular/biochemical pathways leading to lack of proper differentiation 
(anaplasia), accelerated growth rates (mitosis), decrease in cell death rate (inhibition 
of apoptosis), and acquisition of changes enabling the cell to invade tissue and 
colonize other organs (metastasis). Use of biomarkers involves one or several of these 
alterations as an index of the probability of tumor formation. Thus, these biomarkers 
serve as a means to detect exposure to carcinogenic influences, as prognostic or 
diagnostic indicators or as intermediate endpoints in intervention trials. 
Intermediate markers of chemoprevention are molecular, biochemical, cellular 
or tissue changes, which accurately reflect the reduction in tumor incidence with the 
administration of chemopreventive agents (Augenlicht, 1997). These are thus 
considered as "signposts" of carcinogenic tissue damage. In many epithelial tissues, 
an early biomarker indicating the probability of cancer developnnent is increased cell 
proliferation with accompanying DNA aneuploidy. Other biomarkers include genetic 
and epigenetic alterations such as loss of heterozygosity, p53 mutations, increased 
expression of the epidermal growth factor receptor, and genomic instability (Kelloff et 
al, 1994b; Lippman et al, 1990). As surrogate end points, they have potential for 
assessing the efficacy of chemopreventive agents with a cost effectiveness and 
relative speed, which is not possible using cancer incidence as the end point (Kelloff ef 
al, 1994b &c). 
Besides improving trial efficiencies, biomarkers are integral to applied 
chemoprevention research because of their unique potential to offer both insights into 
mechanism of action and sound rationale for the design of large scale intervention 
trials (Lippman et al, 1993; Kelloff ef al, 1994 b & c). A number of intervention targets 
have been identified to study the chemopreventive properties of test compounds. The 
most widely accepted out of them are briefly described here. 
A. Induction of Apoptosis: Apoptosis (programmed cell death) is known to play an 
important role in protective mechanism against neoplastic development by eliminating 
damaged or abnormal cells (Lowe & Lin, 2000). The induction of apoptosis in cancer 
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cells may represent a unifying concept for the mechanism of cancer chemoprevention 
because aberrant proliferation and modulated apoptosis represent crucial early events 
in cancer development (Schulte-Hermann et al, 1995). Many types of cancers contain 
mutations that delay or prevent the apoptotic response and thus promote the 
genetically unstable cells. (La Casse et al, 1998) This indicates that chemicals 
possessing chemopreventive properties may act by inducing cell death. Thus, the 
measurement of level and tissue distribution of apoptotic cells may be a important 
biomarker of the progression to malignancy which can be modulated by 
chemopreventive agents. 
B. Modulators of oncogenes and tumor suppressor gene expression: The 
mutations in protooncogenes and tumor suppressor genes are the key factors involved 
in tumor development. This genetic instability is clinically useful for diagnosis, 
monitoring for residual disease and disease recurrence. However, these structural 
gene alterations cannot be modulated. The importance of identification of such 
alterations in terms of chemoprevention studies is that such sequences generally 
control important pathways of differentiation, cell proliferation and apoptosis within the 
cell. The modulation of intermediate steps of these pathways can serve as important 
targets for intervention strategies (Augenlicht, 1997). 
During the course of neoplastic conversion, a number of oncogenes are 
expressed (Table 5). The ras gene family members were among the first oncogenes 
identified and shown to have decisive roles in cell cycle and in neoplastic development 
(Barbacid, 1987). A feature of the ras proteins is that they must be anchored in the cell 
membranes to function, which is through farnesylation of the protein i.e. the addition of 
a specific lipid moiety to the protein (Marshall, 1993). Specific inhibitors of this step as 
a means of inhibiting activity of the transforming ras protein may serve as a marker of 
the probability of tumor formation. The ras family members function in a pathway of 
signal transduction through a cascade of cytoplasmic kinases and phosphatases, 
which may also be modulated by chemopreventive agents (McCormick, 1993). Certain 
other oncogenes are also known to play a vital role in the process of tumor 
development viz. HER-2/neu, myc, fos. Various chemopreventive compounds such as 
N-(4-hydroxyphenyl) retinamide, apigenin, curcumin and limonene have been shown 
to modulate the activities of these oncogenes thereby exerting their anticarcinogenic 
effects (Parija & Das, 2003; Jinno etal, 1999; Lin etal, 1997). 
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Table 5: Functions of Representative Oncogenes and Tumor 
Suppressor Genes. 
Functions of gene product Genes 
Oncogenes 
Growth factors 
Receptor/protein tyrosine kinase 
Protein tyrosine kinase 
Mennbrane associated G proteins 
Cytoplasimic protein serine 
kinases 
Nuclear transcription factors 
Unknown, undetermined 
sis, fgf 
met, neu 
src, ret 
ras, gip-2 
raf, pim-1 
myc, fos, 
jun 
bcl-2, crk 
Tumor suppressor ( 
GTPase-activation 
Cell cycle-regulated nuclear 
transcriptional repressor 
Cell cycle-regulated nuclear 
transcriptional factor 
Zinc-finger transcriptional factors 
Mismatch DNA repair 
Zinc finger transcriptional factor 
(?) 
NF1 
RB-1 
p53 
WT-1 
hMLH1 
BRAC1 
Cell localization 
Extracellular 
Extra cell/cell membrane 
Cell membrane/ cytoplasmic 
Cell membrane/cytoplasmic 
Cytoplasmic 
Nuclear 
Mitochondrial/cytoplasmic 
jenes 
Cell membrane/cytoplasmic 
Nuclear 
Nuclear 
Nuclear 
Nuclear (?) 
Unknown 
[Sorce: Pitot & Dragan, 2001] 
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The tumor suppressor genes normally function to inhibit or "put the breal<s on" on the 
cell growth and thus controlling the cell cycle. The family of tumor suppressor genes 
(p53, rb, WT1, BRCA1, NF1 etc.) has been found to be involved in controlling 
proliferation and differentiation in cells (Table 5). In particular, their function is 
associated with control of abnormal growth in carcinogenesis. The p53 gene is one of 
the most frequently mutated sequences in human tumors (Hollstein et al, 1991). Wild 
type p53 protein monitors the integrity of the genome and functions as a cell cycle 
checkpoint at the G1-S boundary, determining that whether cells progress through the 
cell cycle and replicate or whether they enter into a pathway leading to apoptosis. This 
function can be abrogated by the mutations of the gene leading to the over-expression 
of mutated p53. One of the effectors of the p53 is the protein p21, also known as 
WAF1/CIP1, which inhibits cyclin dependent kinases (CDK). Since, WAF1/CIP1 levels 
are modulated during development and can be induced during differentiation, levels of 
expression of this gene or activity of the protein could be an important marker of 
propensity of cells to continue proliferating. 
Therefore, the knowledge about the genes that are targeted during cancer 
development and the specific mechanism(s) by which they contribute to this process, 
is essential for more effective chemoprevention. The detection of mutations or altered 
expression of these genes could help to identify individuals at increased risk of cancer. 
This may also provide specific targets for chemoprevention, as well as useful 
biomarkers that can be used as intermediate end points for assessing the efficacy of 
chemopreventive agents. 
C. Multiple Drug Resistance Reversal: Multiple drug resistance (MDR) is a 
phenomenon often exhibited by tumor cells during the course of chemotherapy and 
has been a major obstacle in cancer treatment (Gottesmann & Pastan, 1993). The 
MDR is conferred to cells by the over- expression of MDR-1 gene transcript, P-
glycoprotein (P-gp). P-gp is 170-180 kDa protein product belonging to superfamily of 
ATP-binding transporters that actively extrudes a wide range of structurally diverse 
amphipathic drugs out of the cell. These drugs mainly include anthracyclins, vinca 
alkaloids, epipodophyllotoxins, taxanes etc. (Sugawara, 1990; Ambudkar et al, 1999). 
Enhanced efflux of these compounds reduces their intracellular accumulation with 
concomitant decrease in their cytotoxicity. P-gp is found to be over-expressed in 
various human cancers and cancerous cell lines expressing MDR phenotype. The 
level of P-gp expression is correlated with the degree of resistance particularly at low 
to moderate levels of resistance (Sugawara, 1990). However, certain anticancer drug 
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such as adriamycin and some other compounds like calcium channel blockers and 
calmodulin inhibitors, have been found to reverse MDR (Robert, 1997; Tan et al, 
2000). Unfortunately, most of these compounds are not useful in clinical applications 
because of their lack of potency or unacceptable side-effects/toxicity at doses required 
for effectiveness (Ford & Halt, 1990). In a recent study conducted in our laboratory has 
shown that ISC a known cancer chemopreventive compound of dietary origin, 
effectively inhibits the vinca alkaloid induced P-gp over-expression (Arora & Shukia, 
2003a). Thus, modulation of P-gp expression by means of diet derived agents can also 
be an effective approach in cancer chemotherapy. 
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GARLIC 
History 
Interest in the potential benefits of garlic {Allium sativum) 
has origins in antiquity and is one of the earliest documented 
examples of plants used for maintenance of health and treatment 
of disease (Block, 1985; Kahn, 1996). The word gadic originates 
from the Anglo-Saxon "gar-leac" or "spear-plant" (Pickering, 1979). 
"Allium", the ancient Latin name for garlic, is derived from the 
Celtic all, signifying hot or burning. The species name "satium" 
means planted cultivated or sown (not wild). The genus "Allium" of the lily family 
(Liliaceae) include upwards of 700 species including onions, chives, shallots and 
leeks. 
The medicinal uses of garlic are known since beginning of recorded history and 
it was found in Egyptian pyramids and ancient Greek temples (Block, 1985). It was the 
first plant reported to possess anticarcinogenic properties as Egyptians used it for the 
treatment of tumors over 3500 years ago (Block, 1985; Lau et al, 1990). Garlic is 
mentioned in the Bible and has been a traditional treatment in many countries notably 
the Near East, China and India (Rivlin, 2001). In China, garlic was frequently used in 
traditional system of medicine as a combination therapy to aid respiration and 
digestion (Woodward, 1996). In India, three ancient medical traditions i.e. Tibbia, 
Unani and Ayurvedic made extensive use of gariic as a central part of wound healing 
(Moyers, 1996). The leading survival medical text, Charak-Samhita, written more than 
2000 years ago, recommends garlic for the treatment of various diseases (Woodward, 
1996). 
Gariic thus acquired a reputation in the folklore of many cultures over the 
centuries as a formidable prophylatic and therapeutic medicinal agent. Gariic has long 
been taken as a tonic, a bactericide and a popular remedy for various ailments 
(Blackwood & Fulder, 1986). Gariic was given to the original Olympic athletes in 
Greece, as perhaps one of the pioneer "performance enhancing" agents. More 
recently however, it has been recognized as a medicinal plant for the prevention of 
coronary heart diseases (Fogarty, 1993; Steiner et al, 1996; Rahman, 2001), 
immunological disorders (Jeong & Lee, 1998; Kyo et al, 2001); and cancer 
(Wargovich, 1986; Singh & Shukia, 1998 a & b, Pinto & Rivlin, 2001; Arora & Shukia, 
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2003b). Besides garlic lias also been shown to possess various pharmacological 
properties such as antioxidant (Kourounakis & Rekka, 1991); antimicrobial (O'Gara e^ 
a/, 2000; Tsao & Yin, 2001); antiallergic (Usui & Suzuki, 1996) and is also effective 
against memory loss (Moriguchi e^ a/, 1994). 
Although there is no standard intake of garlic around the world, the German 
Kommission E monograph (1988) proposed that daily intake of 1-2 cloves garlic or 4 
gms of intact garlic have health benefits for human beings. Unfortunately, this 
recommendation is not substantiated with scientific references. In many clinical 
studies, the daily dose of dehydrated garlic powder has been 900 mg/day (Amagese ef 
a/, 2001). In 1990, NCI initiated the designer food program to determine which food 
played an important role in cancer prevention and concluded that garlic may be the 
most potent food having cancer preventing properties (Caragay, 1992). 
Garlic Constituents 
Dozens of compounds have been identified from garlic and its volatile oil 
including 33 sulfur compounds, 17 amino acids, germanium, calcium, copper, iron, 
potassium, magnesium, selenium, zinc, vitamin A, B1 & C (Abdullah et al, 1988). The 
primary sulfur containing constituents in intact garlic are the 7-glutamyl-S-alk(en)yl-L-
cysteines and S-alk-(en)yl-L-cysteine sulfoxides, and alliin (Lancaster & Shaw, 1989). 
On average, a garlic bulb contains upto 0.9% y-glutamyl cysteines and upto 1.8% 
alliin, which accumulates naturally during the storage of garlic bulbs at room 
temperature. When garlic is "damaged by external factors" i.e. attacked by a microbe, 
crushed, cut or chewed or when it is dehydrated, pulverized and then exposed to 
water, the vacuolar enzyme allinase, rapidly lyses alliin to form the cytotoxic and 
odiferous alkyl alkane thiosulfinates such as allicin (Fig. 4). Allicin and other 
thiosulfinates decompose instantly to hundreds of oil soluble organosulfur compounds 
in a short period of time. These include diallyl sulfide (DAS), diallyl disulfide (DADS), 
diallyl trisulfide (DAT), diallyl tetrasulfide (DATS), methyl allyl disulfide, methyl allyl 
trisulfide, 2-vinyl-1, 3-dithiin, 3-vinyl-1, 2-dithiin (Fenwick & Hanley, 1985) and E, Z-
ajoene (Block et al, 1984) (Fig. 5). At the same time 7-glutamyl cysteines are 
converted to S-allyl cysteine (SAC), the water-soluble organosulfur via a pathway other 
than the alliin/allicin pathway (Fig. 4). However, the major health benefits of gadic are 
attributed to its organosulfur constituents, A brief review of medicinal properties of 
major organosulfur constituents of garlic are given below: 
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Allicin-. Allicin is the major thiosulfinate compound found in crushed garlic discovered 
by Cavallito & Bailey (1944). When a garlic bulb is cut or bruised, the active enzyme 
allinase converts allin (s-allyl-L-cystene sulfoxide) into allicin (diallyl thiosulfinate). It is 
a fairly unstable compound, which quickly converts into DAS, DADS, DATS and 
polysulfide compounds (Block, 1985). The total allicin yield has been determined as 
2.5mg/gm of fresh crushed garlic or about 5-20mg per clove (Guyonnet et al, 2001). 
Allicin is responsible for the characteristic odor of fresh garlic (Whitaker, 1976) and is 
considered as one of the most important biologically active compounds found in 
crushed garlic (Koch & Lawson, 1994). A number of therapeutic applications of garlic 
involve allicin and its derivatives (Augusti, 1974; Wargovich, 1987; Sparnins et al, 
1988; Prasad ef al, 1995). In Russia, allicin is famous as 'Penicillin' as it is active 
against many bacteria that are resistant to antibiotic. 
Diallyl sulfide (DADS): DADS is one of the lipid soluble organosulfur present in 
garlic and constitutes about 40% of the essential oil in garlic (Sheen et al, 1992). 
DADS has been reported to lower the levels of cholesterol (Omkumar et al, 1993). It 
has also been shown to posses antimutagenic (Guyonnet et al, 2001); antibacterial 
(O'Gara ef al, 2000; Tsao & Yin, 2001) and antineoplastic activities (Ip et al, 1992 
Dwivedi et al, 1992). Several possible mechanisms for its growth inhibitory activities 
have been reported including induction of apoptosis (Sundaram & Milner, 1996), cell 
cycle regulation (Frantz et al, 2000) and modulation of tumor suppressor and 
oncogene products (Hong etal, 2000; Singh, 2001). 
Diallyl trisulfide (DAT): DAT accounts for approximately 18% of the steam distilled 
garlic oil and shown to possess various beneficial health effects. It has been reported 
to have antimicrobial (O'Gara ef al, 2000; Tsao & Yin, 2001), antimutagenic (Marks ef 
al, 1992) and antineoplastic activities (Sparnins etal, 1988). 
Diallyl sulfide (DAS): DAS, a lipophilic thioether, is one of the organosulfur 
compound, found exclusively in garlic. The concentration of DAS in garlic has been 
reported to be about 30-100 ^ig/gms of fresh garlic (Yu ef al, 1989). DAS is known to 
possess versatile medicinal properties such as immunosuppressive (Jeong & Lee, 
1998); antihypotensive (Reuter ef al, 1996), antioxidative (Wu ef al, 2001; Fanelli ef al, 
1998), cardioprotective (Ou ef al, 2003), antihepatotoxic (Green ef al, 2003), 
antimutagenic (LeBon ef al, 1997) and antineoplastic (Singh & Shukia, 1998 a & b; 
Pinto & Rivlin, 2001) (Table 6). Much attention is focused on the investigations of DAS 
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Table 6: Beneficial Health Effects of DAS 
Effect 
Antibacterial 
Anticarcinogenic 
Antigenotoxic 
Antioxidant 
Anti-Proiiferative 
Cardioprotective 
Detoxification 
Inhibition of lipid peroxidation 
Immunomodulatory 
Modulation of lipid and lipoprotein 
metabolism 
Reference 
Tsao & Yin, 2001; 
Sivametal, 1997 
Nagabhushan et al, 1992; 
Singh & Shukia, 1998 a & b, 
Arora & Shukia, 2003b 
LeBonetal, 1997, 
Shukia et al, 2003 
Fanellietal, 1998; 
Wu et al, 2001 
Hu & Wargovich, 1989; 
Shukia et al, 2002 
Ou et al, 2003; 
Rahman, 2001 
Guyonnet et al, 1999; 
Shukia etal, 1999 
Grudzinski et al, 2001 
Jeong & Lee, 1998 
Ide & Lau, 1997, 
Ou et al, 2003 
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in the prevention of cancer (Fukusliima et al, 1997; Pinto & Rivlin, 2001; Yang et al, 
2001). 
Health Effects 
Antioxidant activities: The antioxidant agents in garlic are reported to be its sulfur 
containing compounds (Kourounakis & Rekka, 1991; Horie et al, 1992; Prasad et al, 
1995). The oral administration of DAS is reported to protect against 
pentachlorophenol-induced oxidative DNA damage (Sai-Kato et al, 1995) and to 
attenuate lipid peroxidation in mice infected with Trichinella spiralis (Grudzinski ef al, 
2001). Furthermore, garlic oil and allyl compounds have been shown to play 
differential role in the modulation of GSH-related antioxidant system in rat liver and red 
blood cells (Wu et al, 2001). DAS is reported to react with free radicals generated 
during UVC activation of hydrogen peroxide or tertbutyl hydroperoxide (Fanelli et al, 
1998). Thus, garlic has been reported to have antioxidant activities that may contribute 
to the benefits reported for its various preparations. 
Protection against coronary heart diseases: Garlic and its various extracts 
possess beneficial health effects for the prevention against a wide array of 
cardiovascular diseases (Rahman, 2001). It has been shown that garlic consumption 
lowers the lipid and serum triglyceride levels (Reuter et al, 1996). Garlic and its 
organosulfur compounds have also been shown to cause reduced blood pressure, 
increased fibrinolytic activity and inhibited blood platelet aggregation (Reuter et al, 
1996; Steiner et al, 1996). Certain organosulfur compounds, including DAS have been 
shown to be protecting low-density lipoproteins against oxidation and glycation, thus 
preventing cardiovascular diseases (Ou e^ al, 2003). Aqueous garlic extract (AGE) and 
organosulfur compounds are reported to inhibit cholesterol synthesis in human and 
animal studies (Yeh & Liu, 2001). AGE is reported to inhibit lipid peroxidation and 
oxidative modification of low-density lipoproteins (Ide & Lau, 1997) and reduction in 
serum cholesterol and other lipids leading to the prevention of heart diseases and 
stroke (Steiner ef al, 1996). Bordia et al, (1996) reported that long-term administration 
of garlic led to the inhibition of platelet aggregation in healthy subjects and patients 
with coronary artery disease. 
Antimicrobial activity: Even before the era of sulfonamides and modern antibiotics, 
garlic preparations were used in epidemics of typhus, paratyphus, cholera, dysentery, 
amoebic dysentery, diptheria, tuberculosis, influenza and poliomyelitis (Reuter et al. 
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1996). In vitro, garlic extracts were found to be effective against a broad spectrum of 
Gram-negative and Gram-positive bacteria (Fenwick & Hanley, 1985). Tlie 
antibacterial activity of garlic extract, DAS and DADS are well documented in the 
literature. The inhibitory effects of garlic extract, DAS, DADS, DAT and DATS have 
been observed against Helicobacter pyroli and Psuedomonas aerugenosa, (Sivam et 
al 1997; O'Gara etal, 2000; Tsao & Yin, 2001). 
Antimutagenic Activities: The antimutagenic potential of garlic along with its 
organosulfur compounds are well documented in cell lines, bacterial and rodent 
models (Knasmuller et al, 1998; Guyonnet et al, 2001; Shukia & Taneja, 2001, 2002). 
DAS, DADS, DPS and DPDS have also been shown to reduce mutagenicity of styrene 
oxide and 4-nitroquinoline,1-oxide in Ames test (Guyonnet et al, 2001). Allium 
derivatives are reported to inhibit mutagenic potential of various xenobiotics in 
Salmonella typhimurium (Ikken et al, 1999) and E. Co// assay (Ishikawa et al, 1996; 
Kumar & Berwal, 1998). Dion et al, (1997) reported that both water soluble SAC and 
lipid soluble DADS retarded the mutagenicity of nitrosomorpholine in Salmonella 
typhimurium tester strain TA100. DADS is reported to decrease the formation of 
micronuclei or DNA breaks induced by BaP in HepG2 cells (Knasmuller et al, 1998) 
and a mixture of DAS, DADS & DAT inhibited micronuclei formation induced by BaP in 
mouse bone marrow cells (Marks et al, 1992). Pretreatment of DAS is also shown to 
reduce N-methyl-nitro-N-nitrosoguanidine (MNNG) induced nuclear aberrations in 
Wistar rats (Hu & Wargovich, 1989). Work from our laboratory also shown the 
antimutagenic potential of aqueous garlic extract against cyclophosphamide induced 
all types of chromosomal aberrations i.e breaks, fragments, exchanges and multiples 
in Swiss mice (Shukia & Taneja, 2002). 
Anticarcinogenic Activities: Garlic and its organosulfur compounds are reported 
to inhibit proliferation and promotion of a variety of tumors (Fukushima et al, 1997; 
Pinto & Rivlin, 2001). Studies have demonstrated that garlic constituents inhibit the 
growth of transplantable tumors and have antipromotional activity against a number of 
tumor cell lines (Sundaram & Milner, 1996; Sakamoto et al, 1997; Shukia et al, 2002). 
Animal studies provide compelling evidence that garlic and its associated sulfur 
compounds are potential antitumorigenic agents capable of reducing experimentally 
induced colon, esophageal, pulmonary, skin, forestomach and breast cancers 
(Hussain etal, 1990; Sumiyoshi & Wargovich, 1990; Ip etal, 1992; Amagese & Milner, 
1993; Shukia et al, 1999; Singh & Shukia, 1998 a & b; Song & Milner, 1999). The allyl 
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sulfur compounds present in garlic account for much of its anticancer effect, and these 
have been shown to be effective both in the initiation and promotion phases of the 
carcinogenic process (Belman, 1983). DAS inhibits the development of colon 
carcinomas, skin, esophagus carcinomas, pulmonary adenomas and forestomach 
tumors in rodents when administered before carcinogen exposure (Wargovich, 1987; 
Sparnins et al, 1988; Wattenberg et al, 1989; Wargovich et al, 1992, Singh & Shukia 
1998 a & b). In addition, it has been found to inhibit hepatocarcinogenesis and skin 
tumors when administered after the initiating procedure (Wattenberg et al, 1989, Singh 
& Shukia, 1998 a &b). 
A number of in vitro studies have also demonstrated the inhibitory effects of 
organosulfides on the growth of human tumor cell lines HT-29, HCT-15 (colon), SK 
MEL-2 (skin), A549 (lung), HepG2 (hepatic) and LNCaP (prostrate) (Sundaram & 
Milner, 1996; Pinto et al, 1997; Sakamoto et al, 1997; Hirsch et al, 2000; Iciek et al, 
2001). Garlic extract significantly inhibit the anchorage independent growth of MCF-7 
cell line (Li et al, 1995). DAS, DADS and garlic extracts were effective in reducing 
antiproliferative genes in non-small cell lung cancer cells and modulate the apoptosis 
associated cellular proteins (Hong et al, 2000). 
Epidemiological studies have revealed an inverse relationship between garlic 
consumption and the incidence of certain forms of cancer including stomach, colon, 
esophageal and laryngeal cancers (Buiatti et al, 1989; Hu et al, 1991, 1994; Zheng et 
al, 1992; Gao et al, 1994; Steinmetz et al, 1994). A study conducted in China, involving 
564 patients with stomach cancer and 1131 controls with a high incidence of gastric 
cancer revealed a significant reduction in gastric cancer risk due to increased 
consumption of Allium vegetables (You et al, 1988, 1989). A similar protective effect 
against the incidence of colorectal cancer has been established in Japanese 
population in Hawaii (Haenszel et al, 1972). A lower risk of colon cancer for American 
consumers of garlic was reported in the Iowa women's Health Study (Steinmetz et al, 
1994). The only known study in which garlic has been used to treat patients with 
advanced stages of cancer was conducted by Spivak (1962) where he showed that 
garlic juice preparation administrated in doses of 0.2-2ml intravenously or 1-5ml 
intramuscularly daily for 3-7 days to patients with cancer at various sites, showed 
positive treatment results of differing degrees. There is a single case report, of a man 
whose pituitary tumor shrank by 50% during the 5 months in which he ate 5-7gms 
fresh garlic daily (Rainov & Burkert, 1993). Although the minimum daily intake required 
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for reducing cancev risk remains to be determined, garlic had been categorized as a 
dietary anticarcinogen (Lau etal, 1990) 
Mechanism of action 
A host of studies provides compelling evidence that garlic and its organic allyl 
sulfur components are effective inhibitors of the cancer process. These studies reveal 
that the benefits of garlic are not limited to a specific species, to a particular tissue or 
to a specific carcinogen (Table 7). Several mechanisms are likely to account for this 
protection including blockage of N-nitroso compounds formation, suppression in the 
bioactivation of several carcinogens, modulation of the antioxidant and/or drug 
metabolizing enzyme systems, enhanced DNA repair, reduced cell proliferation, 
induction of apoptosis and/or involvement of oncogene and tumor suppressor genes. It 
is likely that several of these cellular events are occurring simultaneously and account 
for the widespread protection that is observed experimentally after supplementation of 
gariic or its constituents. 
Cytochrome P4502E1 (CYP2E1) is reported to be vulnerable to the effects of 
allyl sulfur compounds as it plays a key role in the metabolism of chemical carcinogens 
by catalyzing either detoxication reactions or chemical activation resulting in the 
formation of toxic metabolites (Chen etal, 1994; Jeong & Lee, 1998; Yang etal, 2001). 
An autocatalytic destruction of CYP2E1 has been reported which accounts for the 
chemoprotective effects of DAS and other allyl sulfur compounds against carcinogens 
(Jin & Baillie, 1997). A number of studies showed that DAS and DADS were quite 
effective in modulating phase I and phase II metabolizing enzymes (Reicks & 
Crankshaw, 1996; Jeong & Lee, 1998; Singh ef a/, 1998) and also showed the 
antioxidant activity (Dwivedi et al, 1998; Chen et al, 1999). Jeong & Lee (1998) 
reported that the protective effects of DAS against N-nitrosodimethyl amine (NDMA)-
induced immunotoxicity might be due to its ability to block bioactivation of NDMA 
mainly by the inhibition of CYP2E1. DAS is also reported to inhibit the bioactivation of 
carcinogenic arylamines in human and rat liver microsomes to produce a 
chemoprotective effect (Mammons ef al, 1999). Gariic compounds can also act by 
blocking DNA alkylation, a primary step in nitrosamine carcinogenesis (Hong et al, 
1992; Lin ef a/, 1994). 
Phase II enzymes are involved in detoxication pathways by catalyzing the 
elimination of reactive intermediates of xenobiotices, therefore, induction of phase II 
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Table 7: Modulatory Effects of Garlic and other Allyl sulfur compounds on 
Chemical Carcinogens 
Carcinogen 
1,2-Dimethylhydrazine 
3-Methylcholanthrene 
4-(Methylnitrosamino)-1 -(3-
pyridyl)-1-butanone 
7,12Dimethylbenzanthracene 
Aflatoxin B1 
Benzo(a)pyrene 
Methylnitronitrosoguanidine 
N-Nitrosodiethylamine 
N-Nitrosodimethylamine 
N-Nitrosomethylbenzylamine 
Vinyl Carbamate 
N-methyl-N-nitrosourea 
Site 
Colon 
Cervix 
Lung 
Nasal 
Mammary 
Skin 
Forestomach 
Buccal pouch 
Liver 
Forestomach 
Lung 
Skin 
Gastric 
Colon 
Nasal 
Liver 
Nasal 
Skin 
Esophagus 
Skin 
Mammary 
Host 
Rat 
Mouse 
Mouse 
Rat 
Rat 
Mouse 
Hamster 
Hamster 
Rat 
Mouse 
Mouse 
Mouse 
Rat 
Rat 
Rat 
Rat 
Rat 
Mouse 
Rat 
Mouse 
Rat 
References 
Wargovich, 1987; 
Sumiyoshi & Wargovich, 1990 
Hussain et al, 1990 
Hongetal, 1992 
Hongetal, 1991 
Liuetal, 1992; 
Song & Milner, 1999 
Singh & Shukia, 1998 a& b 
Nagabhushan et al, 1992 
Nagabhushan et al, 1992; 
Balasenthil et al, 1999 
Haber-Mignard et al, 1996 
Sparnins et al, 1988 
Sparnins et al, 1988 
Singh & Shukia, 1998b 
Hu & Wargovich, 1989 
Linetal, 1994 
Linetal, 1994 
Haber-Mignard et al, 1996 
Linetal, 1994 
Surh et al, 1995 
Wargovich et al, 1988 
Surhetal, 1995 
Schaffer et al, 1996 
[Adapted from: Milner, 2001] 
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enzymes is considered as a major mechanism of protection against genotoxic insult 
(Talalay et al, 1995; Will<inson & Clapper, 1997). The ability of certain compounds to 
induce phase II enzymes have been used to predict their chemopreventive potency 
(Prochaska et al, 1992; Egner et al, 1994). A number of studies have shown that 
organosulfur compounds strongly induce glutathione-S-transferase (GST) activity in 
different organs of rats and mice, thus reducing the chances of genotoxicity (Reddy et 
al, 1993; Siess et al, 1997; Guyonnet et al, 1999; Munday & Munday, 1999). These 
compounds also influence the expression of other phase II enzymes such as epoxide 
hydrolase (EH), quinone reductase (QR) and UDP-glucuronsyltransferase (UGT) 
(Siess etal, 1997; Singh etal, 1998; Guyonnet etal, 1999; Munday & Munday, 1999). 
The epigenetic changes are also found to related to inhibition of cancer 
progression after treatment with allyl sulfur compounds. Two extensively studied 
mechanisms for epigenetic gene regulation are patterns of DNA methylation and 
histone acetylation/ deacetylations. Several studies indicate that DNA 
hypermethylation is an important factor involved in the activity of key regulatory genes 
(Esteller, 2003 a & b; Gonzalez-Gomez ef al, 2003). DNA methylation and histone 
acetylation can be modified by enhanced intake of garlic and/or related allyl sulfur 
compounds. In another study Leudeke ef al, (1992) reported that DAS inhibited the 
formation of 0^-methyldeoxy guanosine in esophagus (26%), nasal mucosa (51%), 
trachea (68%) and lung (78%) induced by N-nitrosomethyl benzylamine. Similarly, Lin 
et al (1994) and Schaffer et al (1996) provide evidences that DAD, SAC and 
deodorized garlic are effective in retarding the DNA methylation caused by N-methyl-
N-nitrosourea. 
The mechanism of action of garlic and its derivatives at the molecular level is 
not yet well understood. However, some studies have shown that allicin, DAS, DADS 
and DAT, possess inhibitory effects on the proliferation of tumor cells associated with 
induction of apoptosis and cell cycle regulation (Sakamato et al, 1997; Zheng et al, 
1997; Frantz et al, 2000; Hong ef al, 2000). DAS, DADS and garlic extract were 
shown to be effective in reducing the expression of anti-apoptotic genes like Bcl-2 and 
the induction of pro-apoptotic genes like Bax and the tumor suppressor gene p53 in 
non-small ceil lung cancer cell lines. Bottone ef al (2002) have shown that DADS 
induced apoptosis and non-steroidal anti-inflammatory drug (NSAID) activated gene, 
NAG-1 protein expression occur via p53 dependent mechanisms in human colorectal 
HCT 116 cells. Allyl sulfides are also recognized for their ability to suppress cell 
proliferation by blocking cells in G2/M phase corresponding with depressed p34cdc2 
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kinase activity, increased histone acetylation, increased intracellular calcium and 
elevated peroxide production (Knowles & Milner, 2000). DADS has also been shov/n to 
inhibit the growth of H-ras oncogene transformed tumors in nude mice by inhibiting 
membrane association of tumoral p21'^^ (Singh, 2001; Singh etal, 1996). 
Thus, the pharmacological roles of ally! sulfides in prevention and treatment of 
cancer have been well documented in literature but molecular mechanism of action of 
allyl sulfide compounds especially DAS is not well defined. Therefore, in the present 
study attempts are being made to provide insight into the molecular mechanism of 
DAS induced tumor suppression. The effect of DAS on biomarkers of cancer 
chemoprevention (apoptosis, oncogenic expression and tumor suppression gene) as 
intermediate end points, is evaluated in the present dissertation. Attempts are also 
being made to evaluate the potential of DAS in reversing multiple drug resistance for 
its use in chemoprophylactic studies. 
There are many biological plausible reasons, which showed that plant food 
could prevent/delay the appearance of many diseases including cancer. These include 
carotenoids, vitamin C, vitamin E, selenium, dietary fibres and their components 
dithiolthiones, isothiocyanates, indoles, allium compounds, plant steroids and 
limonene. Among these garlic has been reported to possess therapeutic properties 
from centuries and is probably the most widely studied medicinal plant (Agarwal, 
1996). Apart from other beneficial health effects, garlic has been reported to have anti-
tumorigenic activities in a number of tissues including those of breast and skin (Milner, 
1996; Singh & Shukia, 1998 a & b; Wargovich etal, 1992). Although its mechanism of 
action is still not clear but garlic contains a number of organosulfur compounds such 
as SAC, S-allyl mercaptocysteine, allicin, ajoene, DAS and other structurally related 
compounds, which are widely believed to be active agents in preventing cancer 
(Agarwal, 1996). 
Future Prospects of Chemoprevention 
Since the success in treating cancer by chemotherapy, surgery or radiotherapy 
is still not up to the expectations, therefore, rendering chemoprevention is an important 
and promising alternative strategy in the management of the disease. Epidemiological 
studies suggest that, in terms of reducing cancer burden, enormous benefit might be 
derived from dietary manipulation or supplementation. The role of dietary constituents 
in terms of chemoprevention still needs to be defined at a much greater depth because 
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of their no toxicity, bio-availability and synergistlc/antagonistic effects. A more detailed 
understanding of the carcinogenic process, and the way in which chemopreventive 
agents inhibit it, is vital as this would result in the design of more effective intervention 
protocols. Furthermore, the combination of dietary chemopreventive agents can 
effectively enhances the potential use of phytochemicals. The characterization of the 
chemopreventive activity of food constituents and related compounds will ultimately 
help formulate dietary advice for the general population and/or prophylactic drug 
strategies for individuals at particular risk of developing cancer. Such research has the 
potential to improve, in a fundamental way in reducing the global cancer burden. 
In the view of these perspectives, the present study was designed and 
executed to elucidate the cancer chemopreventive properties and the mechanism of 
inhibition of DAS, an organosulfur compound from garlic with the following objectives: 
I. To study the mechanism of cancer chemopreventive properties of DAS by 
using apoptosis as a biomarker. 
II. To study the role of DAS on H-ras oncogene in DMBA induced mouse skin 
carcinogenesis and its modulatory effect on oncoprotein p27//'asexpression. 
III. To study the effects of DAS on expression levels of wild type and mutant tumor 
suppressor gene product (p53) in mouse skin tumors. 
IV. To study the multidrug reversing potential of DAS in both in vitro and in vivo 
model systems through modulation of P-gp expression. 
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Introduction 
The use of alternatives to the medicines in the form of food and food 
products is an effective approach for the treatment of chronic diseases, including 
cancer. Thus, the intervention of chemopreventive strategies for controlling genetic 
diseases using dietary constituents provides a strong rationale to arrest or reverse the 
process of carcinogenesis before invasion and metastasis occur. During the past few 
years, cancer chemoprevention by dietary constituents has received a great deal of 
attention as a means of effective cancer control (Pezzuto, 1996; Martinez & 
Giovanucci, 1997; Kelloff et al, 1999). Studies on the tumor inhibitory compounds of 
plant origin have yielded an impressive array of novel structures. Besides, 
epidemiological studies suggest that consumption of diets containing fruits and 
vegetables may reduce the risk of developing cancer (El-Bayoumy et al, 1997; Reddy 
et al, 1997; Gescher et al, 1998). A number of dietary agents are also known to 
possess the anticancer properties in cancer cell lines and rodent bioassays at various 
sites including breast, prostate, colon and lung (Pezzuto, 1996; El-Bayoumy et al, 
1997; Wargovich, 1997; Gescher et al, 1998; Greenwald et al, 2001). These include 
green and black tea polyphenols, ISC, sulforaphane, vitamin D, vitamin E, selenium 
and calcium (Kelloff et al, 1999). 
In the recent past, a great deal of attention has been devoted to organosulfur 
compounds from garlic with potential chemopreventive properties (Fukushima et al, 
1997; Pinto & Rivlin, 2001). One that has received considerable emphasis is DAS, a 
sulfur containing volatile compound in garlic {Allium sativum). Laboratory investigations 
provide sufficient evidence that it reduces the incidence of a multitude of chemically 
induced lung, skin, colon, esophageal and forestomach neoplasia (Wargovich et al, 
1992; Hu et al, 1996a; Singh & Shukia, 1998 a & b; Yang et al, 2001). It has also been 
shown to inhibit aflatoxin B1 and NOMA induced liver preneoplastic foci in rats (Haber-
Mignard et al, 1996). Several in vitro studies have also demonstrated its inhibitory 
effects on the tumor cells (Hageman et al, 1997; Hong et al, 2000). One of the 
classical models for evaluating the carcinogenic and anticarcinogenic potential of 
various test chemicals is the mouse skin model of carcinogenesis (Shukia et al, 1992; 
Slaga et al, 1995; Singh & Shukia, 1998 a & b; Marks & Furstenberger, 2000). The 
topical application of DAS has been reported to inhibit the development of tumors in 
both complete and two-stage model of mouse skin carcinogenesis by our laboratory 
(Singh & Shukia, 1998 a & b). DAS has also shown to possess antiproliferative effects 
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on the growth of transplantable Ehrlich ascetic tumor cells and inhibit angiogenesis in 
Swiss albino mice (Shukia et al, 2002). The possible mechanism for the antineoplastic 
activity of DAS has been suggested to be due to its antioxidant properties, capability of 
modulating several phase I and phase II enzymes and its antimutagenic potential 
(Guyonnet et al. 1999; Smith & Yang, 2000; Yang et al, 2001; Shukia et al, 2003). But 
thorough investigations into the molecular mechanisms of action of diallyl sulfide are 
still required. Several possible mechanisms are being explored by researchers to 
understand the mechanism of cancer preventive potential of DAS. 
Apoptosis has been characterized as a fundamental cellular activity occurring 
under a wide variety of physiological and pathological conditions (Steller, 1995). The 
term "apoptosis" is a Greek word meaning "falling of leaves" and was originally defined 
to include certain morphological characteristics, including membrane blebbing, nuclear 
and cytoplasmic shrinkage and chromatin condensation. This event was first observed 
in a nematode larvae Caenorhabditis elegans, where this hermaphrodite worm 
undergoes this event during late embryogenesis in which normal cells apparently 
undergo apoptosis (Vaux et al, 1994). Apoptosis is also reported to play a key role in 
maintaining homeostasis in multicellular organism (Kerr et al, 1972). The outstanding 
feature of apoptosis is its remarkable stereotyped morphology showing condensation 
of nuclear heterochromatin, cell shrinkage and loss of positional organization of 
organelles in the cytoplasm (Kerr et al, 1972; Wyllie et al, 1980). It plays an essential 
role as a protective mechanism against neoplastic development by eliminating 
unwanted (genetically damaged cells or excess) cells that have been improperly 
induced to divide by a mitotic stimulus (Schwartzman & Cilowski, 1993; Thompson, 
1995). It has been observed that the inherent capacity of the tumor cells to respond to 
apoptosis correlates with the expression of several oncogenes or tumor suppressor 
genes such as bcl-2, c-myc, ras or p53 and may be prognostic of the treatment 
(Compton, 1992; Wyllie, 1992; Schwaetzman & Cidlowski, 1993). The p53 gene, which 
is strongly implicated in animal and human carcinogenesis, is a significant regulator of 
the process of apoptosis (Stoner et al, 1997). While apoptotic pathway is related to 
induction of p53, this pathway is held in check by the anti-apoptotic gene bcl-2 (Reed, 
1994). Apoptotic cell death can be distinguished from necrotic cell death (Table 8). In 
apoptosis damaged or abnormal cells appear to initiate their own program of death 
through the activation of endogenous proteases (Thornberry, 1997). This results to 
disruption in cytoskeleton structure, cell shrinkage and membrane blebbing. 
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Table 8: Morphological and Biochemical Characteristics of Apoptosis and 
Necrosis 
Nuclei 
Cytoplasmic 
organelles 
Cell membrane 
Cell volume 
In tissues 
Tissue response 
Nuclear DNA 
damage 
Nuclear gene 
expression 
Mitochondrial DNA 
damage 
Enzyme activation 
DNases 
Proteases 
Transglutaminase 
Membrane 
function 
Cell internal milieu 
pH 
Ca'* 
Na*/lC pump 
Morphological Differences 
Apoptosis 
Pyknosis and 
karyorrhexis 
(dense 
condensation of 
chromatin) 
Intact 
Apoptotic bodies 
blebbing 
Cells shrink 
Single cells 
affected 
No response 
Biochemica 
Nucleosomal 
and/or 50-300 kb 
fragments: ladders 
on agarose gels 
Usually needed 
Spared 
Necessary 
Necessary 
Frequent 
Intact 
Slightly acidic (pH 
6.4) 
Often increases 
May be intact 
Necrosis 
Karyolysis, 
preceded by 
irregular chromatin 
clumping 
Disrupted 
Blebbing and loss 
of integrity 
Cells swell 
Usually group of 
cells affected 
Inflammation 
Differences 
Random: smears 
on gels 
Not needed 
Occurs early 
Not necessary 
Loss of function 
Acidic 
Always increases 
Defective 
Similarities or 
confounding 
variables 
Damage occurs 
in both 
Secondary 
damage in 
apoptosis 
Changes in 
both events 
There may be 
no detectable 
changes 
In epithelia, 
superficial cells 
are apoptotic 
and in groups 
-
Similarities or 
confounding 
variables 
Takes place in 
both but more 
in apoptosis 
Not needed in 
cells "primed for 
apoptosis" 
-
Lysosomal 
DNase and 
proteases are 
activated in 
necrosis 
-
Both acidic 
Seen in both 
(Source: Ramachandra & Studzinski, 1995) 
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Apoptosis also involves certain characteristic changes within the nucleus, 
which shows a characteristic laddering pattern of ollgonucleosomal fragnnents. This 
results from inter-nucleosomal chromatin cleavage by endogenous endonucleases in 
multiples of 180 base pairs (Telford et al, 1991). This fragmentation is regarded as the 
hallmark of apoptosis. In cells undergoing apoptosis there is activation of a family of 
proteases called 'caspases', so named because they have an obligatory cystiene 
residue within the active site and cleave peptides adjacent to an aspartic acid residue 
(Thornberry, 1997). Activation of caspases appears to be directly responsible for many 
of the molecular and structural changes in apoptosis. The major biochemical and 
functional changes are shown in Fig. 6. Growing evidence from both in vitro and in vivo 
studies demonstrates that suppression of apoptosis is involved in tumor promotion by 
chemical agents (Taraphdar et al, 2001). Therefore, inhibition of apoptosis is one 
mechanism of tumor formation and many chemopreventive agents are known to act 
through the induction of apoptosis (Bursch et al, 1992; Lowe & Lin, 2000). Induction of 
apoptosis is, therefore being appreciated as an ideal way for the elimination of cancer 
cells and apoptosis inducing agents are being viewed as potential agents for the 
chemoprevention and for treatment of cancer (Taraphdar et al, 2001). 
A number of naturally occurring compounds have been shown to possess 
inhibitory effects on the proliferation of tumor cells associated with induction of 
apoptosis (Katdare et al, 1998; Yang et al, 1998; Taraphdar et al, 2001). Certain 
phytochemicals are known to induce apoptosis in neoplastic cells but not in normal 
cells (Chiano et al, 1995; Hirano et al, 1995; Jiang et al, 1996a) (Table 9). It has 
become increasingly clear that apoptosis is an important mode of action for many 
antitumor agents including ionizing radiation (Radford et al, 1994), alkylating agents 
such as cisplatin and 1,3-bis (2-chloroethly)-1-nitrosourea (D'Amino & Mckenna, 
1994), cytokine tumor necrosis factor (TNF) (Shih & Stuntman, 1996) and taxol (Gibb 
et al, 1997). Besides, ISC, curcumin, tea polyphenols and soy isoflavone genistin 
inhibits the aberrant proliferation by the regulation of cell cycle blockage and induction 
of apoptosis (Katdare et al, 1998; Yang et al, 1998; Khar et al, 1999). Gallic acid 
selectively induces cell death in various transformed cell lines such as PLC/PRF/5 
(human hepatoma), HL-60 RG (human promyelocytic leukemia), P388 D1 (mouse 
lymphoid neoplasma), HeLa (human epithelial carcinoma) and dRLh-84 (rat 
hepatoma) (Inone et al, 1994). Curcumin, the major pigment in turmeric induces 
apoptosis in transformed rodent and human cells in culture (Jiang et al, 1996 a & b; 
Samaha et al, 1997). Resveratrol, a phytoalexin present in grapes and other food 
products, induces apoptosis in both solid and transplantable cancer cells by triggering 
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Table 9: Phytochemicals Capable of Inducing Apoptosis 
Agent 
Gallic acid, 
Caffeic acid, 
Tannic acid. 
Curcumin, 
Resveratoi, 
Capsaicin 
Genistein, 
Genistin, 
Daidzein, 
Biochanin A, 
Quercetin, 
Apigenin, 
Kaempferol 
Tea Polyphenols: 
(-)Epigallocatechin 
gallate, 
(-)-Epicatechin 
gallate. 
(-)-Epigallocatechin, 
(-)-Epicatechin 
Theaflavin 
Cell Line 
Myelogenous Leukemia 
(HL-60, ML-1,U-937, 
THP-1) 
Promyelocytic Leukemia 
(HL-60),Prostrate Cancer 
(PCa, LNCGP, PC-3, 
DO-145), Lung Cancer 
(H-460), Bladder Cancer 
(HT-1376, UM-UC-3,RT-
4,J-82,TCCSUP),Hepato-
cellularCarcinoma (HCC), 
Colon Cancer (Caco-2, 
HT-29) 
Lung Cancer (PC-9), 
Lymphoid Leukemia 
(M0LT-4B), Stomach 
cancer (KATO 111) 
Parameters 
Cytotoxicity, 
DNA 
fragmentation. 
Morphological 
characteristics 
Cytotoxicity, 
Cell cycle arrest, 
Morphological 
characteristics 
Cytotoxicity, 
DNA Synthesis, 
DNA 
fragmentation 
References 
Inoueetal, 1994; 
Sakagami et al, 1995; 
Jiang etal, 1996a; 
Wolvetang et al, 1996; 
Samahaetal, 1997; 
Clement etal, 1998; 
Surhetal, 1998, 1999; 
Huang etal, 1999. 
Gorezycg et al, 1993; 
Kuo, 1996; 
Davis et al, 1998; 
Wang et al, 1999; 
Zhou etal, 1999 
Ahmad et al, 1997; 
Okabe et al, 1997; 
Hibasami et al, 1998; 
Yang et al, 1998. 
(Source: Taraphdar et al, 2001) 
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the CD95 signaling system (Clement et a/, 1998), and decrease in bcl-2 expression 
(Surh et al, 1999). Zhou et al (1998) reported that pure soy isoflavones such as 
genistein, daidzein and biochanin A, exhibited dose-dependent growth inhibition of 
murine and human bladder cancer cell lines through the induction of apoptosis. Oral 
administration of black tea is reported to inhibit proliferation and enhances apoptosis in 
both non-malignant and malignant epidermal tumors in two-stage mouse skin model of 
carcinogenesis (Lu e^ al, 1997). Black tea inhibited DNA synthesis and enhanced 
apoptosis of non-malignant as well as malignant tumor cells (Conney et al, 1999). Tea 
polyphenols, EGCG and ECG inhibits the growth of human lung cancer line PC-9 by 
inducing DNA fragmentation and reducing TNF-a level (Okabe ef al, 1997; Suganuma 
efa/, 1996, 1999). 
Studies on the apoptosis inducing potential of allium derivatives have shown 
that allicin, an organosulfide from garlic possess inhibitory effects on the proliferation 
of tumor cells associated with induction of apoptosis (Zheng et al, 1997). Other 
organosulfides from garlic, such as DADS, DAT, suppress the in vitro proliferation of 
human A549 lung tumor cells through apoptosis (Sakamato et al, 1997). Hong e^ al 
(2000) showed that DAS, DADS and garlic extract are effective in reducing the 
expression of anti-apoptotic genes (such as bcl-2) and the induction of pro-apoptotic 
genes (such as bax) and the tumor suppressor gene p53 in non-small cell lung cancer 
cell lines, suggesting that modulation of apoptosis associated cellular proteins may be 
the mechanism for apoptosis. However, not much information is available regarding 
the anti-proliferative activities of DAS via induction of apoptosis in solid tumors. 
Therefore, in present study, we investigated the antitumorigenic potential of DAS in 
mouse skin model of carcinogenesis and its mechanism of tumor suppression using 
apoptosis as a biomarker. The apoptosis inducing potential of DAS was investigated 
using multifacet approaches i.e. flow cytometry, terminal deoxynucleotidyl transferase 
mediated dUTP nick end labeling (TUNEL) assay and formation of DNA ladder on 
agarose gels, a hallmark of apoptosis. 
Material and Methods 
Materials: 7,12-Dimethyl benzanthracene (DMBA), Propidium Iodide (PI), Ethidium 
Bromide and Diallyl Sulfide were purchased from Sigma (St Louis, USA). Apoptosis 
detection kit. Fluorescein was obtained from Promega. Medicons and Filcons were 
purchased from Beckton Dickinson, U.S.A. Rests of the chemicals used in the study 
were of analytical grade purity and were procured locally. 
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Animals: Swiss albino mice, male {Mus musculus L.) (body weight 10-12 gm) (Fig. 
7a) were obtained from ITRC animal colony. Animals were kept for a quarantine period 
of one week under controlled temperature (22+2 °C) and humidity (55+5%) with 12 h 
light /dark cycle. Animals were fed a synthetic solid pellet diet (Ms Ashirwad Limited, 
Chandiagarh, India Ltd.) containing all essential nutrients and water ad libitum. 
Animal Bioassay: Mouse skin tumors were induced with DMBA as a complete 
carcinogen. For the induction of tumors, dorsal skin hair were clipped on the 
interscapular region over a 2cm^ area (Fig. 7b) using electric clippers (Oster, USA) 
which were not lubricated with any oil or grease during the course of experiment. Only 
those animals which were found in the resting phase (telogen) of hair cycle initially 
were selected for the study. The animals were divided into five groups, comprising of 
25 animals each. All the treatments were given topically on shaved dorsal skin as per 
dose and schedule given below: 
Gr. I (Untreated) No Treatment 
Gr.ll (ACE+DMBA) iOOfil Acetone applied topically followed 1 hr. 
later by 5 [ig DMBA/animal in 100 i^l acetone, 3 
times/wk for 28 wks. 
Gr.lll (DAS+DMBA) 10 mg/kg b.wt. DAS applied topically in 100 ^1 
acetone followed 1 hr. later by 5 ng DMBA/animal 
in 100 |iil acetone, 3 times/wk for 28 wks. 
Gr.lV. (DMBA+DAS) 5 [ig DMBA/animal applied topically in 100 |ul 
acetone followed 1 hr. later by 10 mg/kg b.wt. 
DAS in 100 \x\ acetone, 3 times/wk for 28 wks 
Gr.V (ACE+DAS) 100|il Acetone applied topically followed 1 hr. 
later by 10 mg/kg b.wt. DAS in 100 |il acetone, 3 
times/wk for 28 wks 
Animals from all the groups were examined every week for fross 
morphological changes including body weight changes and development of tumors 
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a 
Figure 7: Swiss Albino Mice, a) Normal mouse; b) Normal mouse with 
shaved dorsal skin (Treatment site). 
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locally on the skin during the entire study period. At the end of the study period i.e. 28 
weeks all the surviving animals were sacrificed to check the development of tumors in 
the internal organs, if any. Skin from the painted area (with or without tumors) was 
excised and a part was fixed in 10% buffered formaline for 72 hrs. The formaline fixed 
tissue samples were dehydrated in ascending grades of ethanol (50%, 70%, 90% and 
100%), cleared in xylene and embedded in paraffin. Tissue sections (5|a) were cut 
using microtome (American Opticals, U.S.A.), stained with haematoxylin and eosin and 
examined under the microscope (Leica, Germany). Histopathological classification of 
skin tumors was ascertained as described by Bogovaski (1979). Part of the skin was 
snap frozen in liquid nitrogen and stored at -80°C in ultra deep freezer (Revco, USA) 
until required for flow cytometric analysis and genomic DNA isolation. 
Flow Cytometric Analysis: The dorsal skin with or without tumors was washed in 
chilled phosphate buffered saline (PBS) and immediately transferred to ice. The fat 
layer of the skin was removed with the help of sterilized scalpel blade. The skin with or 
without tumors was chopped finely with the help of scissors and their single cell 
suspensions were prepared in sterilized Medicons (50 ^m) by using Medimachine 
(Becton Dickinson, U.S.A) and were filtered through Filcons (30 ^m). For flow 
cytometric studies, about 1x 10^ cells in approximately 1ml of suspension were 
pelleted (Ormerod et al, 1992), resuspended in 1ml PBS and fixed in 2ml 70% ice-cold 
ethanol. Cells were centrifuged (M B Cooling centrifuge, India) at 5000 rpm for 10 min 
from the fixative and treated with Triton X-100 (0.2%) for 5 min. After incubation, cells 
were again centrifuged, resuspended in 1ml PBS, 100 j^g/ml RNAse was added and 
incubated at 37°C for SOmin. After further centrifugation, cells were resuspended in 
1ml PBS and 50 iig/ml PI and incubated for 18 hrs. at 4°C. The data was acquired on 
Flow Cell Cytometer (BD-LSR, Becton Dickinson, USA) using Cell Quest and analyzed 
by Mod Fit LT 2.0 software. 
DNA fragmentation assay: Genomic DNA was isolated from frozen skin/tumor 
tissue as per the method of Meniaitis et al (1989) with minor modifications (Ormerod 
et al, 1992). In brief, single cell suspensions of skin/tumor tissues were prepared 
individually and centrifuged (M.B. Cooling, India) at 10,000 g for 20 min at 4°C. The 
pellets so obtained were incubated for 30 min in lysis buffer (10 mM Tris-HCI, 10 mM 
EDTA and 4 M NaCI). RNA was digested with 2 pg/ml RNAse. Proteinase K was 
added in the medium to give the final concentration of 100 |jg/ml and mixtures were 
incubated overnight at 37°C. After incubation, DNA was extracted with an equal 
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volume of equilibrated plienol. The two layers, aqueous and phenolic, were then mixed 
by inverting the tube gently to avoid shearing of the genomic DNA. After properly 
mixing the two layers for about 10 min, these layers were separated by centrifugation 
at 5000 rpm for 10 min at 4°C. The aqueous layer was then transferred carefully to a 
fresh tube and then equal volumes of Sevag Mixture (Phenol:Chloroform:lsoamyl 
Alcohol,25:24:1(v/v)) was added and was again mixed gently and centrifuged. The 
aqueous layer was again transferred to a fresh tube and equal volumes of chloroform: 
isoamyl alcohol (24:1) was added, mixed and centrifuged. Aqueous layer was taken 
into a fresh tube and chilled ethanol (100%) was added in 2:1 ratio. The salt 
concentration was raised by adding 2M sodium acetate. The tubes were then kept for 
1 hr at -20°C for the precipitation of genomic DNA. The precipitate was then spooled, 
washed with 70% ethanol, air dried and dissolved in appropriate amounts of TE 
(10mM Tris, pH 7.5, 1mM EDTA) buffer. The DNA was then quantitated 
spectrophotometrically (GENESYS ™ 10 series, Rochester, USA). 
Quantitation of DNA: The quantitation of DNA isolated from skin/tumor tissue was 
performed spectrophotometrically as per the procedure of Meniatis et al (1989) at 
260nm and 280nm. The reading at 260 nm allows the calculation of the concentration 
of nucleic acid in the samples. An O.D. of 1 corresponds to approximately 50 i^ g/ml for 
double stranded DNA. The ratio between the readings at 260 and 280 nm 
(OD260/OD280) provides an estimate of the purity of the nucleic acid. Pure preparations 
of DNA have OD260/OD280 values ranging between 1.8-2.0. 
Agarose Gel Electroplioresis: The DNA (~2pg) was subjected to agarose (0.8%) 
gel electrophoresis (Bio Rad, USA) for 2-3 hrs. at 50 V in TBE buffer (45 mM Tris 
borate, 1 mM EDTA) consisting of 0.5 mg/ml ethidium bromide and visualized under 
UV light for DNA laddering using gel documentation system (Herolab, Gmbh, 
Germany). 
TUNEL assay: Paraffin embedded sections of skin/tumor tissues were studied for 
their apoptotic status by utilizing the TUNEL assay, which detects fluorescein-12-dUTP 
labeled 3'-0H ends of genomic DNA. The apoptotic cells were detected in situ using 
Promega Detection System, Fluorescein as per manufacturer instruction (Fig. 8). 
Briefly, the tissue sections were deparaffinized in xylene twice for 5 min each and 
rehydrated in descending grades of ethanol (100%, 95%, 85%, 70% & 50%) for 3min 
each. Sections were then washed once with 0.85% NaCI, then with PBS and fixed with 
4% methanol free formaldehyde solution in PBS for 15 min at room temperature. After 
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ParafTin Embedded Sections 
i 
Deparaffinized in Xylene (twice) i 
Hydrate with descending grades of alcohiol i 
Permeabilize with Proteinase K i 
Pre-equilibrate i 
Label DNA strand breaks with fluorescein -12 - dUTP 
(Add incubation buffer containing equilibration buffer, nucleotide mix & TDT enz.) 
r-OM 
^K- ' 
^^ c^  i 
Termination of reaction 
(2 X SSC) 
i 
Wash 
i 
Stain with Propidium Iodide 
1 
Analyze 
(Propidium Iodide stains both apoptotic & non-apoptotic cells red. Fluorescein -12 - dUTP gets 
incorporated at the 3'OH ends of the fragmented DNA, resulting in localized green 
Fluorescence within the nucleus of apoptotic cells) 
Figure 8: Schematic Representation of Terminal deoxynucleotidyl Transferase (TDT) 
mediated dUTP Nick End Labelling (TUNEL) Assay in Mouse Skin Tumors 
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fixing, sections were again rinsed twice with PBS each of 5 min duration. Tissue 
sections were permeabilized with 100 1^ of the 20 ng/ml Proteinase K for 20 min, and 
again fixed in 4% methanol free formaldehyde solution in PBS with in between rinses 
of PBS of 5 min each. Then the sections were equilibrated with the equilibration buffer 
provided with the kit for 10 min at room temperature. After equilibration, 50 |il of TdT 
incubation buffer containing 5 fil nucleotide mixture and 1 |il TdT enzymes/ section 
was added and the slides were then incubated at 37°C for 60 min inside a humid 
chamber in dark to allow the tailing reaction to occur. The reaction was terminated by 
immersing the slides in 2xStandard Saline Citrate (SSC) in a coplin jar for 15 min and 
the slides were washed thrice in PBS to remove the un-incorporated fluorescein-12-
dUTP. Sections were stained with Img/ml propidium iodide solution for 15 min at room 
temperature in dark and washed in deionized water thrice. Apoptotic cells were 
visualized immediately under a fluorescence microscope (Leica, Germany) for the 
incorporation of fluorescein 12-dUTP at the 3'-0H ends of fragmented DNA, resulting 
in localized green fluorescence within the nucleus of the apoptotic cells. The apoptotic 
index is expressed as the amount of positive staining/ lesion. This was quantitatively 
assessed by estimation of the number and intensity of the stained cells/field using 
Leica image analysis system in 25 longitudinal sections. 
Statistical analysis: Statistical analysis of the tumor data recorded was performed 
with student't' test. P< 0.05 was considered significant. Differences in apoptotic index 
were compared using one-way ANOVA. F values with a probability < 0.05 were 
regarded as significant. 
Results 
Animal bioassay: During the entire course of study i.e. 28 weeks no increased rate 
of mortality or change in diet and water consumption was noticed in any of the group. 
The topical application of DAS resulted a significant protection in DMBA induced 
mouse skin carcinogenesis. The lesions at the site of application were observed. The 
lesions were confined to the painted area on the dorsal skin of mice and they were 
broadly classified as tumorous and non-tumorous lesions. The non-tumorous lesions 
were observed in the animals belonging to Gr. Ill & IV, which included initial loss of fur 
followed by poor hair growth at the site of application, hyperkeratinization and scaly 
skin. After about 8 weeks of exposure, a persistent baldness was observed in the 
painted area. The animals belonging to Gr. II (ACE+ DMBA) showed an almost similar 
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pattern of development of non-tumorous lesions as in Gr. Ill & IV but tumorous lesions 
also made their appearance in this group later on. 
The tumors initially appeared as pinkish minute wart like growth developing into 
finger like projections firmly attached to the base with fragile tops. In due course of 
time, these tumors grow in size and were about 3-10 mm in height and 4-12 mm in 
diameter in few cases (Fig. 9a). There were also the signs of hemorrhages and 
necrosis in some of the tumors. Some closely related tumors were coalesced in due 
course of time. Some tumors showed inversion of the tissue at their places, 
characteristic of malignant conversion (Fig. 9b), mostly observed in positive control 
group (Gr. II, ACE+ DMBA). The tumor development was not observed in either Gr. V 
(ACE+ DAS) or Gr. I (untreated). This confirms that there was no spontaneous 
development of tumors or any toxicity associated with DAS exposure during the course 
of study. 
The animal bioassay revealed a significant delay in the onset of skin 
tumorigenesis in DAS supplemented Swiss mice (Gr. Ill and Gr. IV) by more than three 
weeks in comparison to the animals exposed to DMBA alone (Gr. II) (Table 10). The 
induction of first tumor was observed on 53'^ day of DMBA application in Gr. II but 
onset of tumorigenesis was recorded on 75'^  and 74"^  day in Gr. Ill and Gr. IV 
respectively (Table 10). The antitumor activity of DAS was also evident in the present 
set of investigations as 100% tumorigenesis was never achieved in DAS 
supplemented animals during the entire course of experiment (Table 10). Till the 
termination of the experiment, only 76% animals developed tumors in Gr. Ill and 80% 
animals showed growth on the back in Gr. IV (Fig. 10a). In DAS supplemented group 
24 & 20 % of animals remained tumor free till the termination of experiment i.e. 28 
weeks in Gr. Ill & IV respectively. 
The multiplicity of tumors was also effectively inhibited by DAS application as 
the cumulative number of tumors was found to be significantly less in DAS 
supplemented animals in comparison to animals treated with DMBA alone (Fig. 10b). 
The average number of tumor per mouse was found to be about 3.0+0.5 and 4.5+0.6 
in groups where DAS was given one-hour prior and after the DMBA treatment 
respectively, in comparison to 6.1+0.8 in DMBA exposed animals (Table 10). A 
comparatively higher incidence of mortality was recorded in Gr. II in comparison to Gr. 
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Figure 9: Mouse with skin tumors, a) Mouse with pedunculated 
squamous cell papillomas; b) Mouse with pedunculated 
squamous cell carcinoma 
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Figure 10: Tumor inhibrtory effects of DAS In terms of reduction in a) Percentage of 
animals with tumors and b) Cumulative number of tumors. 
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III and Gr. IV, after about 23 weeks of exposure. The DAS application was also found 
to intiibit the malignant transformation of DMBA induced skin tumors (Table 10). 
The histopathological examination of the tumors following hematoxylin and 
eosin staining revealed both non-malignant and malignant nature of tumors (Fig.11, 
12). The majority of the tumors were benign skin papillomas, keratoacanthomas and 
certain tumors showing both papillomatous growth and acanthomous changes and 
hence was designated as 'mixed type' of tumors. Among the squamous cell papillomas 
about 70% of the tumors were pedunculated and remaining were flat type of 
squamous cell papillomas. Certain areas of the mouse skin became multilayered (6-8 
layers) in place of normal 3-4 layers showing increased cell volume but the staining 
properties and other morphological features were remained unchanged. These areas 
are termed as 'focal epidermal hyperplastic lesions' (Fig.lib). 
Pedunculated squamous cell papillomas were having a relatively thin stalk 
usually flexible at the base (Fig. 11c). In this type of tumors, the outgrowth from the 
skin surface consists of mainly three well defined layers: an inner layer of connective 
tissue or stroma, an intermediate layer of hyperplastic, relatively regular stratified 
squamous cell epithelium, and a peripheral layer of keratinized epithelial cells, that 
form a confluent keratin mass of variable, sometimes of considerable thickness. The 
stroma is mainly consists of connective tissue fibers and carries blood vessels thus 
regarded as 'supply line' of the tumors. The flat squamous cell papillomas showed 
almost the same pattern but here the breadth of the tumor was usually more than the 
height and had no stalk (Fig. l i d ) . 
In keratoacanthomas the hair shaft of the hair follicles were replaced 
progressively by the horny masses of keratin. The striking feature of this type of tumor 
was the presence of keratin pearls within the tumors (Fig. 12a). In few cases, the 
tumors had both; an arboreal pattern of growth of squamous cells and horny masses 
of keratin developed from the hair element of the skin and hence were designated as 
mixed type of tumors (Fig. 12b). 
The malignant epidermal tumors, squmaous cell carcinoma (Fig. 12 c & d) 
showed very heterogenous structures. Polymorphism is commonly observed which is 
one of the markers of the manifestation of the malignancy. In few smaller tumors, 
increasing occurrence of atypism was also observed which is regarded as new 
population of the cells originating from a single nucleated cell. In squamous cell 
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Figure 11: Photomicrographs showing mouse skin/tumors (Hematoxylin and Eosin 
stained, magnification 128X) 
a) Normal mouse skin 
b) Mouse skin showing focal areas of hyperplastic transformations. 
c) Flat squamous cell papillomas of mouse skin 
d) Pedunculated squamous cell papillomas of mouse skin 
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Figure 12: Photomicrographs showing mouse skin tumors (Hematoxylin and Eosin 
stained, magnification 128X) 
a) Keratoacanthoma showing large keratin pearls 
b) Mixed type of tumor showing both papillamatous and keratoacanthomous growth 
c) Squamous cell carcinoma 
d) Squamous cell carcinoma at higher magnification (512 X) 
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carcinoma usually confluent large, clusters and clumps of the cells were observed in 
few tumors. The irregularity of the cells was more evident in large tumors. Here, the 
nuclei of various size and shapes, from round to rod shape, having different staining 
properties were also observed along with many mitotic figures. In some cases, 
multinucleated cells, giant cells and cells under various stages of necrobiosis were 
also apparent. 
Flow Cytometric Analysis: Flow cytometric analysis of mouse skin/tumors 
revealed the presence of a clear peak before G1 phase in tumor samples. The log was 
drawn against cell number (y-axis) and amount of the fluorescence detected on Argon 
488nm laser. The untreated mouse skin cells showed a typical DNA histogram with 
majority of the cells in the G1 phase with persistent number of cells in the S and G2/M 
phase (Fig. 13a). In case of tumor cells of DMBA treated group (Gr. II), appearance of 
a small peak before the G1 peak was observed (Fig. 13b). The quantitation of the this 
peak was performed by using analysis software, ModFit 2.0 which revealed that 15.4% 
of the total cell populations were under the phase prior to G1 phase and hence were 
termed as 'sub G1' peak. This sub G1 peak is a characteristic of apoptotic DNA. The 
tumor cells obtained from Gr. Ill i.e. DAS+DMBA showed a distinct sub G1 peak 
indicating that 42.8% cells were showing the presence of apoptotic population (Fig. 13 
c). The application of DAS after DMBA administration (Gr. IV) showed no significant 
difference on its apoptosis inducing potential in comparison to Gr. Ill where DAS was 
given prior to DMBA. The quantitative analysis showed that the 34.6% of the total cells 
were under the apoptotic phase (Fig. 13d). Due to this increase in sub G1 cells, the 
percentages of G1, S and G2/M cells were significantly reduced in both the groups 
(Gr. Ill & Gr. IV) 
DNA fragmentation Analysis: The DNA fragmentation analysis of mouse skin/ 
tumors on agarose gels revealed a higher amount of apoptotic DNA in DAS 
supplemented groups (Gr. Ill & IV) (Fig. 14, lanes c & d). The nucleus of apoptotic 
cells has undergone internucleosomal chromatin cleavage by endogenous 
endonucleases in multiples of 180bp. This resulted in a characteristic laddering of 
oligonucleosomal fragments or 'DNA ladder formation', a hallmark feature of apoptosis 
on agarose gels. However, untreated mouse skin DNA did not show any 
oligonucleosomal fragmentation when subjected to agarose gel electrophoresis (Fig. 
14, lane a). In tumors obtained from the Gr.ll (ACE+DMBA), DNA fragmentation was 
also evident (Fig. 14, lane b). Although the extent of the DNA fragmentation was 
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Figure 14: DNA agarose gel electrophoresis of mouse skin tumor cells. 
DNA was extracted from the skin/tumors as described In 
material & methods. About 2 ^g of genomic DNA was loaded 
and electrophoreses at 40 volts. Induction of apoptosis (ladder 
formation) can be readily seen in DAS treated group. Lane M; 
Markers, a: Gr. I (Untreated), lane b: Gr. II (ACE+DMBA), lane 
c: Gr. IV (DMBA+DAS), lane d: Gr. Ill (DAS+DMBA), 
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significantly lowered in comparison to DAS administered groups (Fig. 14, lanes b, c & 
d). Therefore, it was confirmed that DAS could induce a significantly high incidence of 
apoptosis in mouse skin tumors. 
TUNEL Analysis: Apoptotic status of sl<in tumors following DAS treatment by 
TUNEL assay showed induction of apoptosis in both non-malignant and malignant 
tumors of DAS treated groups (Fig. 15,16). The apoptotic index in nonmalignant 
tumors was 0.94 + 0.2 in DMBA treated group (Gr II), which increased to 1.67 + 0.2 
and 1.58 + 0.2 in DAS pre- (Gr. Ill) and post-treated (Gr. IV) groups (Table 11). Thus, 
DAS causes 78 and 68% increase in the TUNEL positive cells (apoptotic bodies) in 
nonmalignant tumors in comparison to the DMBA exposed group respectively (Fig. 
15,16). 
Examination of the nonmalignant tumors viz. focal epidermal hyperplasia, 
squamous cell papilloma and keratoacanthoma revealed 49%, 38% and 105% 
increase in the TUNEL positive cells, respectively in Gr. Ill and about 44%, 34 % and 
93% increase in Gr. IV. Similarly TUNEL assay showed about 94% and 82% increase 
in case of malignant tumors i.e. squamous cell carcinoma in Gr. Ill & Gr. IV 
respectively over Gr. II. The apoptotic indices for malignant tumors in Gr. Ill & Gr IV 
were found to be about 1.73+0.3 and 1.62+0.27 respectively compared to 0.89+0.2 of 
Gr II (Table 11). However, no significant difference in apoptotic index was observed 
with TUNEL assay in both malignant and non-malignant tumors of the skin following 
DAS treatment (Gr. Ill & Gr. IV) (Table 11). The other morphological alterations like 
condensation of chromatin into crescent shaped caps, decrease in nuclear size, 
blebbing of the cytoplasm into small multiple apoptotic bodies were also evident in Gr. 
II, Gr. l l l&Gr. IV. 
Discussion 
The search for new chemopreventive and chemoprophylactic agents that are 
more effective and non-toxic has kindled great interest among researchers in 
organosulfur compounds from garlic (Fukushima et al, 1997; Pinto & Rivlin, 2001). 
Garlic is known for its therapeutic properties since ancient times and is probably the 
most widely studied medicinal plant (Agarwal, 1996). DAS, an active component of 
garlic responsible in part for its strong taste and odor is being viewed as a potential 
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Figure 6: Biochemical and functional changes during apoptosis 
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a 
Figure 16: Photomicrographs of skin/skin tumors showing increase in apoptotic 
bodies following DAS administration in TUNEL assay, (a) Gr. I 
(Untreated), (b) Gr. II (ACE+ DMBA only), (c) Gr. Ill (DAS+DMBA), (d) 
Gr. IV (DMBA+DAS). 
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anti-proliferative agent as has been shown to protect against a variety of chemically 
induced toxicity and carcinogenesis in animals (Wargovich ef a/, 1992; Haber-Mignard 
Bt al, 1996; Hu et al, 1996a). DAS is reported to inhibit the development of colon, 
esophageal carcinomas, pulmonary adenomas, skin papillomas/carcinomas and 
forestomach tumors in rodents when administered before carcinogen exposure 
(Wargovich, 1987; Sparnins et al, 1988; Wargovich ef al, 1988; Wattenberg ef al, 
1989; Singh & Shukia, 1998 a & b). Epidemiological studies have shown that a lower 
risk of stomach cancer is associated with higher intake of allium vegetables in 
Shandong province of China (You ef al, 1988; Han, 1993). Similarly an inverse 
relationship was observed between cooked garlic consumption and colon, rectal and 
esophageal cancers (Hu ef al, 1991,1994; Gao ef al, 1994; Giovannucci ef al, 1994; 
Dorant ef al, 1996). The mouse skin model of carcinogenesis has been widely used 
both for studies on mechanisms involved in chemical carcinogenesis and for testing of 
carcinogenic or anticarcinogenic agents of natural or synthetic origin (Berenblum, 
1975; Shukia ef a/, 1988, 1992; Mukhtar & Aganwal, 1996; Singh & Shukia, 1998 a &b; 
Srivastava & Shukia, 1998). The results of the present study demonstrate the 
antitumorigenic potential of DAS in mouse skin carcinogenesis. 
DAS has earlier been shown to possess antitumorigenic properties in complete 
as well as two-stage initiation promotion mouse skin carcinogenesis from our 
laboratory (Singh & Shukia, 1998 a & b). The results of the present investigation 
further lended support for cancer chemopreventive properties of DAS both by long-
term carcinogenesis and mechanistic studies. An important feature of the study was 
that DAS suppressed the tumor in both the cases, i.e. given either one-hour prior to or 
after the carcinogen. However, somewhat greater degree of protection from chemically 
induced tumors was observed when DAS was given one hour prior to DMBA exposure 
(Table 10). Apart from its antitumor activity, DAS has been reported to ameliorate the 
toxicity of various xenobiotics including drugs viz cyclophosphamide (Goldberg & 
Josephy, 1987), ethanol (Morimoto et al, 1995) and acetaminophen (Hu et al, 1996a). 
The anticarcinogenic effects of DAS and other biologically active constituents of garlic 
was linked primarily to their antioxidant effects and induction of xenobiotic metabolizing 
enzyme systems (Guyonnet ef al, 1999; Smith & Yang, 2000; Yang ef al, 2001). 
Various natural compounds are known to exert their anticarcinogenic effects through 
their antioxidant activities (Ruby ef al, 1995; Gerhauser ef al, 1997; Frie & Higdon, 
2003; Rietveld & Wiseman, 2003). Ruby ef al (1995) investigated the antioxidant 
potential of natural curcuminoids, which indicates their potential use as 
chemopreventive agent in the inhibition of Ehrlich ascites tumor in mice. Protective 
56 
Cancer Chemoprevention & Induction ofApoptosis by DAS 
effects of tea have also been well reviewed in various experimental and 
epidemiological studies ( Frie & Higdon, 2003; Rietveld & Wiseman, 2003). 
DAS is reported to cause selective inhibition of P450 2E1 activity, suppression 
of its level in microsomes and induction of P-450 2B1 in rats (Yang, 1993). Inhibition of 
azoxymethane induced colon carcinogenesis by DAS may be associated in part, with 
increased activities of phase II enzymes such as GST, NAD(P)H-dependent, QR, UGT 
in the liver and colon (Reddy et al, 1993). The anti-neoplastic activity of DAS, may at 
least in part be due to the elevation of all the three classes of GST (Maurya & Singh, 
1991), GST-a and n forms mediate the conjugation of sulphydryl group of glutathione 
with toxic electrophiles and efficiently detoxify the electrophilic metabolites of 
carcinogen, which might be responsible for the suppression of neoplasia in mouse skin 
(Hayes & Pulford, 1995) 
It is now well-established fact that majority of anticarcinogenic agents comprise 
a diverse group of compounds with different mechanisms of action, but their ultimate 
ability to induce apoptosis may represent a unifying concept for the mechanism of 
chemoprevention (Taraphdar et al, 2001). Therefore, the apoptosis inducing potential 
of DAS in solid tumors was worth to study in order to provide insight into its molecular 
mechanism of cancer chemoprevention. Consistent with the earlier reports on the 
mechanism of inhibition of allium derivatives via induction of apoptosis (Knowles & 
Milner, 1999), DAS in the present study showed a marked stimulatory effect on the 
apoptotic indexes in both malignant and non-malignant tumors as measured by 
TUNEL assay. TUNEL assay is being used successfully for the quantitation of 
apoptosis in paraffin sections especially for that tissue in which morphological 
determination is difficult such as tumor tissue (Rao et al, 1998; Yamamoto et al, 1998). 
This assay allows the detection of both double as well as single stranded DNA breaks 
by labeling the free 3'-0H termini with modified nucleotides (e.g. Biotin dUTP, DIG-
dUTP, fluorescein-dUTP) in an enzymatic reaction. 
The biochemical hallmark of apoptosis i.e. the extensive cleavage of the cell's 
DNA into oligonucleosomal sized fragments by a Ca'^ '^-dependent endonucleases, 
resulting in typical ladder patterns after DNA agarose gel electrophoresis (Arends et al, 
1990), was also evident following DAS exposure in DMBA induced solid tumors (Fig. 
14). The appearance of sub G1 fraction on flow cytometric analysis provides further 
support to our observation. In the literature, the presence of a sub G1 peak has only 
been found in association with apoptosis. It has been shown in cultures of murine 
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thymocytes (Nicoletti et al, 1991; Swat et al, 1991; Telford et al, 1991) and in a murine 
haemopoetic cell line (Rodriguez-Tarduchy et al, 1990) that the induction of apoptosis 
is accompanied by the appearance of a sub G1 peak in the DNA histogram. Earlier 
studies on other closely related organosulfides from garlic like DADS and DAT have 
been shown to suppress the in vitro proliferation of tumor cells through the induction of 
apoptosis (Sundaram & Milner, 1996; Sakamoto et al, 1997; Nakagawa et al, 2001). 
Ajoene and allicin, other active components of garlic have also been shown to possess 
inhibitory effects via induction of apoptosis in human promyeloleukemic cells, 
accompanied by generation of reactive oxygen species and activation of nuclear factor 
kappa (Zheng et al, 1997; Dirsch et al, 1998). S-allylmercapto cysteine, a stable 
thioallyl compound induces apoptosis in erythroleukemia, breast and prostrate cancer 
cell lines (Sigounas et al, 1997 a & b). Hong et al (2000) have shown that the effect of 
DAS, DADS and crude garlic extract on the expression of certain closely associated 
oncogenes bcl-2, bax and p53 in non small lung cancer cell lines and suggest that 
modulation of apoptosis associated cellular protein may be the possible mechanism for 
apoptosis. 
Cellular apoptosis in concert with the proliferation and cyto-differentiation plays 
an important role in homeostasis (Steller, 1995; Jacobson et al, 1997). During 
carcinogenesis, aberrant proliferation disrupts growth control leading to down 
regulation of apoptosis (Cotter et al, 1990; Stewart, 1994). Genetic studies on 
apoptotic cell death have shown that positive regulation of p53 and negative regulation 
of bcl-2 play an integral role in mediating apoptosis (Miyashita et al, 1994; Silverstini et 
al, 1994). Thus, inverse correlation of the two gene products, together with 
upregulated cell cycle progression, may lead to aberrant hyper proliferation and 
carcinogenesis. It is noteworthy that an inverse correlation has been observed 
between p53 and bcl-2 expression in advanced breast cancers (Sierra et al, 1996), 
raising the possibility that the two genes may participate in a common pathway for the 
control of cell survival. The data generated from the present experiments showing 
induction of apoptosis by DAS in solid tumors therefore emphasizes the need for future 
experiments to focus on understanding the role of p53 and/or bcl-2 in the mechanisms 
for induction of apoptosis by DAS. The status of immunoreactivity to cell cycle 
regulatory and apoptosis specific gene products, together with analysis of gene 
expression at RNA and protein levels should elucidate the responsible mechanisms. 
Thus from the present study we can conclude that naturally occurring 
phytochemicals present in garlic can significantly inhibit the development of chemically 
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induced solid tumors of mouse skin by inducing apoptosis. This is the first report 
showing mechanistic pathway of DAS mediated inhibition of chemically induced 
tumors by apoptosis using multifunctional approaches. The underlying mechanism(s) 
for inducing apoptosis of tumor cells by DAS needs more indepth research on the 
array of genes involved in regulation of apoptosis such as bax, bcl, p53 and p21. 
However, the results of the present study conclusively revealed that DAS could be 
used as a dietary adjuvant for controlling the neoplastic growth. 
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Chapter-ll 
Role of P53 And P21/Wafl in 
Diallyl Sulfide Mediated Tumor 
Suppression in Mouse Skin 
Modulatory Effects of DAS on p53 & p21/wafl 
Introduction 
Tumorigenesis is a multistep evolutionary process in which clones of normal 
cells incur changes, which provide a growth advantage and may predispose the cells 
in these clones to further growth promoting changes (Nowell, 1989). Underlying 
many of these growth-promoting changes are mutations in the growth regulatory 
genes of the cell, the 'oncogenes' and 'tumor suppressor genes' (Pearson & 
Vogelstein, 1990). These genetic alterations occur very frequently and therefore, 
could be utilized as diagnostic tools or as intermediate end points for 
chemoprevention studies (Conti & Gimenez-Conti, 1996). 
The existence of tumor suppressor genes had been predicted in 1971 from 
the finding that the development of retinoblastoma involves two genetic alterations, 
presumably inactivation of both copies of cellular gene (Knudson, 1971). The 
development of second primary tumors in patients who had been successfully treated 
for retinoblastoma suggested that changes in the rb gene might be involved in the 
development of many human tumors, and several such tumor suppressor genes are 
cloned (Stanbridge, 1990). These genes normally function to inhibit or "put the 
breaks on" on the cell growth and thus controlling the cell cycle. The family of tumor 
suppressor genes encompasses several members namely p53, rb, WT1, BRCA1, 
NF1 etc. which have been found to be involved in controlling proliferation and 
differentiation in cells (Cowell, 1990; Levine, 1990; Yuspa et al, 1994). In particular, 
their function is associated with control of abnormal growth in carcinogenesis and 
thus named as 'tumor suppressor genes'. 
p53 is a gene that has received wide attention as a tumor suppressor gene 
(Cowell, 1990). The p53 gene was first identified in 1979 as a host cell protein, 
binding to the DNA virus SV40 (Lane & Crawford, 1979) and later on described as a 
tumor suppressor (Levine, 1990). In humans, the p53 gene contains 11 exons and is 
located on chromosome 17p13.1 while the mouse gene, which also contains 11 
exons, is located on chromosome 11 (Soussi & May, 1996). In both human and 
mouse, the coded protein is of 53kD, the human protein containing 393 amino acids 
and mouse protein 390 amino acids. The p53 protein (Fig. 17) consists of an acidic N-
terminus with a transactivation domain, a hydrophobic central DNA-binding core and 
a basic C-terminus with regulatory and oligomerisation domains (Hainaut & 
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Modulatory Effects of DAS on p53 & p21/wafl 
Vahakangas, 1997). The DNA binding domain of the p53 protein is connposed of two 
beta sheets and a zinc atom, which stabilizes the structure (Cho ef a/, 1994). 
p53 mutations are lil<ely to be a primary tumor-initiating event in those 
humans and animals which inherit p53 mutations (Harvey et al, 1993; Malkin, 1994). 
In mouse skin model of cancer development, mutations of p53 and loss of 
heterozygosity (LOH) on chromosome 11 were found in about 25% of carcinomas, 
and in low frequencies in benign papillomas (Burns et al, 1991). Mutations detected 
in the p53 gene were found to be dependent upon the treatment regimen used 
(Brown et al, 1995). Tumors induced by initiation with DMBA and TPA promotion 
exhibited typical loss of function mutations in p53, such as frame shift mutations, 
deletions and point mutations introducing stop codons, in addition the wild type allele 
was lost (Ruggeri ef al, 1991). In contrast, carcinomas induced by repeated 
carcinogen treatment using DMBA or the methylating agent MNNG showed 
carcinogen specific alterations in p53 (Ruggeri et al, 1991). The p53 mutations 
detected in carcinomas, induced by DMBA or MNNG treatment, mostly G to A 
transition was detected. Loss of remaining wild type allele was not observed in these 
tumors. Similarly, no p53 abnormalities were detected in early stage papillomas cell 
lines but 50% of late stage tumors cell lines had protein abnormalities (Ruggeri et al, 
1991). The literature survey shows that the p53 mutations, play an important role in 
skin tumor development in the progression rather than initiation or promotion stage 
(Conti etal, 1991; Ruggeri etal, 1991). 
The p53 protein normally controlling the integrity of the genome is, wild type 
p53 {wtp53) and acts as a safe guard against cancer. However, mutational events 
can lead to the alterations in the p53 genes thus resulting in expression of mutant 
p53 (mutp53). In the course of studying the mechanism(s) by which wtp53 functions 
as a tumor suppressor, several biochemical properties and activities of wild type and 
mutant p53 protein have been documented, confirming their role in maintaining the 
balance between normal to neoplastic cells (Zambetti & Levine, 1993). In general, 
wtp53 protein has a short half-life of almost 30 min (Gronostajski ef al, 1984), inhibits 
the growth of tumor cells in culture (Chen et al, 1990; Mercer ef al, 1991) and inhibits 
the transformation of primary fibroblasts by cooperating oncogenes (Elihayu ef al, 
1989; Finlay ef al, 1989). wtp53 protein displays a non-specific and specific DNA 
binding activity, which is required for its function in transcriptional transactivation (El-
Deiry ef al, 1992; Funk ef al, 1992). This protein can form complexes with SV 40 
large T antigen (Lane & Crawford, 1979; Linzler & Levine, 1979) as well as with 
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several other DNA tumor virus oncogenic products (Sarnow et al, 1982; Werness et 
al, 1990). In contrast mutp53 has a comparatively long half life of several hours 
(Hinds et al, 1990; iggo et al, 1990), fails to suppress cell growth of tumor cells 
(Baker et al, 1990; Diller et al, 1990) and does not inhibit the transformation of 
primary fibroblasts by cooperating oncogenes (Elihayu et al, 1989; Finlay et al, 
1989). The hot spot mutp53 proteins do not complex with SV 40 large T antigen 
(Chenefa/, 1990). 
The primary functions of the wtp53 are inhibition of abnormal growth of cells 
(Sionov & Haupt, 1999), DNA repair (Albrechtsen et al, 1999), ce)) cycle contro\ 
(Stewart & Pietenpol, 2001), inhibition of angiogenesis (Vogelstein ef al, 2000) and 
triggering of programmed cell death (Heinrichs & Deppert, 2003). Because these 
processes ensure genomic integrity or destroy the damaged cell, p53 gene has been 
called the "guardian of the genome" (Lane, 1992). p53 is a sequence specific nuclear 
transcription factor, that affects its target genes either by transcriptional activation or 
by modulating other protein activities by direct binding (El-Deiry, 1998; Murphy ef a/,. 
1999; Guimaraes & Hainaut, 2002). The p53-induced activation of target genes may 
result in the induction of growth arrest or apoptosis (Heinrichs & Deppert, 2003) (Fig. 
18). Several biochemical activities have also been ascribed to p53 that may mediate 
the biological effects of the protein (Albrechtsen etal, 1999; Vousden & Lu, 2002). 
One of transcriptionally upregulated gene by p53 is the waf1. The protein 
product of waf1 is the p21 protein, the first cyclin dependent kinase (CDK) identified 
(El-Deiry et al, 1993; Harper et al, 1993; Noda et al, 1994). The p21 protein is 
suggested to be the mediator of tumor suppressing activity of p53 through inhibition 
of CDK (Deng et al, 1995; Del Sal et al, 1996). The p21 is also known to be the 
regulator of CDK activity and to be induced in relation to cellular senescence (Harper 
et al, 1993; Noda et al, 1994). p21 expression is shown to increased in different cell 
types in response to a wide variety of stressful stimuli, including DNA damaging 
drugs or ionizing radiation, agents affecting DNA replication or mitosis, TGFp, 
differentiating agent or oncogenic ras (El-Diery et al, 1993, 1994; Datto et al, 1995; 
Ahmad et al, 1998). The response to some of these factors (e.g. DNA damage or 
mutant ras) is mediated primarily through transcriptional activation of the p21/waf1 
gene by p53 (El-Diery et al, 1993, 1994). Other p21 inducers such as TGF-(3 induces 
p21/waf1 in a p53 independent manner (Datto et al, 1995). The activation of p53 
causes induction of p21/waf1, which in turn inhibits CDK cyclin activity and arrests 
62 
^ 
^ Q 
>> 
-c 
"—, 
> 
^ 
< 
<N 
CI, 
=8 
Ci. 
c 
C/^  
iZ 
CJ 
b 
-i! 
^ 
1 
tf) 
(A 
O 
*^ Q. 
O 
a 
ns 
4-< 
C 
•o 
c 
0) a 0) 
•o 
c 
o 
4 ^ 
a 
I . 
u (/) 
c 
ns 
> ^ 
'J o 
(0 
p 
^ 
p 
-^ 
v 
o •^ 
> w 
o £ 
O 
^ 
^ 
^ 
"(0 
Q. 
< 
z 
Q 
^ 
^ 
c 
o 
c 
o 
a 0) 
•D 
c 
1 
c 
o 
4-> 
a 
^ 
o (A 
C (Q 
(A 
(A 
O 
4-> 
a 
o 
a 
ra 
W) 
Jti 
HiZ 
ra X 
TO 
-Q 
'^— 
C 
.2 OT (0 
a 
X 
0) 
<M 
O 
-Q 
— • 
•D 
C 
5: . rog 
^ 
c 
'35 
(0 0) 
Q 
X 
(1) 
o 
4-< S c 
"2 o 
o-t 
c w 
CQ 
A 
c 
o 
5 
a 
V) 
o 
o (0 
'ro 
a 
^ 
w 
Q 
Q. 
X 
73 
C 
re 
m Q. 
X, 
X 
LL 
1-
C 
(l> 
•*•> 
o 
a 
CO 
•o 
c 
O 
4-1 
ra 3 
E 
D 
U 
a o ro 
• o 
c 
cc 
c 
o 
^^  CD 
3 
E 
D 
o 
o 05 
00 
lO 
Q. 
O 
W 
• o 
CD 
0 
. C 
C) 
.r 
^ 
<u 
en 
CD 
E CD 
•D 
< 
z 
Q O ) 
c 
^ 
^ 
p 
CO 
>^  CD 
^ 
,r 
• * — • 
CD 
n 
QJ 
^ 
M— 
o 
c 
o 
" • ^ 
CD 
l_ 
(/3 
CD 
n CI) 
u. 
f 1 
CD 
E 
(D 
x: 
o C/J 
CO 
t_ 
o 
o 
CD 
k— 0 
c 
c 
CD 
O 
Q. 
1 C 
CD 
O 
Q . 
• n 
c CD 
1_ 
U 
C/3 
(/) 0) L_ 
C} 
X 
CD 
CD 
C 
CD 
c 
— (/> CD 
C35 
C 
CD 
1 _ 
O 
^^  
c 
<D 
_J 
U 
CD 
CO 
C^  
3 
CO 
00 
(U 
3 
i l 
Modulatory Effects of DAS on p53 & p21/wafl 
the cell cycle at G1 or G2 cell cycle checkpoints (Colman et al, 2000; Taylor & Stark, 
2001; Winters, 2002) This arrest gives time for DNA repair before replication or 
mitosis and thus links p21 directly to the tumor suppressor functions of p53. 
Thus, therapeutic strategies targeting the oncogenic consequences of 
p21/waf1 expression may provide a new approach to chemoprevention and 
treatment of cancer. Being central to the pathways regulating cellular responses to 
DNA damaging agents, modulation of p53 and its effector molecules such as 
p21/waf1 levels could serve as an effective way of intervention against cancer (Conti 
& Gimenez-Conti, 1996; Mukhtar & Ahmad, 1999; Sherr & Roberts, 1999). Many 
chemopreventive natural food components and commonly used chemotherapeutic 
agents are known to exert their anticancer properties through the regulation of p53 
dependent pathways (Lotem & Sachs, 1993; Schwartz ef al, 1993; Dong, 2003). The 
antitumor activity of resveratrol was shown to occur through extracellular signal 
regulated protein kinases and p38 kinase mediated p53 activation and induction of 
apoptosis (She et al, 2001; Dong, 2003). Inhibition of BaP induced lung 
tumorigenesis in A/J mice by dietary N-acetylcysteine conjugates of benzyl and 
phenethyl isothiocyanates during the post-initiation phase is associated with 
activation of mitogen activated protein kinases and p53 activity and induction of 
apoptosis (Yang ef al, 2002). Similarly, p53 has been implicated in the anticancer 
mechanism of vitamin E (Schwartz etal, 1993), retinoids (Shin et al, 1997), capsaicin 
(Kim ef al, 1997) and n-butyrate (Mahyar-Roemer & Roemer, 2001). 
Studies on the molecular mechanism of tumor suppression by allium 
derivatives are very few. In the only study reported for implicating p53 and p21/waf1, 
it was shown that DAS, DADS and garlic extract are effective in reducing the 
expression of anti-apoptotic genes (such as bcl-2) and the induction of pro-apoptotic 
genes (such as bax) and the tumor suppressor gene p53 in non-small cell lung 
cancer cell lines (Hong ef al, 2000). In the present set of investigations, we studied 
the role of tumor suppressor protein p53 and its effector molecule p21/waf1 in DAS 
mediated growth inhibition of DMBA induced mouse skin tumors. 
Material and Methods 
Materials: DMBA and DAS were purchased from Sigma (St Louis, USA). Anti-p53 
antibody specific for wild type protein (clone PAb 1620, Ab-5) and polyclonal p21/ 
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waf1 (Ab-5) were procured from Oncogene research products (Cambridge, MA, 
USA). Mammalian mutp53, (Clone PAb 240) was obtained from Boerhinger 
Mannheim (Germany). The horseradish conjugate isotypes were obtained from 
Banglore Genei (India) and the FITC conjugates were procured from Becton 
Dickinson (USA). The nitrocellulose membranes were obtained from Sartorious, 
(Germany). The rest of the chemicals were of analytical grade of purity and were 
procured locally. 
Animal Bioassay: The mouse skin tumors were developed in Swiss albino mice 
using DMBA as a carcinogen. The tumors were developed on the dorsal skin of mice 
as described in detail in Material and Methods, Chapter 1 of this dissertation. The 
tumors so obtained were kept frozen (-80°C) till further experimentation. 
Preparation of Nuclear Fractions Containing p53lp21: The skin/tumor tissue 
was removed and subcutaneous fat was scrapped off on ice. The nuclear fraction 
was prepared as per the method of Serpi et al (1999). Briefly, skin/ tumor tissue was 
chopped finely with the help of sterilized scissors and surgical blades, and 10% (w/v) 
homogenate was prepared by using Ultra-Turrax, homogenizer (Germany) in lysis 
buffer (containing 20% glycerol, 20mM HEPES, lOmM NaCI, 1.5 mM MgCb, 0.1% 
Nonidet P40, 0.2mM EDTA, ImM DTT, l^ig/ml Pepstatin A, 1|ag/ml Aprotinin and 100 
ng/ml PMSF) on ice, and then centrifuged in a refrigerated centrifuge (M. B. Cooling, 
India) for 5 min at 2000 rpm. To the pellets, ~1ml of nuclear lysis buffer (500mM 
instead of lOmM NaCI) was added, mixed vigorously with the help of micropipette 
and incubated for 30 min in an ice bath. The samples were then centrifuged at 15000 
rpm for 15 min at 4°C and the supernatant (nuclear extract) was collected and 
freezed in aliquots at -80°C until further used. 
Protein Estimation: The protein estimation was performed routinely by the Folin-
Phenol method of Lowry et al (1951). Peptide bonds form a complex with alkaline 
copper sulfate reagent, which gives a blue color with Folin's reagent. Briefly, 0.1 ml of 
the homogenate (10% w/v) was diluted to 1ml with distilled water. Then 5.0 ml of 
alkaline copper reagent (containing sodium carbonate (2%), CUSOA (1%) and sodium 
potassium tartarate (2%) in IN NaOH) was added. Following 10 min after addition of 
alkaline copper sulfate reagent to allow complex formation, 0.5 ml of Folin's reagent 
(1:1 diluted with distilled water) was added. After 30 min the blue color developed, 
was read at 660nm. For standard bovine serum albumin (0.1 mg/ml) was used. 
64 
Modulatory Effects of DAS on p53 & p21/wafl 
Western blotting: Western blotting was carried out as described by Towbin ef a/ 
(1979). The proteins were separated electroplioretically (Laemnnii, 1970) in a 10% 
polyacrylamide gel at constant voltage (80V) and transferred to nitrocellulose 
membrane for 2hrs. at constant voltage (300 V). Specific molecular weight standards 
(Sigma, USA) were also run in one lane in each gel. To avoid unspecific binding the 
membrane was incubated overnight at 4°C with TBS (1.29 gms Tris, 9.0 gms NaCI; in 
one liter distilled water, pH 7.4) containing 5% non-fat dry milk powder. The complete 
transfer of the proteins to the membrane was confirmed by staining the 
polyacrylamide gels with 0.1% coomassie brilliant blue dye (in propanohacetic acid: 
distilled water, 20:12.5:67.5 ml v/v). The membrane was then incubated for 2 hrs at 
4°C with appropriate antibodies i.e. anti-p53 wild type protein (0.25 lag/ml) (Clone 
PAb 1620), mutant anti-p53 protein (0.25 iig/ml) (Clone PAb 240) and polyclonal anti-
p21/waf1 (0.25 f.ig/ml) at dilutions recommended by the suppliers in 1% milk-TBS-T 
(0.05% Tween 20 in TBS). The blots were then washed five times for 10 min each in 
TBS-T. The blots were then conjugated with horse-radish peroxidase labeled anti-
goat secondary antibody at 4°C (dilution 1:5000) for 6 hrs. After incubation, the blots 
were again washed five times for 10 min each with TBS-T and finally with TBS for 10 
min. The complex formed by the protein and the antibody was detected using 
chromagen 3,3'-diaminobenzidine tetrahydrochloride (DAB) in 0.05M Tris, pH7.3 
containing 30% (v/v) hydrogen peroxide in dark for 3-5 min. After staining blots were 
washed with distilled water, dried and recorded. 
Densitometric Analysis of Western blots: The intensity of the bands was 
quantitated using Easy Win 32 software on Gel Documentation System (Herolab, 
Gmbh, Germany). The intensity of each band was expressed in terms of pixel density 
for each band. 
Immunohistochemistry: For immunohistochemistry, the frozen skin/tumor tissues 
were taken and sections of lO^m thickness were cut using cryostat microtome 
(Reichert-Jung, USA). The sections were fixed in neutral 10% formalin and the 
endogenous peroxidase activity was quenched with methanol: H2O2 solution (100 
ml: 333 pi). After quenching the non-specific binding was minimized by incubation 
with normal goat serum (1:30) for 2 hrs. at 4°C. The slides were sequentially 
incubated with anti p53 antibody for wild type and mutant and p21/waf1 antibody in a 
moist chamber with for 72 hrs. After the incubation period, the sections were again 
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incubated for 2 hrs. with normal goat serum and then with HRP conjugated antigoat 
IgG for 6 hrs. at 4°C. The slides were washed with PBS between incubations and 
after a final rinse with PBS the slides were washed finally with acetate buffer (0.1 M, 
pH 5.2). The color was developed using DAB in Tris buffer (0.05M, pH 7.3) 
containing H2O2. 
image Analysis: The immunostained slides were analyzed and scored, using Leica 
Image Analysis System, Germany (Fig. 19). The quantitative stereology was 
performed with Leica QWin 500 Image analysis software, for each slide in triplicates 
with at least six microscopic fields. The statistical analyses were done by one way 
ANOVA and P<0.05 was considered significant. 
Preparation of Single Cell Suspensions for Flow Cytometry: The single cell 
suspensions of skin/tumor tissue from different treated and control groups for the flow 
cytometric analysis of p53lp21 protein were prepared as described in Material and 
Methods, chapter-1, using Medimachine (Becton Dickinson, U.S.A). 
Flow cytometric Analysis of p53 protein: About 1 ml of cell suspension 
containing ~ 1x 10^ cells (as counted on haemocytometer) were taken and fixed in 
chilled 70% ethanol for 30 min in ice bath. After fixation, cells were centrifuged 
(Tarson, India) at 2000 rpm at room temperature for 5 min. The cells were then 
permeabilized with 0.2% Triton X-100 for 20 min in ice bath and recentrifuged. The 
pellets were then resuspended in PBS and incubated with respective p53 antibody 
viz. anti-p53 antibody wild type protein (clone PAb 1620) and mutant anti p53 protein 
(clone PAb 240) (2|iig/ml in PBS containing 1% BSA) for 1 hr at room temperature. 
After incubation the cells were again pelleted, washed once with PBS and treated 
with FITC-conjugated isotype specific secondary antibody for detecting the 
respective protein levels. Cells were then analyzed on a flow cell cytometer (BD-LSR, 
Beckton Dickinson, USA) equipped with 488 nm Argon laser light source. Total 
10,000 events were acquired for analysis using Cell Quest Software. Cells were 
properly gated and histogram plot of FITC-fluorescence (x-axis) versus counts (y-
axis) has been shown in logarithmic fluorescence intensity. 
Flow cytometric Analysis of p21/waf1 protein: The flow cytometric analysis of 
p21 protein was done as described above for p53 with the exception that the primary 
antibody used was polyclonal anW-p21/waf1 (2|jg/ml in PBS containing 1% BSA). 
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Figure 19: Leica QWin Image Analysis System 
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Statistical analysis: Statistical analysis of the data was performed with student't' 
test and ANOVA. P< 0.05 was considered significant. 
Results 
The results of the present investigations showed a modulatory effect of DAS 
on the expression of tumor suppressor gene p53 (both wild and mutant type) and its 
effector molecule p21/waf1 in mouse skin tumors. Thus the chemopreventive 
property of DAS seems to be through the p53 dependent mechanism. The results are 
summarized below: 
Effect of DAS on the expression of wtp53: 
The levels of wtp53 protein were over-expressed in tumors obtained by 
DMBA application (Gr. II) in comparison to normal mouse skin (Gr. I), where this 
protein was found in detectable limits (Fig. 20, lanes a & b). A comparatively high 
level of expression of this protein was observed in tumors of DAS supplemented 
groups (Gr. Ill & Gr. IV), indicating that wtp53 protein plays an important role in the 
inhibition of neoplastic changes. However, no significant change in the protein level 
was obsen/ed in tumors where DAS was given prior or after the carcinogen 
application (Fig. 20, lanes c & d). In Gr. V where only DAS was applied to mouse 
skin, levels of wtp53 were comparable to the normal levels (Fig. 20, lanes a & e) 
These qualitative observations were confirmed by quantitating the blots by 
densitometry (Fig. 20). The normal wtp53 level recorded by densitometry was 845 
pixels. An increase of 132% in the pixel density of wtp53 was observed in tumor 
tissue of DMBA exposed animals (Gr. II). However, a further significant increase (P< 
0.05) in the wt p53 protein was recorded in DAS supplemented and DMBA induced 
tumors. In the tumors where DAS was given prior to DMBA (Gr. Ill), the expression 
of wtp53 was 224% more over control group. Similarly, in tumors of Gr. IV 
(DMBA+DAS) the wtp53 expression was 205% over normal tissue. When the 
expression of wtp53 was calculated over DMBA induced tumors, this increase was 
40% and 31% indicating that wtp53 expression checks the cells to go into neoplastic 
state. 
The quantitative stereology of immuno-stained skin/tumor sections for wtp53, 
further lended support to our observation that DAS supplementation increases the 
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Figure 20: Showing western blot and its densitometric analysis of vdp53 
expression in mouse skin/tumors in different groups, (lane a; 
Untreated, b: ACE+ DMBA, c: DMBA+ DAS, d: DAS+ DMBA 
e: ACE+ DAS). 
* Values are significantly different over untreated control, P<0.01 
# Values are significantly different over positive control, P<0.05 
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wtp53 expression, thus attempting to control the cell to acquire the malignant 
phenotype. The photomicrographs showed a varied degree of wtp53 expression 
among the different treatment regimen (Fig. 21). In the normal mouse skin 2.68% of 
the total area showed presence of wtp53. The area showing staining of wtp53 was 
significantly increased (P<0.05) to 8.03% in DMBA induced tumors (Table 12). In 
DAS supplemented groups the levels of wtp53 were further increased showing 17.56 
and 13.69% of the area positive for wtp53 in Gr. Ill and Gr. IV respectively. In the 
DAS exposed skin 2.87% of the area showed the presence of wtp53. The percent 
increase in the area (mm^/cm^) in the levels of wtp53 was 66.55 and 54.21% 
respectively in DAS pre and post supplemented group over DMBA exposed group 
(Table 12). 
The results of the flow cytometric analysis further confirmed the findings of 
western blotting and immunohistochemistry. The FITC fluorescence was recorded in 
the form of histograms for each group and overlay was prepared showing differential 
expression of wtp53 (Fig. 22). The mean fluorescence intensity (MFI) for normal 
mouse skin was 1.68, which increased to 5.31 for DMBA induced tumors (Gr. II). A 
further increase in the fluorescence was recorded in the DAS supplemented groups 
(Gr. Ill & IV) suggesting increase in the levels of wtp53 by DAS. The MFI was 15.41 
for DAS+ DMBA and 10.21 for DMBA+ DAS group respectively. In groups where only 
DAS was given the FITC fluorescence was 1.92, which was close to the normal 
values. The comparable levels of wtp53 in the normal skin (Gr. I) and DAS exposed 
skin (Gr. V) shows the nontoxic nature of DAS. 
Effect of DAS on the expression of mutp53: 
The mouse skin from the animals of control group (Gr. I) showed presence of 
detectable level of mutp53, which was found to over-expressed in tumors obtained 
with DMBA application (Fig. 23, lanes a & b). The over expression of mutp53 
observed in DMBA induced tumors was significantly low (P<0.05) in tumors were 
DAS was given along with the DMBA (Gr. Ill & IV) indicating down regulation of 
induced levels of mutp53 by DAS (Fig. 23, lanes c & d). However, no significant 
difference in expression levels of mutp53 was observed in tumors where DAS was 
given prior and after the DMBA exposure (Fig. 23,lanes c & d). 
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Figure 21: Photomicrographs of mouse sl<in/tumors showing immunohistochemical 
reactivity with ivfp53 in different groups (128X). (a) Untreated, (b) 
ACE+DMBA, (c) DMBA+ DAS, (d) DAS+DMBA, (e) ACE + DAS 
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Figure 22: An overlay of flow cytometric analysis of wtp53 protein expression in 
mouse skin/tumors. The horizontal axis represents FITC fluorescence 
versus counts on vertical axis. Gr. I: Untreated; Gr. II: ACE+ DMBA; 
Gr. Ill: DAS+ DMBA; Gr. IV: DMBA+ DAS; Gr. V: ACE+ DAS 
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Figure 23: Showing western blot and its densitometric analysis of mutp53 
expression in mouse skin/tumors in different groups, (lane a: 
Untreated, b: ACE+ DMBA, c: DMBA+ DAS, d: DAS+ DMBA 
e: ACE+ DAS). 
* Values are significantly different over untreated control, P<0.01 
# Values are significantly different over positive control, P<0.05 
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The quantitation of mutp53 levels by densitometric analysis of blots confirmed 
the down-regulation of the protein by DAS. The intensity of band in normal skin was 
recorded to be 356 pixels. An increase of 318 % in the level of mutp53 was observed 
in tumor tissue of DMBA exposed animals over normal. However, a significant 
decrease (P<0.05) in the levels of mutp53 was recorded in DAS administrated 
groups (Gr. Ill & Gr. IV). In DAS supplemented tumors the expression of the mutp53 
was found to decrease by 44.9 % in DAS pretreated, whereas in DAS post treated 
tumors the expression of the protein was decreased by 41.7% over DMBA induced 
tumors (Gr. II). 
The immunohistochemical analysis of mutp53 in different groups showed 
varied degrees of expression (Fig. 24). In the control mouse skin 2.08% of total area 
showed presence of mutp53 whereas, in the DMBA induced tumors the mutp53 
levels were significantly higher showing 14.75% area stained positive towards 
mutp53. A significant decrease (P<0.05) in percent area showing the presence of 
mutp53 was observed in tumors obtained from DAS supplemented groups (Gr. Ill & 
Gr. IV). In tumors where DAS was given before the DMBA exposure, 10.23% area 
was positive. Whereas, in group where DAS was given after the DMBA 
administration, 11.02% area showed presence of mutp53 (Table 12). No significant 
difference in the percentage area showing mutp53 levels was obtained in tumors 
where DAS was given prior to and after the DMBA exposure. The DAS exposed skin 
showed 2.56% area positive for mutp53, which was found to near to normal levels. 
The percent decrease in the area (mm /^cm )^ showing staining for mutp53 was 53.41 
and 44.26 % in DAS supplemented groups (Table 12). 
The observations of western blotting and immunohistochemistry that DAS 
inhibits the levels of mutp53 in DMBA induced tumors were further confirmed by flow 
cytometry (Fig. 25). The normal skin showed low expression levels of mutp53 with 
MFI of 1.06. In DMBA induced tumors a significant increase in the fluorescence was 
recorded with MFI 16.41 indicating over expression of mutp53. The FITC 
fluorescence was found to decrease in DAS supplemented groups with MFI 3.76 in 
Gr.lll and 8.13 in Gr. IV, suggesting down regulation of mutp53 by DAS (Fig. 25). The 
DAS exposed skin showed levels of mutp53 close to normal levels with MFI 1.65 
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Figure 24: Photomicrographs of mouse skin/tumors showing immunohistochemical 
reactivity with mutp53 in different groups (128X) (a) Untreated, (b) 
ACE+DMBA, (c) DMBA+ DAS, (d) DAS+ DMBA, (e) ACE + DAS 
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Figure 25: An overiay of flow cytometric analysis of mutp53 protein expression 
in mouse skin/tumors. The horizontal axis represents FITC fluorescence 
versus counts on vertical axis. Gr. I: Untreated; Gr. II: ACE+ DMBA; 
Gr. Ill: DAS+ DMBA; Gr. IV: DMBA+ DAS; Gr. V: ACE+ DAS 
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Effect of DAS on the expression of p21/waf1: 
The effect of DAS on the levels of p21/waf1 was also investigated, as it is 
known to be transcriptionally upregulated by the induced levels of wtp53. The 
upregulation of p21/waf1 is associated with the tumor suppressor function of the 
wtp53 and thus might be involved in the molecular mechanism of antitumorigenic 
properties of DAS. The western blot analysis showed detectable levels oi p21/waf1 in 
normal mouse skin (Fig. 26, lane a). The DMBA induced tumor showed significantly 
elevated levels o^ p21/waf1 (Fig. 26, lane b). The DMBA induced levels of p21/waf1 
were further found to increased in DAS supplemented groups (Gr. Ill & IV). However, 
in tumors where DAS was given prior to and after DMBA, no significant change in the 
levels of p21/ waf1 was observed (Fig. 26, lanes c & d). In Gr. V, where only DAS 
was given, the levels of p21/waf1 were comparable to that of the normal levels (Fig. 
26, lanes a & e). 
These qualitative results were also quantitated by densitometric analysis of 
the blots. The normal p21/waf1 level recorded by densitometry was 478 pixels. An 
increase of 72% in the pixel density of p21/ waf1 was observed in tumor tissue of 
DMBA exposed animals (Gr. II). A further significant increase in the levels of p21/ 
waf1 was recorded in the tumor tissue of the animals where DAS was given along 
with the DMBA exposure. In the DAS pretreated tumors, the expression of p21/waf1 
was 200% more over control group (Gr. I). Similarly in the DAS post treated group 
(Gr. IV), the p21/waf1 expression was 184% higher over normal skin (Gr. I). When 
the expression of p21/waf1 was calculated over positive control (Gr. II), the increase 
in the levels were 74 and 65% in DAS+DMBA and DMBA+DAS groups respectively. 
This suggests that DAS induces levels of p21/waf1. 
The results of western blotting were confirmed by immunohistochemical 
detection of the p21/WAF1 expression in different treatment regimen (Fig. 27). The 
image analysis of the immunostained section of normal skin showed 1.59% area 
positive for p21/ waf1. In the DMBA induced tumor the total area showing presence 
of p21/waf1 increased significantly as compared to normal levels. In DMBA induced 
tumors 5.09% of the total area showed the presence of p21/waf1. In DAS 
supplemented groups, the total area showing p21/waf1 expression increased further 
to 7.09% and 9.12% in DMBA+DAS and DAS+DMBA groups respectively (Table 12). 
In DAS exposed skin 1.46% area showed the expression of p21/waf1, which was 
found to be similar to that of the normal levels suggesting nontoxic nature of DAS. 
71 
Modulatory Effects of DAS on pS3 & p21/wafl 
2000 
Figure 26: Showing western blot and its densitometric analysis of p21/waf1 
expression in mouse skin/tumors in different groups, (lane a: 
Untreated, b: ACE+ DMBA, c: DMBA+ DAS, d; DAS+ DMBA, 
e: ACE+ DAS) 
* Values are significantly different over untreated control, P<0.01 
# Values are significantly different over positive control, P<0.05 
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Figure 27: Photomicrographs of mouse skin/tumors showing immunohistochemical 
reactivity with p21/waf1 in different groups (128X). (a) Untreated, (b) 
ACE+DMBA, (c) DIVIBA+ DAS, (d) DAS+DMBA, (e) ACE + DAS 
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The percent increase in the area (nnm /^cm )^ positive for p21/waf1 levels was 72.86 
and 61.22% in groups where DAS was given before or after the DMBA exposure in 
comparison to group where DMBA was given alone (Table 12). 
The flow cytometric analysis of p21/waf1 expression in different experimental 
and control groups provided further support to our observations. A significant 
increase in the fluorescence was observed in the DMBA induced tumors as 
compared to the normal levels indicating over expression of p21/waf1 in Gr. II. The 
shift in the fluorescence was from 6.34 for untreated to 22.42 for DMBA induced 
tumors (Fig. 28). This shift in the fluorescence was further enhanced in DAS treated 
tumors. In tumors where DAS was given before the DMBA exposure, MFI of 53.35 
was recorded. Similarly, in tumors where DAS was given after DMBA exposure, MFI 
was 44.24. In group where animals were given DAS only, the fluorescence was 
recorded at 8.07 channel value indicating normal levels o1 p21/waf1 expression. 
Discussion 
The tumor suppressor gene p53 is regarded as a key factor in maintaining the 
balance between cell growth and cell death in the living system (Agarwal et al, 1998; 
Mowat, 1998). The importance of this gene can be drawn from the fact this gene is 
reported to be mutated in about 80% of the all human malignancies (Hollstein et al, 
1991). Due to its importance in regulation of cell cycle, alterations in p53 are critical 
events in carcinogenesis. The wtp53 was found to be polymorphic with a single 
nucleotide polymorphism in the exon 4 in codon 72 (Matlashewski et al, 1987). The 
substitution of guanine to cytosine changes the resultant amino acid from arginine to 
proline, thus leading to the expression of mutp53. This altered protein is biologically 
and biochemically differs in nature (Thomas et al, 1999; Martin et al, 2000). The 
wtp53 in response to toxic insults to DNA triggers a chain of cell cycle regulatory 
events to check the proliferation of altered cells to repair or minimize the damage 
(Agarwal et al, 1998; Mowat, 1998). In tumors, loss of wtp53 function prevents the 
activation of this growth control pathway (Burns et al, 1991). This failure to induce 
transcriptionally active wtp53 play a role in the unregulated growth of the tumors and 
also in the failure to respond to chemotherapeutic agents, which normally trigger 
wtp53, regulate cell arrest or death (El-Diery et al, 1994). 
Studies have shown the accumulation of both wt and mutp53 following 
exposure with known carcinogens such as DMBA and BaP (Schwartz & Shklar, 
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FITC- fluorescence 
Figure 28: An overlay of flow cytometric analysis of p21/waf1 protein expression 
in mouse skin/tumors. The horizontal axis represents FITC fluorescence 
versus counts on vertical axis. Gr. I: Untreated; Gr. II: ACE+ DMBA; 
Gr. Ill: DAS+ DMBA; Gr. IV: DMBA+ DAS; Gr. V: ACE+ DAS 
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1996; Ember et al, 1998, Serpi et al, 1999). In consistent with tinese findings, in the 
present study, the DMBA exposure was found to induce the levels of wtp53 in mouse 
skin tumors (Fig. 20-22). DAS supplementation further increased the levels of wtp53 
in DMBA induced mouse skin tumors. The increase in the wtp53 expression was 
consistent in all the three methods viz. western blotting, flow cytometry and 
immunohistochemistry employed for the detection of p53, thus increasing the 
credibility of the results. The immunohistochemical staining of the skin tumors 
revealed an increase of 66 and 54% in the levels of wtp53 following pre and post 
DAS supplementation (Table 12). The importance of immuno-localization further 
indicates that DAS increases the stability of the wtp53. The densitometry of western 
blots shows an increase in DAS supplemented tumor cells by 40 and 31% 
respectively (Fig. 20). This increase in immunoreactivity to the wtp53 has also been 
shown in various other studies for evaluating the chemopreventive potential of 
natural products (Schwartz et al, 1993; Schwartz & Shklar, 1996; Narayanan et al, 
1998). These immunohistochemical observations and increased expression of wtp53 
in western blots suggesting that DAS exerts its chemopreventive property by 
modulating wtp53 expression in mouse skin tumor cells (Fig. 20 & 21). In case of 
mutp53 an increased expression was recorded in the tumor cells from DMBA 
induced mouse skin tumors mainly because of the malignant characteristics of 
tumors (Fig. 23-25). The administration of DAS along with DMBA was able to check 
the levels of mutp53 expression as evident in all the three methods employed in the 
present investigation. The immunohistochemical localization of the mutp53 showed 
53 and 44% decrease in the levels of the protein following DAS supplementation 
(Fig. 24). A shift in fluorescence towards the affinity to mutp53 was evident in DAS 
supplemented tumors (Fig. 25). Thus, it is likely that DAS suppresses the growth of 
DMBA induced tumors by increasing the levels of wtp53 and down regulating the 
levels of mutp53 as observed with other chemopreventive agents e.g. carotenoids, 
retinoids etc. (Schwartz, 1999). 
Since the balance between the wt and mutp53 determines the fate of the cell, 
many chemopreventive agents are known to exert their anticancer effects by 
modulating their expression levels. The results of the present study showing 
upregulation of wtp53 and suppressing the expression of mutp53 are in accordance 
with the previous reports where natural and dietary compounds have been shown to 
exert their preventive property through modulating the balance between wt and mut 
p53 protein expression. Vitamin E has been shown to inhibit DMBA induced buccal 
pouch tumor development by stimulating the expression of wtp53 (Schwartz et al, 
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1993). Similarly retinoids, including vitamin A and its synthetic analogs viz. all trans 
and 9-cis retinoic acid, 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene 
carboxylic acid have been shown to induce the levels of wtp53 to check the growth of 
cancer cells. (Narayanan et al, 1998; Sun et al, 2002). The carotenoids and retinoids 
are also reported to prevent DMBA induced in vitro malignant transformation of oral 
human l<eratinocytes by depressing mutp53 and enhancing tumor suppressor p53 
(Schwartz, 1999). Supplementation of 10 mg/l<;g reduced glutathione by oral 
intubation in Syrian Golden hamsters, has been shown to inhibit the experimental 
oral carcinogenesis by increasing the levels of wtp53 in DMBA induced dysplasia and 
squamous cell carcinoma (Schwartz & Shklar, 1996). Certain other chemopreventive 
agents such as ISC, tea polyphenols EGCC and soy isoflavone genistein have been 
shown to inhibit BaP induced aberrant proliferation through the induction of p53 
dependent apoptosis in human mammary epithelial cells (Katdare etal, 1998). 
The upregulation of wtp53 by chemopreventive agents is most likely 
responsible for the transcriptional induction of p21/waf1 by directly interacting with its 
regulatory elements (El-Diery et al, 1994). Thus, the upregulation of p21/waf1 by 
DAS as observed in the results of the present study in DMBA induced tumors could 
be responsible for the growth inhibitory effects of DAS because of its role in cell cycle 
arrest. The levels of p21/waf1 were increased upto the extent of 73 and 65% in DAS 
pre and post supplemented groups as observed in immunohistochemical staining 
(Fig. 27). The increase in the levels of p21/waf1 was also consistent in western 
blotting and flow cytometry (Fig. 26 & 28). However, further insights into the effect of 
DAS on CDK complexes operated by Cdk2 and Cdc2 (Cdkl) and cell cycle 
checkpoints are required. 
The wtp53 is reported to be upregulated in the cells by its increased half-life 
through inhibition of its degradation time (Harris, 1996; Colman et al, 2000) as well as 
modulation of its stability by post-translational events such as phosphorylation and 
acetylation (Kapoor & Lozano, 1998; Oshiro et al, 2003). Therefore, it .is likely that 
upregulation of wtp53 by DAS can occur via a similar mechanism of action. The 
upregulation of wtp53 may also induce the expression of several p53-regulated 
downstream genes including DR5, bax, fas, and p21/waf1, which may cause growth 
arrest or apoptosis of the neoplastic cells (El-Deiry, 1998; Murphy e^ al, 1999; 
Guimaraes & Hainaut, 2002). Moreover, another plausible reason could be the 
prevention of mutation of p53 to oncogenic forms by promoting DNA repair. This may 
also be attributed to the antioxidant and antigenotoxic properties of the DAS (Sai-
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Kato et al, 1995; Wu et al, 2001; Shukia et al, 2003) as oxidants produced during 
tumorigenic transformation promote genetic instability and mutational damage to the 
DNA. Thus, it could be suggested that DAS exerts its anticancer effect either by 
stimulating a cancer suppressor gene to prevent the action of carcinogenic influences 
or by preventing the mutation of other protooncogenes that may function together 
with mutp53. 
The role of p53 in addition to the induction of p21/waf1, is also in the 
protection of the genome integrity via physical interaction with DNA, as well as in 
regulation of cell propensity to apoptosis (Mowat, 1998; Heinrichs & Deppert, 2003). 
Many chemopreventive agents are known to exert their anticancer effects through 
the induction of apoptosis via p53 dependent mechanisms. Shin ef al (1997) have 
shown the accumulation of p53 protein and retinoic acid receptor beta as a 
mechanism of chemopreventive efficacy of retinoids in clinical settings. Resveratrol, 
a natural chemopreventive phytoalexin of wine and grapes, is known to suppress cell 
transformation and induce apoptosis through a p53 dependent pathway (Huang et al, 
1999; She et al, 2001). Capsaicin, a principal pungent ingredient from hot red and 
chili peppers has been shown to induce apoptotic death of cultured human gastric 
cancer cells mediated via over expression of the p53 tumor suppressor gene and/or 
c-myc proto-oncogene (Kim ef al, 1997). Similarly DADS, has been shown to induce 
apoptosis and non-steroidal anti-inflammatory drug (NSAID) activated gene {NAG-1} 
protein expression, via p53 dependent mechanisms in human colorectal HCT 116 
cells (Bottone et al, 2002). Similarly, Hong et al (2000) have shown that the 
mechanism of apoptosis induced by organoallyl sulfur compounds such as DAS, 
DADS or garlic extract was regulated through p53 dependent or p53 independent 
related bax/bcl2 dual pathway in non small cell lung cancer cell lines. Earlier we have 
shown that DAS can induce apoptosis in DMBA induced tumor cells (Arora & Shukia, 
2003a). Thus on this basis and results of the present chapter of this dissertation a 
correlation between the tumor suppressor p53 and apoptosis in the anticancer 
mechanism of DAS could be established. The upregulated wtp53 by DAS induces 
levels of p21/waf1, which in turn may cause tumor cells to undergo apoptosis. 
Thus, from the present study, it can be concluded that dietary agents like 
DAS can act to up-regulate wtp53 and p21/waf1 and down-regulate of mutp53 to 
provide protection in cancer development and retard malignancy. 
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Modulatory Effect of DiallyI Sulfide 
on ras P21 in Skin Carcinogenesis 
Modulation ofp21/ras by DAS 
Introduction 
During the past few decades advances in the molecular oncology had greatly 
increased our understanding of genetic events associated with the propensity for 
uncontrolled proliferation leading to tumorigenesis. Increasing evidence suggests that 
small sets of cellular genes termed 'proto-oncogenes' are the targets for genetic 
alterations and contribute to the neoplastic transformation of cells. The proto-
oncogenes can be activated as oncogenes by point mutations, gross DNA 
rearrangements such as translocations and gene amplifications. The activation of 
proto-oncogenes by genetic alterations results in the altered levels of expression of the 
normal protein product or in normal or altered levels of expression of an abnormal 
protein. Such knowledge had opened up potentially exploitable targets for the 
intervention of carcinogenic process. The proto-oncogenes are expressed during 
regulated growth such as embryogenesis, regeneration of damaged liver and 
stimulation of cell mitosis by growth factors (Stanley, 1995). Proto-oncogenes are 
highly conserved being detected in species as divergent as yeast, drosophila, rodents 
and humans. These coding genes include growth factor receptors (net/, erbB, fms), 
regulatory proteins in signal transduction {ras family), nuclear regulatory proteins {myc, 
myb, fos) and tyrosine kinases {scr, abl). Thus the encoded proteins appear to play a 
crucial role in normal cellular growth and differentiation. 
The ras genes have been the focus of intense research since 1982 when their 
transforming alleles were first identified in human tumors (Barbacid, 1987). The ras 
genes are highly conserved and expressed constitutively in different cell types, 
suggesting that the ras proteins have essential cellular functions (Lowy & Willumsen, 
1993; Malumbres & Pellicer, 1998). The acronym 'ras'is derived from the word 'rat 
sarcoma' because these genes were first identified as the transforming principle of the 
Harvey and Kirsten strains of rat sarcoma viruses (Harvey, 1964; Kirsten & Mayer, 
1969), two acute transforming retroviruses generated by transduction of the rat H-ras-1 
and K-ras-2 cellular genes respectively (DeFeo et al, 1981; Ellis et al, 1981). The 
members of the ras family of proto-oncogenes include H-ras-1, K-ras-2 and N-ras in 
the mammalian genome. The third form N-ras was detected in human & rodent tumors 
but not in retroviruses (Hall e^  al, 1983). 
The members of the ras family are implicated in carcinogenesis as they are 
consistently found to be mutated in about one half of almost all animal and human 
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cancers in a wide variety of tissues (Rodenhuis, 1992; Stanley, 1995). Different cancer 
types preferentially exhibit transforming mutations in a particular member of the ras 
family as demonstrated by the high frequency of H-ras mutations in bladder 
carcinomas, K-ras mutations in lung, colon and hepatic carcinomas and N-ras 
mutations in melanomas and hematopoietic cancers. The ras proto-oncogene is 
activated to an oncogene by specific point mutations, frequently at codons 12, 13 or 61 
and less commonly at 117 and 146 (Sloan etal, 1990). Activated ras proto-oncogenes 
have been detected in a relatively high percentage of colon (47%), pancreatic (81%), 
lung (32%), thyroid (56%) endometrical (47%), ovary (75%), squamous cell 
carcinomas at sun exposed body sites (47%) and to a lesser extent in several other 
types of human tumors (Anderson et al, 1992). The ras oncogenes have also been 
detected in spontaneous and chemically induced tumors generated in numerous 
rodent model systems (Nelson et al, 1992; Vageli et al, 1996; Chakravarti et al, 1998; 
Wei et al, 1999). Analysis of mouse skin papillomas and carcinomas using the NIH3T3 
transformation assay revealed that the great majority of the tumors induced by DMBA 
have a specific A to T transversion at the second nucleotide of codon 61 of the H-ras 
gene (Quintanilla et al, 1986; Nelson et al, 1992). In contrast, tumors initiated by 
MNNG or BaP contain G to A or G to T mutations of the second base in codon 12 
respectively (Bos & van KreijI, 1992). Similariy, in the rat mammary tumor model 
system tumors induced by DMBA contain an activated H-ras gene only infrequently in 
the codon 61 (Zarbl et al, 1985). 
The ras family of proto oncogenes encode 21-kDa protein {p21/ras), which 
occupies a central position in the signal transduction pathway from the cell membrane 
to the nucleus and appears to play a critical role in the control of cell growth, 
differentiation and survival (Malumbres & Pellicer, 1998; Reuther & Der, 2000; Pruitt & 
Der, 2001). It comprises a family of GTP- dependent proteins (G-proteins) that cycles 
between a GTP-binding active 'ON' state and a GDP-binding inactive 'OFF' state (Fig. 
29). Activation of either normal or oncogenic ras protein occurs by the release of 
bound GDP and its replacement with GTP. This exchange is catalyzed by a family of 
proteins termed 'guanine nucleotide exchange factors' (GEFs) (Cherfils & Chardin, 
1999). Deactivation of ras protein occurs by the hydrolysis of bound GTP to GDP by 
ras. This reaction is also enhanced by the interaction with a family of proteins termed 
'guanosine triphosphatase (GTPase)-activating proteins' (GAPs) (Donovan et al, 
2002). The activation of cell surface receptor introduces GDP-GTP exchange on ras 
and the conversion of inactive ras-GTP (Scheffzek et a/^^-^^^^flJShp^nals through 
a series of downstream regulators and begins % serine threonine kirfese-signaling 
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Signal: cellular growth, proliferation, differentiation 
Figure 29: The switch function of ras. The ras cycles between the active GTP-
bound and the inactive GDP-bound state. iVIitogenic signals activate 
guanine GEFs which increases the rate of dissociation of GDP and 
stabilize the nucleotide free form of ras, leading to binding of GTP to ras 
proteins. The ras can also be activated by the inhibition of the GAPs. 
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cascade (Hunter, 1997; Campbell et al, 1998). Thus, the degree to which ras proteins 
are activated in cells at any time depends on the relative activities of GEFs and GAPs. 
Oncogenic forms of ras contain amino acid substitutions that reduce their intrinsic 
GTPase activity and their ability to respond GAPs (Campbell et al, 1998), leading to 
accumulation of ras in the activated GTP bound state in many tumor cells. 
There are several points during activation at \Nh\ch the function of the 
oncogene product ras can be inhibited and can be related to chemoprevention 
strategies. Approaches to blocking ras function have included such varied methods as 
blocking protein expression, post-translational processing, membrane anchorage, 
GTPase sensitivity, effector interaction and selective targeting of cells in which ras 
signaling is active (Aoki et al, 1995; Coffey et al, 1998; Marom et al, 1998; Adjei, 
2001). The most thoroughly Investigated of any class of anti-ras compounds are the 
farnesyl transferase inhibitors, designed to inhibit the post-translational modifications 
of newly synthesized ras by a farnesyl isoprenoid group (James et al, 1993; Kohl et al, 
1993; Kloog & Cox, 2000). The post-translational modifications to the 3' end of p21/ras 
i.e. farnesylation is necessary for ras to be localized to the inner side of the plasma 
membrane and such membrane localization is critical for ras growth promoting and 
transforming activities (Jackson et al, 1990; Der & Cox, 1991; Kato e^  al, 1992; 
Sinensky & Lutz, 1992). The transfer of the farnesyl group from farnesyl 
pyrophosphate (FPP) is catalyzed by a specific cytosolic enzyme farnesyl transferase 
(FTase) (Cho & Lee, 2002). The FPP pool originates from the mevalonic acid pathway 
of cholesterol biosynthesis (Goldstein & Brown, 1990). Mevalonate, a precursor of 
various cellular isoprenoids including FPP, is synthesized from 3-hydroxy, 3-methyl 
glutaryl coenzyme A (HMG-CoA), a reaction catalyzed by HMG-CoA reductase 
(Goldstein & Brown, 1990). Therefore, inhibition of p21/ras farnesylation can be 
achieved either by inhibiting FTase activity or by lowering the FPP pool through 
inhibition of HMG-CoA reductase activity. 
Since p21/ras plays a crucial role in the onset of tumorigenesis, therefore 
attempts to achieve cancer chemoprevention at this level will be an effective approach. 
The review of literature showed very few studies targeted at p21/ras modulation by 
naturally occurring compound. Thus, the present investigation is aimed to study the 
modulation of p21/ras oncoprotein by DAS in mouse skin tumors in order to study its 
molecular mechanism of action in cancer chemoprevention. 
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Material and Methods 
Materials: 7,12-Dimethyl benzanthracene, Diallyl sulfide and Coomassie Brilliant 
Blue were purchased from Sigma (St Louis, USA). The monoclonal pan-ras (clone 
F111-85, Ab-2) antibody was procured from Oncogene Research Products 
(Cambridge, USA). The horseradish conjugate isotypes were obtained from Banglore 
Genei (India) and the FITC conjugates were procured from Becton Dickinson (USA). 
The nitrocellulose membranes were obtained from Sartorious, (Germany). The rest of 
the chemicals were of analytical grade of purity and were procured locally. 
p21/ras Studies: 
I. Short-term studies: The effect of DAS on the expression of p21/ras was 
investigated following DMBA exposure on mouse skin. Sixty male Swiss albino mice 
(body weight 10-12 gm) were taken for the study from the ITRC animal breeding 
colony and were maintained as described in chapter 1. The animals were divided into 
three sets of five different groups consisting of four animals each. The treatments were 
given topically on shaved dorsal skin as per dose and schedule given below: 
Gr. I-A,B,C (ACE) 100|il Acetone applied topically, once only. 
Gr.ll-A,B,C (ACE+DMBA) 100^1 Acetone applied topically followed 24 hr. 
later by 5 |ig DMBA/animal in 100 )il acetone. 
Gr. III-A,B,C (DAS+DMBA) 10 mg/kg b.wt. DAS applied topically in 100 1^ 
acetone followed 24 hr. later by 5 \ig 
DMBA/animal in 100 fil acetone. 
Gr. IV-A,B,C (DMBA+DAS) 5 fig DMBA/animal applied topically in 100 |xl 
acetone followed 24 hr. later by 10 mg/kg b.wt. 
DAS in 100 |al acetone. 
Gr. V-A,B,C (ACE+DAS) lOO i^l Acetone applied topically followed 24 hr. 
later by 10 mg/kg b.wt. DAS in 100 |LII acetone. 
All the animals from the set A, B & C were sacrificed by cervical dislocation 
after 24, 48 & 72 hrs of last treatment. The skin from the painted area was excised out, 
washed in chilled PBS and fat layer was scarped off with the help of sterilized scalpel 
blade. The skins were stored at -80°C in ultra deep freezer (Revco, USA) until used for 
further experimentation. 
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II. Long-term studies: The long term p21/ras studies were conducted in mouse skin 
tumors, obtained from the treatment schedule described in detail in Material and 
Methods, Chapter 1 and Chapter 2 of this dissertation. 
Preparation of Cytosolic and Membrane Fractions Containing p21/ras: The 
cytosolic and membrane fractions containing ras proteins were prepared as described 
by Limtral<ul et al (2001). Briefly, skin/tissue were washed with cold PBS, chopped 
finely with the help of sterilized scissors and surgical blades and 10% (w/v) 
homogenate was prepared by using Ultra-Turrax, homogenizer (Germany) in buffer 
(containing 20mM Tris-HCI, pH 7.5, 5mM MgClz, 1 mM EDTA, ImM DTT, ImM PMSF, 
20|ig/ml aprotinin and 10 ixg/ml leupeptin). The homogenate was centrifuged (M.B. 
cooling, India) at 700g for 5 min at 4°C to remove debris and nuclei. The supernatant 
was further centrifuged at lO.OOOg (M.B. Cooling, India) for 30 min at 4°C. The 
supernatant was collected as cytosolic fraction and the membrane pellet was 
resuspended in buffer containing 1% NP-40, 0.5% sodium oxycholate, 0.1% SDS, 0.6 
mM PMSF and 1 mM sodium orthovanadate in PBS, pH 7.4, vortexed for 30 min and 
then centrifuged at (M.B. cooling, India) 10,000 g for 30 min at 4°C. The supernatant 
was used as membrane fraction for p21/ras analysis. 
Protein Estimation: The protein estimation was performed routinely by the Folin-
Phenol method of Lowry et al (1951) as described in detail in Material and Methods; 
Chapter 2 of this dissertation. 
SDS-PAGE: The SDS-PAGE was performed according to the method of Laemmli et al 
(1970) using a mini slab gel apparatus (Banglore Genei, India). Electrophoresis was 
carried out in 10% polyacrylamide gels using Tris-glycine buffer (pH 8.3) containing 
0.025 M Tris, 0.192 M glycine and 0.1% SDS. Protein samples (100 |ig) were mixed in 
sample buffer (containing Tris-HCI (0.25M, pH 6.8); p-mercaptoethanol (0.5% v/v), 
SDS (1%w/v), glycerol (10%) and bromophenol blue (0.1%). Samples were then kept 
in boiling water for 3 min. The polyacrylamide gels were electrophoreses for 15 min at 
60 V before loading the protein samples. The protein samples were loaded on to the 
gels and electrophoresis was carried out at a constant voltage of 60V. The gels were 
stained overnight with 0.1% coomassie brilliant blue dye (in propanohacetic acid: 
distilled water, 20:12.5:67.5 v/v). The gels were then destained in acetic acid: 
methanol: distilled water (10:45:45 v/vl) solution and were recorded on gel 
documentation system (Herolab, Gmbh, Germany). The marker protein (Sigma, USA) 
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used (molecular weights given in parentheses) were: albumin, bovine serum (66 kD); 
ovalbumin, chicken egg (45 kD); glyceraldehydes-3-phosphate dehydrogenase, rabbit 
muscle (36 kD); carbonic anhydrase, bovine erythrocytes (29 kD); trypsinogen, bovine 
pancrease (24 kD); trypsin inhibitor, soybean (20 kD). The molecular weight of the 
sample protein was calculated using EasyWin32 software, Herolab Gmbh, Germany. 
Western blotting: Western blotting for p21/ras was carried out in the membrane 
fractions of the skin obtained from short-term treatment of animals and in both 
cytosolic and membrane fractions of tumor tissue, as described in Material and 
Methods, Chapter 2 of this dissertation. The p21/ras levels were detected with 
monoclonal par)-ras antibody (0.25 ^g/ml) in1% milk-TBS-T (0.05% Tween 20 in TBS) 
using chromagen DAB. 
Densitometric Analysis: The intensities of the bands were quantitated using Easy 
Win 32 software on Gel Documentation System (Herolab, Gmbh, Germany). The 
intensity of each band was expressed in terms of pixel density for each band. 
Immunohistochemistry: For immunohistochemistry cryostat sections (10 pm thick) 
of frozen skin/tumor tissues were cut, fixed in 4% formal saline and immunoreacted 
with anti-ras antibody (2.5|xg/ml) as described in Material and Methods, Chapter 2 of 
this dissertation. 
Image Analysis: The immunostained slides were analyzed and scored, using Leica 
Image Analysis System, Germany. The quantitative stereology was performed with 
Leica QWin 500 Image analysis software, for each slide in triplicates with at least six 
microscopic fields. 
Flow cytometric Analysis of p21/ras protein: The flow cytometric analysis of 
p21/ras protein was done as described for p53 in Material and Methods, Chapter 2 of 
this dissertation with the exception that the primary antibody used was monoclonal 
pan-ras (2)ig/ml in PBS containing 1 % BSA). 
Statistical Analysis: The statistical analysis of the data was performed using student t 
test and ANOVA. P< 0.05 was considered significant. 
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Results 
The results of the present set of investigations revealed that DAS can 
effectively check the expression of p21/ras protein in mouse sl<in tunnors. The 
expression of p21/ras was found to be different in various treatment groups confirming 
the effect of DAS on differential expression of this oncoprotein coded by H-ras. This 
observation was confirmed by western blotting and flow cytometric analysis of 
samples. The results of different sets of experiments are summarized below: 
I. Short term studies 
SDS-PAGE analysis: The SDS-PAGE analysis revealed significant changes in the 
expression of protein with molecular weight ranging between 20-24kD in the 
membrane fractions of the skin obtained from different treated groups (Fig. 30 & 31). 
The molecular weight of this protein was found to be 22.13 kD, when calculated using 
Easy Win 32 software (Herolab, Germany). Since this protein is in the membrane 
fractions, then this modulated protein might be the p21/ras, which is known to be 
localized to the inner surface of the plasma membrane. The expression of this protein 
was found to be increased in the DMBA exposed skin (Gr. II A-C) in comparison to the 
control (Gr. I A-C) (Fig. 30, lanes a, c, f, h, k & m). But in DAS supplemented groups 
(Gr. Ill A-C & Gr. IV A-C), the expression of p21/ras was decreased as compared to 
Gr. II A-C (Fig. 30, lanes c-e,h-j,m-o). However, no significant difference in the 
expression level of p21/ras was observed in group where animals were give DAS 
before or after the DMBA exposure. Furthermore, in group where animals were given 
single application of DAS (Gr. V A-C), the levels of the protein were similar to that of 
the control (Fig. 30, lane a, b, f, g, k & 1). When the changes in the expression of 
p21/ras were analyzed in individual groups, time dependent increase in the levels of 
the protein was evident in DMBA exposed group over control (Fig. 31, lanes a-d). But 
this increased expression of p21/ras was found to decrease as the duration of DAS 
exposure increases. In DAS supplemented groups i.e. Gr. Ill A-C & IV A-C, the 
expression o1 p21/ras was significantly less at all the three time intervals viz. 24, 48 & 
72 hr, when compared to Gr. II A-C. The initial over-expression of p21/ras at 24 hr. in 
Gr. Ill A & IV A came down to near normal values at 72 hrs in both the groups (Gr. Ill C 
& IV C) (Fig. 31, lanes e-l). However, no significant change in the expression of 
p21/ras over controls (Gr. I A-C) was observed in Gr. V A-C where only DAS was 
given at all the time intervals (Fig. 31, lanes m-p). 
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The densitometric analysis of the electrophoretogram showed that the levels of 
the protein in untreated skin was 235, 257 & 257 pixels at time intervals of 24, 48 & 72 
hrs respectively. An increase of 131.49% in the levels was observed in DMBA exposed 
group (Gr. II A) at 24 hrs (Fig. 30, lanes a & c). The increase in the protein expression 
was further substantiated with the increase in the duration of exposure. The increase 
of 174.71 and 216.34% was observed at 48 and 72 hrs respectively in Gr. II B,C over 
their respective controls (Gr. I B,C) (Fig. 30, lanes f,h,k,m). In DAS supplemented 
groups, the increase in the protein levels were 90.21, 47.47 & 22.57% and 105.11, 
74.32 & 44.36% in DAS pre (Gr. Ill A-C) and post (Gr. IV A-C) treated group at 24, 48 
and 72 hrs respectively over control group. But when these levels were compared with 
the DMBA exposed group (Gr. II A), a decrease of 17.83 and 11.40 % was evident in 
Gr. Ill A & Gr. IV A at 24 hrs of exposure (Fig. 30, lanes c-e). A decrease of 46.32 and 
62.48% was observed at 48 and 72 hrs in group where DAS was applied before DMBA 
(Gr. Ill B,C) (Fig. 30, lanes h,i,m,n). Whereas, 36.54 and 54.37% decrease in the 
protein expression was evident in group where DAS was given after the DMBA 
exposure (Gr. IV B,C) (Fig. 30, lanes h,j,m,o). No significant difference in the levels of 
the protein was evident where DAS was given alone (Gr. V A-C) at all the time 
intervals (Fig. 30, lanes a,b,f,g,k,l). Similarly, when the changes in the expression 
pattern of the protein was analyzed time dependently in individual groups, 145.16, 
207.37 and 263.57% increase was observed at 24, 48 and 72 hrs in Gr. II A-C over 
normal levels (Gr. I A-C) (Fig. 31, lanes a-d). In DAS supplemented groups the 
increase was 94.25, 6.25 & 27.43 % in Gr. Ill A-C and 122.55, 65.53 & 45.96 % in Gr. 
IV A-C was observed at 24, 48 & 72 hrs respectively (Fig. 31, lanes e-l). In Gr. V A-C, 
the increase was 19.78, 13.92 & 3.66 % over control levels suggesting that DAS alone 
had no effect on the expression of the protein (Fig. 31, lanes m-p). 
Western blot analysis: 
The western blot analysis with pan-ras monoclonal antibody confirmed that this 
modulated protein as observed in SDS-PAGE was p21/ras. The western blots further 
confirmed the increase in the levels of p21/ras in DMBA exposed mouse skin (Gr. II A-
C) over control levels (Gr. I A-C) time dependently (Fig. 32 & 33). These elevated 
levels of the protein were found to decrease in DAS exposed skin (Gr. Ill A-C & IV A-
C) indicating that DAS checks the neoplastic changes at an early stage. However the 
decrease in the levels of p21/ras following DAS exposure was not significant at 24 hrs 
but at 48 and 72 hrs of DAS exposure the decrease was significant (Fig. 32, lanes c-e, 
h-j, m-o; Fig. 33, lanes b-d,f-h,j-l,n-p). However, no significant difference in the levels 
of p21/ras was evident in groups where DAS was given before or after the DMBA 
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exposure (Fig. 32 & 33). In animals where only DAS was applied topically (Gr. V A-C), 
no changes in the levels of the p21/ras was observed at 24, 48 and 72 hrs of exposure 
over controls (Fig. 32 & 33). 
The densitometric analysis of blots confirmed the down-regulation of the 
p21/ras by DAS at an early stage of tumor development. The basal level of p21/ras 
recorded by densitometry was 224, 219 & 220 pixels at 24, 48 & 72 hrs respectively. 
An increase of 145.45, 217.35, 263.01% in the pixel density of p21/ras was observed 
in the skin of DMBA exposed animals (Gr. II A-C) over control levels (Gr. I A-C) (Fig. 
32, lanes a,c,f,h,k,l). The expression of the p21/ras was found to decrease significantly 
in DAS+DMBA (Gr. Ill A-C) and DMBA+DAS (Gr. IV A-C) group over DMBA induced 
skin (Gr. II A-C). The decrease was 18.34, 50.07 & 54.84% in Gr. Ill-A, lll-B & Ill-Cand 
12.52, 41.15 & 48.18 % in Gr. IV-A, IV-B & IV-C (Fig. 32, lanes c-e, h-j, m-o). When 
the levels of p21/ras in DAS supplemented groups were compared over control, the 
levels were 106.70, 58.45 & 63.93% more in DAS pretreated and 121.43, 86.76 & 
88.13 % more in DAS post treated groups at 24, 48 and 72 hrs respectively. Whereas 
skin exposed to DAS alone (Gr. V A-C) showed intensity of 231, 228 & 273 pixels at 
24, 48 and 72 hrs, which were closed to the normal levels. Similar results were 
observed when the blots were quantitated at different time intervals in individual group 
(Fig. 33). This increase in the p21/ras expression was 124.54, 163.00 & 205.49 % at 
24, 48 and 72 hrs respectively in DMBA exposed skin (Gr. II A-C) over control (Gr. I A-
C) (Fig. 33, lanes a-d). In DAS+DMBA group the increase was 82.81, 40.62 & 33.20% 
whereas in DMBA+DAS group the increase was 113.17, 68.72 & 56.79 % at 24, 48 & 
72 hrs of exposure (Fig. 33, lanes e-l). In group where DAS was given alone (Gr. V A-
C), the intensities of the bands were close to the normal values (Fig. 33, lanes m-p) 
Effect of DAS on p21/ras in DMBA induced sl(in tumors: 
The normal mouse skin showed levels of both cytosolic and membrane bound 
p21/ras within the detectable limits (Fig. 34, lane a; Fig. 35, lane a). In Gr. II (ACE+ 
DMBA) high levels of p21/ras were found in both the fractions in comparison to Gr. I 
(untreated) (Fig. 34, lanes a & b; Fig. 35, lanes a & b). The tumors from DAS 
administered groups (Gr. Ill & IV) also showed elevated levels oi p21/ras as compared 
to normal levels (Fig. 34, lanes c & d; Fig. 35, lanes c & d). The levels of cytosolic 
p21/ras in DAS supplemented groups were found to be elevated in comparison to the 
levels of the protein in DMBA induced tumors. Whereas, an opposite trend was evident 
for the levels of membrane bound p21/ras. A significantly diminished level of the 
protein was observed in the membrane fractions from DAS treated groups (Gr. Ill & Gr. 
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1500 
Figure 34: Showing western blot and its densitometric analysis of p21/ras 
expression in cytosolic fractions of mouse skin/tumors in different 
groups, (lane a: Untreated, b: ACE+ DMBA, c: DAS+ DMBA, d: DMBA 
+ DAS, e: ACE+ DAS). 
* Values are significantly different over untreated control, P<0.01 
Modulation ofp21/ras by DAS 
a 
1500 
c 
1 5 
X 
CL 
1000 
500 
Figure 35: Showing western blot and its densitometric analysis oi p21/ras 
expression in membrane fractions of mouse skin/tumors in different 
groups, (lane a: Untreated, b: ACE+ DMBA, c: DAS+DMBA, d: DMBA+ 
DAS, e: ACE+ DAS). 
* Values are significantly different over untreated control, P<0.01 
# Values are significantly different over positive control, P<0.05 
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IV) as compared to that of Gr. II (ACE+ DMBA) (Fig. 35, lanes b, c & d). These results 
thus provide clear evidence that the membrane association of p21/ras is significantly 
inhibited with a concomitant increase in cytosolic p21/ras by DAS administration in 
DMBA induced mouse skin tumors. The levels of both cytosolic and membrane bound 
p21/ras in DAS exposed skin were found to be near to normal levels (Fig. 34, lane e; 
Fig. 35, lane e). 
The quantitation of p21/ras levels by densitometric analysis of blots confirmed 
the down-regulation of the membrane bound protein by DAS. The intensity of band in 
normal skin was recorded to be 365 and 379 pixels in cytosolic and membrane fraction 
respectively. An increase of 207 and 261 % in the level of p21/ras was observed in 
tumor tissue of DMBA exposed animals in cytosolic and membrane fraction 
respectively (Fig. 34 & 35). In DAS administered groups the increase in the cytosolic 
and membrane bound p21/ras in comparison to normal levels was 240 and 167 % for 
DAS+ DMBA (Gr. Ill) and 253 and 140 % for DMBA+ DAS (Gr. IV) (Fig. 34 & 35). In 
cytosolic fractions the level of p21/ras in DAS treated tumors was increased by 11 and 
15 % in DAS pre and post-treated group respectively. Whereas, a significant decrease 
in the levels of the membrane bound protein was evident in DAS supplemented group. 
This decrease was 34 and 26 % in tumors where DAS was given before and after the 
carcinogen exposure. The DAS exposed skin showed 356 and 405 pixel density for 
the levels of cytosolic and membrane bound p21/ras. 
The results of the immunohistochemical staining of the skin/tumor sections 
further lended support to our observation that DAS supplementation decreased the 
p21/ras expression thus checking the growth of neoplastic cells. The 
photomicrographs of different groups showed a varied degree of p21/ras expression 
among the different treatment regimen (Fig. 36). In the normal mouse skin 2.12% of 
the total area showed presence of p21/ras. The area showing level of p21/ras was 
significantly increased to 11.76% in DMBA induced tumors (Table 13). In DAS 
supplemented groups the levels oi p21/ras were decreased showing 7.89 and 8.87 % 
of the area positive for p21/ras in Gr. Ill and Gr. IV respectively. In the DAS exposed 
skin 1.90 % of the area showed the presence of p21/ras. However the percent 
decrease in the area (mm^/crn^) of p21/ras was 55.82 and 46.86% in Gr. Ill and Gr. IV 
respectively (Table 13). 
The results of the flow cytometric analysis further confirmed the findings of 
western blotting and immunohistochemistry. The FITC fluorescence was recorded in 
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Table 13: Effect of DAS on the Expression Levels p21/ras in DMBA 
Induced Mouse Skin Tumors. 
Groups 
Gr. 1 
Gr. II 
Gr. Ill 
Gr. IV 
Gr. V 
Treatment 
Untreated 
ACE+ DMBA 
DAS+ DMBA 
DMBA+ DAS 
ACE+ DAS 
Positive Area 
Fraction (%) 
2.12 
11.76 
7.89 
8.87 
1.90 
Area (mm^/ cm )^ 
(IVIean + SE) 
5.34+0.67 
23.86+1.89* 
10.54+1.86^^ 
12.68+2.04'^ 
5.76+0.78 
inliibition 
(%) 
-
-
55.82* 
46.86* 
-
* % Inhibition was calculated over Gr. II 
* Values are significantly different (P<0.01) over Gr.l when analyzed by one-
way ANOVA. 
•^  Values are significantly different (P < 0. 01) over Gr.ll when analyzed by one 
-way ANOVA 
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Figure 36: Photomicrographs of mouse skin/tumors showing immunohistochemical 
reactivity with p21/ras in different groups (128X). (a) Untreated, (b) 
ACE+DMBA, (c) DAS+DMBA, (d) DMBA+ DAS, (e) ACE + DAS 
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the form of histograms for each group and overlay was prepared showing differential 
expression of p21/ras in different groups (Fig. 37). A significant increase in the 
fluorescence was observed in the tumors obtained by DMBA application as compared 
to the normal levels indicating over expression o\ p21/ras in Gr. II. The shift in the MFI 
was from 1.21 for untreated to 13.77 for DMBA induced tumors (Fig. 37). This shift in 
the fluorescence was decreased in DAS treated tumors. In tumors where DAS was 
given before the DMBA exposure, MFI of 5.42 was recorded. Similarly, in tumors 
where DAS was given after DMBA exposure, MFI was 8.76. In group where animals 
were given DAS only, the fluorescence was recorded at 1.72 channel value indicating 
normal levels of p21/ras expression. 
Discussion 
There are growing evidences which suggests that oncogenic p21/ras has a 
major role in mouse skin tumorigenesis (Oxford & Theodorescu, 2003; Spandidos et 
al, 2002). The ras proto-oncogenes can be activated to induce cell transformation 
through single base substitution mutations resulting in altered p21 product with 
increased transforming ability (Pruitt & Derr, 2001; Spandidos et al, 2002). Because 
the frequency of ras mutations is among the highest for any gene in human cancers, 
development of inhibitors of ras signaling pathway as potential anticancer agents is a 
very important pharmacologic strategy (Dancey, 2002; Ghobrial & Adjei, 2002; 
Downward, 2003). Inhibitors of ras signaling have been shown to revert ras dependent 
transformation and cause regression of ras dependent tumors in animal models 
(Dancey, 2002; Downward, 2003). 
The results of the present study showed significant increase in the levels of 
p21/ras in a time dependent manner following single topical application of initiating 
dose of DMBA. These findings are in accordance with the earlier reports where 
mutations in the H-ras gene have been reported one day after the dibenzo[a,l]pyrene 
exposure suggesting that mutations occurred by pre-replication misrepair (Chakravarti 
et al, 1998). Chakravarti et al (1998) also showed that the frequency of these 
mutations reach at maximum by day 3, rapidly decline between days 7-9 and increase 
again during the clonal expansion of pre-papillomas into tumors. The present study 
also showed the maximum levels o1 p21/ras after 72 hrs of DMBA exposure (Fig. 31 & 
33). 
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Figure 37: An overlay of flow cytometric analysis of p21/ras protein expression 
in mouse skin/tumors. The horizontal axis represents FITC fluorescence 
versus counts on vertical axis. Gr. I: Untreated; Gr. 11: ACE+ DMBA; 
Gr. Ill; DAS+ DMBA; Gr. IV: DMBA+ DAS; Gr. V: ACE+ DAS 
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DAS administration was found to modulate the DMBA induced levels Q\ p21/ras 
oncoprotein as early as 24 hrs after the DMBA treatment indicating that DAS exerts its 
anticarcinogenic effects at the early stages of tumor development. Since 
chemopreventlon aims to prevent the process of carcinogenesis at an early stage, 
DAS could be a potent chemopreventive agent. The modulatory effect of DAS on 
p21/ras levels was also evident in the mouse skin tumors induced with DMBA, known 
to harbor ras mutations, as evident by multifaceted approaches used in the present 
study viz. SDS-PAGE, western blotting, immunohistochemistry and flow cytometry. A 
significant down regulation of p21/ras was observed in the membrane fractions from 
DAS supplemented tumors as compared to that of DMBA exposed tumors (Fig. 35). 
However, an opposite trend was evident for cytosolic p21/ras. Tumors from DAS 
supplemented animals had higher levels of cytosolic p21/ras levels as compared to 
those from DMBA induced tumors (Fig. 34). These results thus provide emphatic 
evidences that the membrane association of p21/ras is significantly inhibited with a 
concomitant increase in cytosolic p21/ras by DAS administration. It is well established 
that the association of p21/ras to the inner surface of the plasma membrane is an 
absolute requirement for triggering ras oncogenicity (Jackson et al, 1990; Der & Cox, 
1991; Kato et al, 1992; Sinensky & Lutz, 1992). Thus, DAS might be involved in the 
modulation of post-translational modification (e.g. farnesylation) and membrane 
association as a plausible mechanism for its growth inhibitory properties. Since both 
FTase and HMG CoA reductase are critical for p21/ras farnesylation and consequently 
its membrane localization, further studies are needed to investigate whether the 
inhibition of tumoral p21/ras membrane localization in DAS treated mice was due to 
the inhibition of FTase and/or HMG CoA reductase activity. 
Several naturally occurring compounds of dietary origin have been reported to 
regulate the growth of tumors that contain activated ras oncogene through the 
inhibition of membrane localization o\ p21/ras (Hohl & Lewis, 1995; Khan et al, 1995; 
Singh et al, 1996 Reuter et al, 2000). Lovastatin has been shown to be selective 
inhibitor of HMG-CoA reductase and thereby depletes the availability of FPP resulting 
in decrease in p21/ras farnesylation and membrane localization (Sinensky et al, 1990). 
Khan et al (1995) have shown an interrelation in the p21/ras membrane localization 
and the expression and activation of protein kinase isozymes in the growth inhibition of 
DMBA-TPA induced mouse skin tumors by lovastatin. Similarly, limonene is reported 
to decreases the levels of antigenic ras in the human derived myeloid THP-1 and 
lymphoid RPMI-8402 cell lines (Hohl & Lewis, 1995). Limonene has also been shown 
to impair the FTase activity by interfering with the incorporation of mevalonic acid 
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derived products into ras proteins (Croweil et al, 1991). Perrilyl alcohol is even more 
potent inhibitor of FTase (Ren & Gould, 1995). Curcumin an active ingredient of 
turmeric has also been reported to significantly inhibit DMBA-TPA induced ras and fos 
gene expression in mouse skin (Limtrakul et al, 2001). Similarly, studies on the allium 
derivatives have shown that DADS an organosulfur compound from garlic inhibits the 
growth of H-ras oncogene transformed tumors implanted in nude mice (Singh e^  al, 
1996). The suppression of tumor growth by DADS was correlated with the inhibition of 
p21/ras membrane association through the depletion of FPP pool by inhibiting HMG-
CoA reductase activity rather than the inhibition of FTase activity (Singh et al, 1996; 
Singh, 2001). 
Thus, the modulatory effect of DAS on the expression of p21/ras in DMBA 
induced early genetic events suggest that DAS is a potent inhibitor of chemically 
induced cancers at the initiation stage of tumorigenesis. The inhibition of levels of 
p21/ras by DAS in mouse skin tumors demonstrates that it can also suppress the 
growth of tumors, which are associated with the activation of ras oncogene. DAS has 
been shown to suppress the development of DMBA induced mouse skin tumors in 
both complete as well as two stage model of skin carcinogenesis (Singh & Shukia, 
1998 a & b; Arora & Shukia, 2003b). However, further insight into the mechanisms that 
underlie activity of the allium derivatives to decrease ras levels will likely include 
detailed analysis of the effects of these compounds on the rates of synthesis and 
degradation of the ras proteins. Such studies will improve our understanding of the 
mechanisms that regulate ras expression and may suggest new approaches that can 
be used to pharmacologically manipulate ras levels in neoplastic cells. 
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Introduction 
The acquisition of resistance by tumor cells to multiple chemotherapeutic 
agents is a major obstacle in the treatment of several types of human malignancies 
and has been often associated with treatment failures (Gottesman, 1993; Pastan & 
Gottesman, 1993). This phenomenon has been termed ^multiple drug resistance' 
(MDR). This resistance is manifested by the over-expression of the MDR-1 gene 
product, P-glycoprotein (P-gp) (Roninson, 1992; Gottesman & Pastan, 1993). P-gp is a 
phosphorylated and glycosylated protein 1280 amino acids long, which intersects the 
plasma membrane and consists of two homologous halves, each contains six 
hydrophobic domains and a hydrophilic nucleotide binding fold (Fig. 38)(Germann, 
1996). These hydrophobic regions represent putative transmembrane domains forming 
a core like structure. 
The gene encoding P-gp belongs to the MDR multigene family (Germann et al, 
1993) and contains two highly homologous genes MDR1 and MDR2 situated in human 
chromosome 7q21.1 (Lincke et al, 1991). Each of these genes includes 28 exons and 
while varying in the length of introns, span on average about 100 kilobases. MDR1 is 
expressed in many types of normal tissue; MDR2 expression is primarily associated 
with the liver. The mouse MDR gene family is composed of three members, 
designated mdr1a, mdr1b and mdr2 (Gros et al, 1991). The mouse genes mdr1a (also 
referred to as mdr1) and mdr2a (also known as mdr3) are corresponding to the human 
MDR1 gene and are involved in drug resistance. The murine mdr2 gene has been 
shown to be involved in the secretion of phophatidylcholine into bile (Smit e^  al, 1993). 
MDR gene homologous have been highly conserved throughout the phylogenesis as 
evident by the presence of MDR like genes in marine sponges (Kurelec et al, 1992), 
plants (Dudler & Hertig, 1992), microorganisms (Henderson et al, 1992; Upcroft et al, 
1992) and in lower to higher vertebrates (Silverman et al, 1991; Deuchars et al, 1992). 
P-gp is naturally expressed in some normal tissues such as epical surfaces of 
the kidney, liver, gastro-intestinal tract, the endothelial cells of the brain and testis, 
adrenal gland, bone marrow stem cells and normal peripheral blood lymphocytes 
(Sugawara et al, 1988; Cordon-cardo et al, 1990; vander Valk et al, 1990). P-gp also 
has a major role in various biologically important protective barriers, such as the 
placental barrier (Smit et al, 1999), blood-testis, and blood-nerve barriers (Ambudkar 
et al, 1999). Thus, modulation of P-gp may be an important strategy in the absorption 
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and penetration of drugs, including anti-infective and cytotoxic agents, tlirough 
these barriers, winich nnay function as sanctuary sites for viral organisms and neoplasia 
(Tan et al, 2000). 
Functionally, this protein belongs to the superfamily of ATP-binding cassette 
transporters, causing cellular efflux of a variety of structurally and functionally diverse 
compounds across the plasma membrane, which also includes the MDR-associated 
protein (MRP or MRP1) (Gottesman & Pastan, 1993; Ambudkar et al. 1999; Kruh & 
Belinsky, 2003). Thus, the over-expression of P-gp in neoplastic cells causes decrease 
in the concentration of anticancer drugs, which in turn decreases their efficacy 
(Gottesman & Pastan, 1993; Ambudkar et al, 1999). P-gp confers resistance against a 
wide spectrum of compounds that are hydrophobic, amphipathic, natural product drugs 
(Table 14). These compounds include not only anticancer drugs, but also therapeutic 
agents such as HIV protease inhibitors (Kim et al, 1998; Lee et al, 1998). Anticancer 
compounds that are associated with P-gp mediated drug resistance include vinca 
alkaloids (i.e. vinblastine and vincristine), anthracyclins (i.e. doxorubicin), taxol, 
colchicine, actinomycin D and mitomycin C (Ambudkar et al, 1999). 
The expression of P-gp has been linked to the development of MDR in various 
hematologic and solid malignancies and the amount of P-gp is correlated with the 
degree of resistance particularly at low to moderate levels of resistance (Sugawara, 
1990). P-gp is expressed in acute leukemias (Zochbauer et al, 1994; Michieli et al, 
1999), breast cancer (Trock et al, 1997), ovarian cancer (vander Zee et al, 1995), head 
and neck tumors (Ng et al, 1998), both HIV and non HIV associated non Hodgkin 
lymphoma (Yuen & Sikic, 1994; Tulpule etal, 2002) and Kapsoi sarcoma (Nicholson et 
al, 1997). 
Because of the role of P-gp in clinical drug resistance, the strategies to inhibit 
the function or expression of this protein are of prime importance. A plethora of agents 
have been developed that modify, modulate or reverse the P-gp mediated MDR 
phenotype. Many natural and synthetic products of various structures, including 
calcium channel blockers (verapamil, nifedipine), calmodulin inhibitors 
(phenothiazines, trifuroperazine), indole alkaloids (reserpine), various steroids 
(progesterone, tamoxifen), immunosuppressive drugs (cyclosporine, rapamycin) and 
antibiotics (rifapicin, tetracyclins) have been shown to modulate P-gp mediated MDR 
(Ross et al, 1993; Watanabe et al, 1995; Malayeri et al, 1996; Sikic et al, 1997). In 
Table 15 some of the MDR reversing agents, which are classified based on their 
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Table 14: Major Substrates for P-glycoprotein involved in Drug 
Resistance 
Anticancer Drugs 
• Vinca Alkaloids (Vinblastine, Vincristine) 
• Anthracyclins (doxorubicin, daunorubicin, epirubicin) 
• Epipodophyllotoxins (etoposide, teniposide) 
• Paclitaxel (taxol) 
• Actinomycin D 
• Topotecan 
• Mithramycin 
• Mitomycin C 
Other Cytotoxic Agents 
• Colchicine 
• Emetine 
• Ethidium bromide 
• Puromycin 
Cyclic and linear peptides 
• Gramicidin D 
• Valinomycin 
• N-Acetyl-leucyl-leucyl-norleucine 
• Yeast a-factor pheromone 
HIV Protease Inhibitors 
• Ritonavir 
• Indinavir 
• Saquinavir 
Other Compounds 
• Hoechst 33342 
• Rhodamine 123 
• Calcein AM 
[Source: Bosch & Croop, 1996] 
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Table 15: Compounds Showing Potential to Reverse Multidrug 
Resistance 
Phenylalkylamines 
Dihydropyridines 
Phenothiazines 
Cyclosporins 
Quinolines 
Triphenylethylenes 
Steroids 
Pteridines 
Triazlnopiperidines 
Acridone 
carboxamides 
Pipecolinates 
Group 1 
Verapamil 
Nicardipine 
Nifedipine 
Trifluoroperazine 
Cyclosporin A 
Quinine 
Quinidine 
Tamoxifen 
Progesterone 
Dipyridamole 
Group 2 
Dexverapamil 
Ro-112933 
Dexniguldipine 
trans-Flupenthirol 
PSC-833 
Cinchonine 
MS-209 
Toremifene 
BIBW 22BS 
Group 3 
S-9788 
GF-120918 
VX-710 
Agents have been classified according to their chemical structures and 
separated into three groups: group 1 for the compounds of previous clinical 
use; group2 for their structural analogs; group 3 for original chemical families 
explored for MDR reversal. 
[Source: Robert, 1997] 
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chemical structures into three groups are listed. Group 1 or the first generation 
modulators includes compounds, which were earlier, used clinically as reversing 
agents; Group II or the second generation modulators consists of structural analogs of 
the first generation compounds whereas; Group III or the third generation compounds 
includes new chemical families of compounds being explored for MDR reversal. Apart 
from these, certain anti P-gp antibodies such as UIC2 (Mechetner & Roninson, 1992) 
and anti-sense oligodeoxynucleotides directed against mdr-1 gene expression (Thierry 
et al, 1993) have also been used as MDR reversing agents. Although the modulators 
identified to date are generally considered to interfere with P-gp by competitive or non-
competitive inhibition of its drug effluxing activity, the exact mechanisms may well 
differ from one drug to another. Some modulators interact with P-gp as single 
molecules, while others need to act in pairs to bring about effective reversal of MDR 
(Ayesh et al, 1996). Furthermore, some chemosensitizers are known to be protein 
kinase C inhibitors and can interfere with P-gp phosphorylation and activity (Hu & 
Robert, 1997). Some modulators have been'shown, to have effect on the intracellular 
distribution of drugs and may play a key role in determining the availability of drug 
inside the tumor cell (Schuurhuis et al, 1993; Bennis et al, 1995). Finally, certain 
modulators have also been shown to have an effect on MDR1 gene expression, which 
might represent another level for regulation of P-gp activity (Chaudhary & Roninson, 
1992; Mulleref a/, 1994; Hu etal, 1996b). 
Thus several classes of drugs are known to improve the responsiveness of 
MDR cells to chemotherapeutic drugs in vitro but unfortunately most of these 
compounds are not useful to tackle the problem of drug resistance at a clinically 
sustainable level due to various reasons. In some cases, there is lack of potency 
alternatively; the MDR reversing agents may expose the patient to unacceptable side 
effects or toxicity at doses required for effectiveness (Ford & Halt, 1990). One such 
compound, verapamil, a very well known MDR reversing agent has been hampered for 
clinical uses as it has severe cardiovascular effects, which occur at the doses required 
for its effectiveness (Salmon et al, 1991). Therefore, these limitations have spurred 
efforts to search for new compounds with low toxicity and high efficacy in modulation 
of MDR such as dexverapamil (Pirker et al, 1995) and cyclosporin derivatives (Ross ef 
al, 1993; Slate et al, 1995). The search of dietary agents for the reversal of MDR is the 
need of the hour as these agents as a modulator of MDR can enhance the antitumor 
activity and exhibit little or virtually no side effects. A number of naturally occurring and 
dietary agents have shown potential to modulate the P-gp expression (Christensen & 
LeBlanc, 1996; Sadzuka ef al, 2000; Zhu et al, 2001; Arora & Shukla, 2003a). Recently 
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tea components mainly polyphenols has shown promising results in reversing 
MDR both in carcinoma cell lines and tumor bearing animals (Sadzuka et al, 2000; Zhu 
et al, 2001). Earlier we have reported that ISC present in cruciferous vegetables has 
potential to reverse the vinca alkaloid induced in vivo P-gp expression without any 
toxic effects at the dose of 5mg/kg i.p (Arora & Shukia, 2003a). In the present study we 
evaluated the role of DAS on P-gp expression both in vitro and in vivo using 
appropriate models. DAS has sufficient evidences for its beneficial health effects 
including anti carcinogenic activity (Agarwal, 1996; Fukushima et al, 1997; Singh & 
Shukia, 1998 a & b; Arora & Shukia, 2003b), without any marked side effects or 
toxicity. But so far no report is available on in vitro or in vivo MDR modulatory activities 
of DAS. Therefore present set of study was conducted in both in vitro using K562 
leukemic cells and in vivo using mouse liver. The K562 cells line is being used in a 
number of studies to check the P-gp modulating potential of test compounds (Ishikawa 
et al, 2000; Shiraki et al, 2002; Labeed et al, 2003, Fernandes et al, 2003). 
MATERIAL AND METHODS 
Cell Culture: The human myelogenous leukemia K562 cell line (Lozzio & Lozzio, 
1975) was procured from National Center for Cell Sciences, Pune, India. Cells were 
grown as suspension in RPMI 1640 medium supplemented with 10% (v/v) heat 
inactivated fetal bovine serum, 1% antibiotic/ antimycotic solution containing 10,000 
units penicillin, 10 mg streptomycin and 25 lag amphotericin B and 2 x 10"^  M L-
glutamine (Gibco BRL, Gaithersburg, MD USA). Cells were incubated at 37°C, in 99% 
humidity and 5% CO2. Cells were passaged every other day, and routinely checked for 
contamination by mycoplasmas or fungi. 
Drugs: Diallyl sulfide (DAS) was purchased from Sigma Chemicals Co. (St. Louis 
MO). Vinblastine sulphate (cytoblastine) (VBL) and Vincristine sulphate (Cytocristine) 
(VCR) were purchased from Cipla Ltd, India. Verapamil (VPL), Doxorubicin (DXR), and 
other cytotoxic drugs were procured from Sigma Chemical Co. (USA). 
Drug Preparation: Stock solutions (100 x 10"^  M) of all drugs were prepared in 
dimethyl sulfoxide (DMSO) and stored as aliquots at -20°C. For cell treatments, drugs 
were further diluted in culture medium to the desired concentrations with the final 
DMSO concentration <0.5%. DAS was dissolved in minimum volumes of ethanol and 
the stock solution (200 x 10'^  M) was prepared in culture medium. 
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Drug Resistant Sublines: The VBL resistant cell line (K562/R10) to the cytotoxicity 
of VBL was established by the progressive adaptation of the parental cells (K562/S) to 
increasing concentrations of VBL (Fig. 39a-h). Briefly, K562/S cells were grown in the 
continuous presence of 0.5 x 10"^  M VBL (K562/R0.5). Cells first showed several 
morphological alterations like elongation, blebbing and condensed cytoplasm in the 
presence of drug but later on get adapted to the VBL. The cells were continued to 
grow in the presence of VBL until the population doubling time was similar to that of 
the control cultures. This procedure was repeated using 1 to 5 fold increments in VBL 
concentration over a span of one year until, cells tolerated the continuous presence of 
10 X 10'® M VBL. Cells were sub cultured at this concentration for more than 100 
population doublings. Cells that were adapted to growth at 0.5, 2.5, 5.0, 7.5 and 10 x 
10"^  M VBL during this process were sub cultured separately for atleast 100 passages, 
after which any VBL induced growth inhibition had disappeared. The sublines selected 
in this way were termed K562/R0.5, K562/R2.5, K562/R5.0, K562/R7.5, K562 /RIO, 
indicating the VBL concentration (10"^ M) at which they were able to grow without a 
detectable inhibition. The K562/R10 subline (Fig. 39h) was used further in the study 
and the MDR phenotype was maintained by continuously growing the cells in the 
presence of 10 x 10"^  M VBL. Cells were grown in VBL free medium for one week, 
before using for further experiments. 
IVITT Assay: The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay was based on the assessment of mitochondrial activity due to the conversion of 
the yellow tetrazolium salt MTT by mitochondrial dehydrogenase of live cells to the 
purple MTT formazon (Mosmann, 1983). For MTT assay, K562/S and K562/R10 (1x 
10^ cells/well) were plated in a 96 well plates, coated with poly-L-lysine and exposed to 
test compounds as detailed in respective experiments for 24, 48 and 72 hrs. Then, 
MTT (10 1^1 of 5mg/ml stock in PBS) was added to each well of the microtitre plate, and 
plates were incubated for an additional 4 hrs in dark at 37°C. The medium was then 
aspirated from the wells and the blue formazon product was dissolved in 100 |il of 
DMSO. The plates were allowed to stand for 10 min at room temperature and read at 
570 nm using a spectrophotometric plate reader (Bio-Rad, Tokyo, Japan). Each data 
point was replicated in triplicate. ICsoS and inhibition curves connecting the data points 
were obtained using the nonlinear regression program Graph Pad Prism 3.03. 
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Figure 39: Photomicrographs showing morphology and adaptive response during the 
selection procedure of K562 parental cells to resistant phenotype following 
treatment with VBL a) K562/S cells; b) K562/S cells in the presence of 5x10'^M 
VBL for 24 hrs; c) K562/S cells in the presence of 5x10"^M VBL for 48 hrs; d) 
K562/S cells in the presence of 5x10"^M VBL for 72 hrs; e) K562/S cells in the 
presence of 10x10"^M VBL for 24 hrs; f) K562/S cells in the presence of 10x10'^M 
VBL for 48 hrs; g) K562/S cells in the presence of 10x10"^M VBL for 72 hrs; h) 
K562/R10 drug resistant cells 
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Pattern of Cross Resistance: The sensitivities of the parental line K562/S 
and the resistant variant K562/R10 to a variety of drugs with disparate mechanisms of 
cytotoxic action was investigated using IVITT assay. K562/S and K562/R10 (1x 10 )^ 
were plated to 96 well microtitre plates with varying concentrations of the test drugs for 
72 hrs. The IC50 was determined by plotting the logarithm of the drug concentrations 
against the number of dead cells using Graph Pad Prism 3.03 software. SD was 
usually within 10% of the mean fold. Fold resistance was determined by dividing the 
IC50 for the resistant line K562/R10 by the IC50 for the sensitive K562/S cells. 
Sensitization of Resistant Cells to Anticancer Drug Toxicity by DAS: To 
determine, whether DAS can sensitize MDR cells towards the cytotoxicity of VBL or 
VCR, both susceptible (K562/S) and resistant {K562/R) cells were plated to 96 well 
microtitre plates (1x 10^ cells/100 \i\ of culture medium). After 24 hrs of plating, cells 
were incubated with varying concentrations of DAS (0.1-87.5 x 10'^ M) for 24, 48 and 
72 hrs. The viability of the cells was assessed by the MTT assay (Mosmann, 1983). 
Cellular accumulation of DXR: To estimate DXR accumulation inside the cells, 
1x10® cells/ml were resuspended in culture tubes in the presence or absence of 
different concentrations of DAS (0.1-87.5 x 10"^  M). DXR (5x10"®M) was added in the 
each tube, gently mixed, and incubated at 37°C for 45 min and intracellular 
accumulation of DXR was analyzed by flow cytometry (BD-LSR, Becton-Dickinson, 
USA). A total of 10,000 cells were counted and mean fluorescence were recorded 
(Cell Quest 2.0) from the histogram and data are expressed in the text as mean 
fluorescence channel numbers. 
Cell Count and preparation of cell extracts for Immunoblotting: About 5 x 
10^ cells/ml were grown in T25 cm^ flasks (Tarson, India) as suspensions with and 
without addition of DAS (8.75 x 10"^  M) and harvested after 24, 48 & 72 hrs of 
exposure. Viable cells were counted by trypan blue exclusion assay (Thompson et al, 
1991). The cells were centrifuged at 1000 rpm for 10 min, washed once in PBS and 
then resuspended in prewarmed sample buffer [Tris-HCI 0.5M, pH 6.8 containing 10% 
(w/v) SDS, 10% (v/v) Glycerol, 5% (v/v) p-mercaptoethanol and 0.1% (w/v) 
bromophenol blue]. Cells were boiled in sample buffer for 10 min, cooled, sonicated 
using a Vibracell ultrasonicator (Sonics & Materials Inc, USA) on ice and stored at -
80°C until used for experimentation. 
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Modulation of P-gp mediated multidrug resistance in vivo: To determine 
the efficacies of DAS to modulate the P-gp mediated drug resistance, a short-term 
animal bioassay was performed. Male, Swiss albino mice {Mus musculus L) of 25+2 
gms were taken for the study from the ITRC animal breeding colony and were 
maintained as described in Material & Methods, Chapter 1 of this dissertation. The 
animals were divided into nine groups consisting of six animals each and the 
treatments were given as summarized in Table 16. The mouse liver was sensitized 
with VBL (2 mg/kg b.wt.) or VCR (1 mg/kg b. wt.) for three consecutive days (days 1-3) 
i.p in 0.9% saline. DAS (5mg/kg b.wt.) was given orally by gastric intubation on day 3 
one hour after the drug treatment. In order to check the efficacy level of DAS, VPL, a 
known MDR modulator was also included in the study at a dose of 10mg/kg b.wt. as 
per schedule of DAS. All the animals were sacrificed by cervical dislocation on day 4 
i.e. 24 hrs after drug treatment. Liver specimens were excised out, rinsed with 
prechilled PBS, immediately frozen in liquid nitrogen and stored at -80°C until use for 
further experiments. 
Immunoblotting: Immunoblots were carried out in plasma membrane enriched 
fractions from liver specimens as well as whole cell lysates of K562/S and K562/R 
cells as described in Material and Methods, Chapter 2. The P-gp expression was 
detected with anti P-gp monoclonal antibody (0.5 i^g/ml) clone JSB1 (Boehringer 
Mannheim, Germany). 
Protein Estimation: Protein concentration was estimated by the routine method of 
Lowry et al (1951) as described in Material and Methods, Chapter 2. 
Immunocytochemical/ Immunohistochemical Staining: For immunocyto-
chemistry, cell smears of K562/S and K562/R cells (1x 10 /^ml) were prepared using 
Autosmear (CF120, Sakura, Japan) at 1000 rpm for 10 min. Whereas, for 
immunohistochemistry cryostat sections (10 pm thick) of frozen liver tissues were cut 
fixed in 4% formal saline and stained with anti-P-gp antibody (2.5^g/ml) as described 
Material and Methods, Chapter 2. 
Image Analysis: The immunostained slides for P-gp were analysed under 
microscope (Leica) attached with CCD camera (JVC). The quantitative stereology was 
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Table16: Treatment Schedule for Evaluation of in vivo P-gp 
Modulatory Activity of DAS. 
Groups 
Gr. 1 (Untreated) 
Gr. II (DAS) 
Gr. Ill (VPL) 
Gr. IV (VBL) 
Gr. V (VBL+DAS) 
Gr. VI (VBL+VPL) 
Gr. VII. (VCR) 
Gr. VIII (VCR+DAS) 
Gr. IX (VCR+VPL) 
Treatment 
No Treatment 
DAS was given orally at a dose of 5 mg/kg.b.wt in 0.9% saline 
on day 3. 
VPL was given at a dose of 10 mg/kg.b.wt in 0.9% saline by 
i.p. administration on day 3. 
VBL at a dose of 2mg/kg.b.wt by i.p. administration for three 
consecutive days in 0.9% saline. 
VBL at a dose of 2mg/kg.b.wt by i.p. administration for three 
consecutive days. DAS was given orally at a dose of 5 
mg/kg.b.wt in 0.9% saline one hour after the last dose of VBL 
VBL as in given in Gr. V, VPL was given at a dose of 
10mg/kg.b.wt by i.p administration in 0.9% saline one hour 
after the last dose of VBL. 
VCR at a dose of 1 mg/kg.b.wt by i.p. administration for three 
consecutive days in 0.9% saline. 
VCR as in Gr VII. DAS was given orally at a dose of 5 
mg/Kg.b.wt by in 0.9% saline one hour after the last dose of 
VCR. 
VCR at a dose of 1 mg/kg.b.wt by i.p. administration for three 
consecutive days. VPL was given at a dose of 10 mg/kg.b.wt 
by i.p. administration in 0.9% saline one hour after the last 
dose of VCR. 
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performed with Leica QWin 500 Image analysis software for each slide in 
triplicates with at least six microscopic fields and P<0.05 was considered significant. 
RESULTS 
in the present study, the MDR reversing potential of DAS was evaluated in vitro 
using K562 human leukemic cells and in vivo using short-term assay in mouse liver. 
Results demonstrates that DAS is capable of modulating the expression levels of P-gp 
significantly in both in vitro and in vivo experiments as summarized below: 
In Vitro 
Resistance Characteristics of K562/R10 Cells: The progressive adaptations of 
parental K562 cells exposed to the increasing concentrations of VBL leads to the 
development of resistant characteristics in the parental cell line (K562/R10). The 
resistant characteristics of these cells were checked by MTT assay. The results 
showed that exposure of K562/S cells to 10 x 10'®M VBL resulted in 75% cell death at 
72 hrs. of exposure. The viability of resistant K562 variants (K562/R2.5, K562yR5, 
K562/R7.5 and K562/R10) was significantly high at the same concentration of VBL 
(Fig. 40 & 41). K562/R 7.5 and K562/R10 sublines showed 91-96% survival rate in the 
presence of 10 x 10'^ M VBL at 72 hrs stage (Fig. 40). A significant correlation was 
observed between the cells survival rate and the degree of resistance in various 
resistant strains towards the cytotoxicity of 10 x 10"® M VBL (Fig. 40). The correlation 
coefficient was found to be r>0.9 (p<=0.001) as calculated by linear regression 
analysis. The increasing exposure of the variants in the presence of VBL (i.e. 24, 48 
and 72 hrs.) doesn't show any significant change in the viability pattern of the cells. 
These observations confirm that the resistant variant (K562/R10) of parental K562 
cells become resistant towards the cytotoxicity of VBL. 
The data for determining the VBL sensitivity of the parent K562 cells and the 
VBL resistant K562/R10 is shown in Table 17. The IC50 for the parental cells is 0.07 x 
10"® M and for K562/R10 cells is 14.86 x 10"® M. The ratio of these values is defined as 
the relative resistance, i.e. the ratio of IC50 of resistant subline to IC50 of parent line and 
is therefore, 212.3 for K562/R10 (Table 17). 
Since the amount of P-gp is correlated with the degree of resistance 
particularly at low to moderate levels of resistance (Sugawara, 1990), the levels of P-
gp among these variants was also characterized with western blots using anti-P-gp 
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Table 17: Cross Resistance Pattern of K562 Sensitive and Resistant 
Leukemic Cells towards Anticancer Drugs. 
Drug 
Bleomycin 
Cisplatin 
Doxorubicin 
Methotrexate 
Vinblastine 
Vincristine 
IC5o(10-*IVI) 
K562/S 
(Sensitive) 
3.25 
0.014 
0.042 
0.03 
0.07 
0.12 
K562/R10 
(Resistant) 
9.10 
0.032 
3.86 
0.046 
14.86 
17.27 
Relative 
Resistance* 
2.8 
2.3 
92 
1.5 
212 
144 
The cross resistance of K562/R10 to a variety of drugs with widely disparate 
mechanisms of cytotoxic action was investigated. Cells were grown in 
suspension culture in the continuous presence of a drug for 72 hrs. The IC50 
was determined by plotting the logarithm of the drug concentrations against the 
number of dead cells. SD was usually within 10% of the mean fold. 
*Relative resistance was calculated by dividing the IC50 values for the resistant 
line K562/R10 by the IC50 values for the sensitive K562/S cells. 
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Figure 41; Showing over-expression of P-gp in resistant (K562/R10) cells over parental 
sensitive (K562/S) cells. 
I] Immunoblot analysis using anti P-gp monoclonal antibody (clone JSB1); lane 
a: K562/R10, b: K562/R5 , c: K562/R2.5, d: K562/S 
II] Intensity plot for the immunoblot using EasyWin 32 software, Herolab, Gmbh, 
Germany. 
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monoclonal antibody clone JSB-1. K562/R10 cells were found to over-express P-
gp in comparison to parental sensitive cells (Fig. 41). The densitometry analysis of the 
blot with the EasyWin 32 software, (Herolab, Gmbh Germany) showed that the 
intensities of the band were 2178, 1340, 623 and 553 pixels in K562/R10, K562/R5, 
K562/R2.5 and K562/S cells respectively (Fig. 41). 
Pattern of cross-resistance: The sensitivities of the parental line K562/S and the 
resistant variant K562/R10 to a 72 hr pulse of other cytotoxic agents were determined 
by MTT assay and the results are summarized in Table 17. K562/R10 was found to be 
more than 200-fold resistant to VBL than K562 and highly cross-resistant to VCR (144-
fold), DXR (92-fold) than K562/S cells. But only slightly resistant to bleomycin (2.8-
fold), cisplatin (2.3-fold) and methotrexate (1.53-fold). The K562/R10 cells showed a 
high degree of resistant to VBL, the selective agent, and also cross-resistant to VCR, 
DXR. 
Sensitization of Resistant cells by DAS: The ability of DAS to sensitize resistant 
K562/R10 cells towards the cytotoxicity of VBL was observed. DAS was assessed at 
increasing concentrations for its ability to sensitize K562/R10 cells to the cytotoxicity of 
VBL (Fig. 42). The results revealed that DAS inhibited the growth of the resistant cells 
to a significant extent over the parental cell line. The results showed that DAS 
sensitized K562/R10 to the cytotoxicity of VBL with 50% sensitization at 72 h of 
exposure of 8.75 x 10'^ M concentration that had no effect on the viability of K562/R10 
and K562/S cells (Fig. 43). At concentration higher than 8.75 x 10"^  M, DAS becomes 
cytotoxic to both resistant and sensitive K562 cells after 48 hrs or 72 hrs. However, at 
24 hrs of exposure, 22% sensitization of K562/R10 cells was observed with 43.78 x 10' 
^M DAS (Fig. 43). In case of parental K562/S cells, 50% sensitization was observed at 
56.8 x 10'^  M DAS. Therefore, the fold reversal caused by DAS in K562/R10 cells was 
found to be 6.5 fold. 
Furthermore, to clarify that this differential growth inhibitory activity of DAS on 
resistant and parental cells was due to the modulation of P-gp expression, a specific 
monoclonal antibody, JSB-1, which recognizes an internal epitope of P-gp was used 
for western blotting and immunocytochemistry. Western blot analysis showed that the 
parental K562/S line expresses low, but detectable amounts of P-gp whereas resistant 
K562/R10 cells over-express P-gp (Fig. 44, lanes e & f). DAS (8.75 x 10"^  M) exposure 
to K562/R10 cells resulted in time dependent reduction in P-gp levels, maximum being 
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Figure 42: Microtitre plates showing sensitization of resistant cells with DAS. 
K562/S and K562/R10 cells (1x10^ cells/well) were plated and 
incubated with increasing concentrations of DAS (0.1-87.6 x 10"^  
M) for a) 24 hrs, b) 48 hrs and c) 72hrs. 
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Figure 44: Showing P-gp modulation in K562/R10 cells by DAS. 
I] Immunoblot analysis using anti P-gp monoclonal antibody (clone JSB1); Lane a: 
K562/S cells exposed to DAS for 72 hrs, b: K562/R10 cells exposed to DAS for 
72 hrs, c: K562/R10 cells exposed to DAS for 48 hrs, d: K562/R10 cells exposed 
to DAS for 24 hrs, e: K562/R10, f: K562/S. 
II] Intensity plot for the immunoblot using EasyWin 32 software, Herolab, Gmbh, 
Germany 
MDR Reversing Potential of DAS 
observed at 72 hrs. (Fig. 44, lanes b-d). However, no effect of DAS on P-gp 
expression was observed on parental K562/S cells even upto 72 hrs of exposure (Fig. 
44, lane a). The Quantitation of the bands was done by densitonnetry. The intensities 
of the bands were found to be 1988 pixels in K562/R10 cells which decreased upto 
1365, 963, 532 pixels following DAS exposure for 24, 48 and 72 hrs respectively. In 
parental sensitive cells the intensities of the bands were almost the same with and 
without DAS exposure (468 & 433 pixels respectively). The immunocytochemical 
staining of K562/S and K562/R10 cells further confirms these observations obtained by 
image analysis. K562/S cells showed 0.64% area positive for P-gp whereas in 
K562/R10 cells 6.75% area was positive for P-gp expression as quantitated using 
Leica Qwin software. The inhibition of P-gp expression in DAS exposed cells was 
found to be 23, 54 & 79% for 24, 48 & 72 hrs respectively (Fig. 45, Table 18). DAS had 
no effect on P-gp expression in parental K562/S cells. 
Effect of DAS on DXR uptake: To explore the effect of DAS on intracellular 
accumulation of DXR, both K562/R10 and K562/S cells were incubated with DXR in 
the presence or absence of various concentrations of DAS. DXR effectively 
accumulated in K562/S cells at 37°C (Fig 46c) and DAS at 8.75x10'^ M did not affect 
this accumulation (Fig. 46d). In K562/R10 cells, the accumulation of DXR was 
extremely reduced (Fig. 46a) as compared to K562/S sensitive cells at 37°C (Fig. 47). 
DAS in a dose dependent manner restored the DXR accumulation in K562/R10 cells to 
a level comparable to that of K562/S cells (Fig. 46b, Fig. 47). Thus, DAS at 8.75 x 10"^  
M enhanced the accumulation of DXR in K562/R10 cells to an extent almost 
comparable with that observed in parental K562 cells incubated without DAS. 
In Vivo 
During the entire course of the experimentation, no overt signs of toxicity were 
observed in both control and treated mice. The results of the western blot and 
immunohistochemical studies confirm over-expression of P-gp and its reversal by DAS 
administration in the rodent liver without any adverse effects. 
Modulation of P-gp by DAS in-vivo: The results of Western blot showed a 
detectable amount of P-gp in normal mouse liver (Fig. 48, lane f). In the animals of Gr. 
IV, sensitization of liver cells with VBL for three consecutive days resulted in over-
expression of P-gp (Fig. 48, lane d), which was down regulated by the administration 
of DAS to near normal levels (Gr. V) (Fig. 48, lane b). Similarly, in the group where 
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Table 18: Effect of DAS on P-glycoprotein Expression in K562 
Multidrug Resistant Cell Line by Image Analysis. 
Treatment 
K562/S 
K562/R10 
K562/R10+DAS(24) 
K562/R10+DAS(48) 
K562/R10+DAS(72) 
K562/S +DAS (72) 
Area (%) 
0.64 
6.75 
5.47 
2.83 
1.04 
0.84 
Area (mm^) 
(Mean + SE) 
4.21+0.54 
24.25+3.16" 
18.65+2.25" 
11.16+1.68 *^* 
5.08+0.84*^  
4.54+0.63 
% Inhibition 
-
-
23 
54* 
79* 
-
* % Inhibition was calculated over K62/R10 
''Values are significantly different (P<0.01) over K562/S when analyzed by one-
way ANOVA. 
"^  Values are significantly different (P < 0. 01) over K562/R10 when analyzed by 
one -way ANOVA. 
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Figure 45: Photomicrographs showing immunostaining of P-gp in K562/S and K562/R10 
cells followed by DAS exposure (128X). a: K562/S cells, b: K562/R10 cells c: 
K562/R10 cells exposed to DAS for 24 hrs, d: K562/R10 cells exposed to 
DAS for 48 hrs, e: K562/R10 cells exposed to DAS for 72 hrs, f: K562/S cells 
exposed to DAS for 72 hrs 
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Figure 46: Effect of DAS on Doxorubicin uptake in K562/S and K562/R10 cells, 
a: K562/R10 cells in presence of doxorubicin, b: K562/R10 cells in 
presence of doxorubicin and DAS, c: K562/S cells in presence of 
doxorubicin, d: K562/S cells in presence of doxorubicin and DAS 
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Figure 48: Showing in vivo reversal of VBL induced P-gp over-expression by DAS 
I] Immunoblot analysis using anti P-gp monoclonal antibody (clone JSB1); 
Lane a: VBL+VPL, b: VBL+DAS, c: VPL, d: VBL, e: DAS, f: Untreated. 
II] Intensity plot for the immunoblot using EasyWin 32 software, Herolab, 
Gmbh, Germany. 
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animals were given VPL (Gr. VI), a well-known MDR reversing agent, the VBL 
induced levels of P-gp were found to be comparable to that of normal levels (Fig. 48, 
lane a). The densitometry of these blots revealed that the intensities of the bands were 
520, 534, 752 pixels in Gr. I, II and III respectively. In VBL treated group the band 
intensity was maximum i.e. 2064 pixels which reduced to 862 and 1068 pixels with the 
treatment of DAS and VPL respectively (Fig. 48). Similarly, VCR induced levels of P-
gp were found to reduced to normal levels with the administration of DAS and VPL 
(Fig. 49, lanes b, d-f). Exposure of either DAS or VPL alone had no effect on the P-gp 
expression (Fig. 48, lanes c & e; Fig. 49, lanes a & c). The intensities of the bands 
were found to be 426, 685, 870 pixels in Grs. I, II and III respectively. Whereas, in 
VCR treated animals (Gr. VII) the band intensity was 1960 pixels, which was, recorded 
715 and 736 pixels in Gr. VIII (VCR+DAS) and Gr. IX (VCR+VPL) respectively. 
Immunohistochemistry: Analyses of innmunostained cryostat liver sections 
using Leica QWin Image analysis system showed elevated levels of P-gp 
following vinca-alkaloid exposure which was reversed up to the normal levels 
with DAS (Fig. 50, a-f). A total of 53.19 +3.2 mm^ and 47.95+ 4.3 mm^ area 
was shown to be positive for P-gp with VBL (Gr. IV) and VCR (Gr. VII) 
treatment respectively in comparison to that of controls (9.43+0.7 mm^) per 
measured frame of 202.5 mm^ (Table 19). Co-administration of VPL inhibited 
the expression of P-gp from 26% area to 8% area in case of VBL and from 24% 
to 9% in the case of VCR (Table 19). Similarly, DAS exposure resulted in the 
decrease of vinca alkaloid induced P-gp levels upto 7-9%, which were 
comparable to that of control (Table 19). Therefore, about 65-73% inhibition of 
vinca alkaloid induced P-gp expression was shown by DAS in comparison to 
65-70% inhibition by VPL (Table 19). 
DISCUSSION 
Cross-resistance to multiple classes of chemotherapeutic agents is a major 
problem in the treatment of several types of human cancers (Gottesman, 1993; Pastan 
& Gottesman, 1993). A major mechanism of this resistance is the enhanced efflux of a 
wide variety of structurally distinct classes of chemotherapeutic agents due to the over 
expression of P-gp (Roninson, 1992). Resistance to vinca alkaloids has been mainly 
associated with P-gp mediated MDR, while several VBL or VCR selected mammalian 
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Table 19: Effect of DAS on P-glycoprotein Expression in IVIouse Liver 
by Image Analysis. 
Groups 
Gr. 1 
Gr. II 
Gr. Ill 
Gr. IV 
Gr. V 
Gr. VI 
Gr. VII 
Gr. VIII 
Gr. IX 
Treatment 
Control 
DAS 
VPL 
VBL 
VBL+ DAS 
VBL+VPL 
VCR 
VCR+ DAS 
VCR+VPL 
Area (%) 
6 
7 
8 
26 
7 
8 
24 
9 
9 
Area (mm') 
(Mean + SE) 
9.43+0.7 
17.16+1.4 
13.41+1.0 
53.19+3.2* 
14.39+0.7^ 
15.26+0.9*^  
47.95+4.3" 
17.88+0.8^^ 
17.33+1.3*^ ^ 
% Inhibition 
-
73* 
71* 
-
65** 
64** 
* % Inhibition was calculated over group IV 
** % Inhibition was calculated over group VII 
"Values are significantly different (P<0.01) over group I when analyzed by one-
way ANOVA. 
•^  Values are significantly different (P < 0. 01) over group IV when analyzed by 
one -way ANOVA. 
Values are significantly different (P < 0. 01) over group VII when analyzed by 
one-way ANOVA 
0 0 
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Figure 49: Showing the in vivo reversal of VCR induced P-gp over-expression by DAS. 
I] Immunoblot analysis using anti P-gp monoclonal antibody (clone JSB1); 
Lane a: VPL, b: VCR+VPL, c: DAS, d; VCR+DAS, e: VCR, f: Untreated. 
II] Intensity plot for the immunoblot using EasyWin 32 software, Herolab, 
Gmbh,Germany. 
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Figure 50: Photomicrographs showing immunoreactivity of P-gp in mouse liver in 
different groups (128X). a: Untreated, b: DAS, c: VBL, d: VBL+DAS, e: VCR, 
f: VCR+DAS. 
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cell lines have displayed lower accumulation of these agents related to P-gp 
or mdr gene over-expression (Tsuruo et al, 1986; Gottesman & Pastan, 1993; 
Ambudkar et al, 1999). Several MDR reversing agents were identified and several 
others are in various stages of clinical development. (Ford & Halt, 1990; Robert, 1997; 
Tan et al, 2000). First generation modulators of MDR such as VPL, quinidine and 
cyclosporin required high doses of drugs to effectively reverse MDR and were 
associated with unaccepatable toxicities (Ozols et al, 1987; Yahanda et al, 1992; Tan 
et al, 2000). Second and third generation inhibitors which either originate from 
chemical series already known to display a chemosensitizing activity or from original 
series, include PSC 833, GF 120918, VX 710 and LY 335979 among others. 
Limitations to the use of these modulators include multiple and redundant cellular 
mechanisms of resistance, alterations in pharmacokinetics of cytotoxic agents, and 
clinical toxicities (Tan et al, 2000). Thus, much of the current research efforts are 
focused on the identification of novel MDR reversing agents of natural or dietary origin 
with little or no toxicity. 
In the present set of investigations, we reported the reversing effects of DAS on 
vinca alkaloid induced P-gp mediated MDR. DAS is a well-known antimutagenic and 
anticarcinogenic agent of dietary origin. Several compounds of dietary origin such as 
I3C from cruciferous vegetables (Christensen & LeBlanc, 1996; Arora & Shukia, 
2003b), tea polyphenols (Sadzuka et al, 2000; Zhu et al, 2001) have already been 
shown from our laboratory and elsewhere to be effective in modulating P-gp mediated 
MDR in both in vitro and in vivo assays. The 13C acid condensation product mixture, 
sensitized B16 melanoma cells that were transfected with the human MDR-1 gene 
(B16/hMDR-1) to the toxicity of VBL and DXR. The ability of I3C administered p.o. to 
reverse MDR was also observed in nude mice in terms of reduction in tumor mass 
(Christensen & LeBlanc, 1996). Similarly I3C was found to modulate the vinca alkaloid 
induced P-gp expression in mouse hepatocytes without eliciting direct toxicity to the 
host (Arora & Shukia, 2003b). Zhu et al (2001) studied tea polyphenols as MDR 
reversal agent for MCF-7 cell line to the cytotoxicity of adriamycin. Similarly, tea 
components such as caffeine, theanine, EGCG and flavonoids may enhance 
doxorubicin induced antitumor activity and increase its concentration in tumors through 
the inhibition of doxorubicin efflux in P388 leukemia cell bearing mice (Sadzuka e^ al, 
2000). These studies suggest that dietary constituents show P-gp modulatory effects 
without any toxicity to the host as observed in the present study with DAS. 
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The present in vitro and in vivo studies clearly demonstrate that DAS is a 
novel, selective and highly potent modulator of P-gp mediated MDR. The in vitro P-gp 
modulating potency is evident by the potentiation of cytotoxic drug activity using MTT 
assay. In the cytotoxicity assay, full reversal of resistance in VBL resistant human 
leukemia K562 cell line was achieved in the presence of DAS in time dependent 
manner (Fig. 43). A clear difference in drug accumulation in resistant cells (K562/R10) 
was observed following sensitization with DAS (Fig. 46, a & b). These observations 
further confirm our findings that dietary constituents such as DAS can sensitize the 
drug resistant cells. In contrast to the modulatory activity in the resistant cell line, DAS 
had no effect on cytotoxic drug activity in non P-gp expressing parental cell lines 
(K562/S). Furthermore, the over-expression of P-gp in K562R/10 cells was effectively 
inhibited by DAS as evident from immunoblotting assays (Fig. 44). Quantitation of 
immunocytochemically stained K562 cells showed that this inhibition in P-gp levels 
was time dependent (Fig. 45, Table 18). Therefore, our results show for the first time 
that DAS possess inhibitory activity on the growth of K562/R10 human leukemic cells 
and not in the parental K562/S cell line, which does not over-express P-gp. The 
promising activity of DAS demonstrated in vitro was confirmed in in vivo efficacy 
studies. Sensitization of mouse liver with VBL or VCR for three consecutive days 
resulted in enhanced expression of P-gp, which was found to reverse to near normal 
levels with DAS administration (Fig. 48 & 49). This reversal was up to the extent of 
73% for VBL and 65% for VCR induced MDR (Fig. 50, Table 19). 
The mechanism of action of P-gp reversing potential of DAS appears to be 
mediated through the inhibition of P-gp. K562A/LB and K562/DXR cells are known to 
over-express P-gp, but K562/S cells do not (Ishigawa e^ a/, 2000). These results 
suggest that the ability of DAS to increase the accumulation of DXR in K562/R10 cells, 
supports the conclusion that DAS acts by interfering with a process of associated with 
the expression of P-gp. Besides, Most of the MDR reversing compounds share some 
common physical characteristics such as cyclicity, lipophilicity and a positive or neutral 
charge at physiological pH (Zamora et al, 1988). The MDR reversing properties of 
DAS may also be attributed to its lipophilic nature and electrophilic sulfur atom. 
Furthermore, DAS undergoes extensive oxidation at various positions (the sulfur atom, 
the allyllic carbon and the terminal double bonds) in the molecule. Enzyme mediated 
oxidation at the sulfur atom of DAS produces diallyl sulfoxide (DASO) and diallyl 
sulfone (DASO2) (Brady et al, 1991). These metabolites are further converted to 
epoxide intermediates (Jin & Baillie, 1997) thought to be responsible for the biological 
effects of DAS. 
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Thus, from the present study, we can conclude that remarkably low levels of 
toxicity of DAS coupled with Its MDR reversing capability may contribute to the known 
anticarcinogenlc properties of this compound. An advantage of using newly identified 
dietary agents, as a modulator of MDR is that they enhance antitumor activity and 
exhibit little or no virtually no side effects without any further increase in the medication 
burden on the patient. The use of natural agents mainly of dietary origin such as DAS 
early in the disease process may retard or prevent the appearance of resistant 
neoplastic clones. Therefore, identification of newer agents with acceptable, little or no 
drug-drug interactions with chemotherapy is the need of the hour as observed in the 
present study with DAS. 
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Molecular Mechanism of Tumor Suppression Carcinogenesis 
General Conclusion of the Study 
The salient features of the present dissertation reveals that diallyl sulfide 
(DAS), a organosuifide fronn garlic, as a potential cancer chemopreventive agent as 
well as to meet out the challenge of one of the most perplexing problem in cancer 
chemotherapy i.e. multiple drug resistance. DAS supplementation retarded the growth; 
onset, multiplicity and malignancy of DMBA induced mouse skin tumors. DAS was 
found capable of inducing apoptosis in the skin tumors, thus suggesting induction of 
apoptosis as one of the key mechanism of its chemopreventive efficacy. DAS was also 
found to modulate the cell cycle regulatory genes viz. tumor suppressor p53 and 
p21/waf1 thus checking the growth of neoplastic cells. DAS was found to shift the 
balance between the wild type and mutant p53 towards tumor suppressor function of 
p53. The induction of wild type p53 by DAS caused the transcriptional activation of 
p21/waf1, which may lead to the pathway to apoptosis. Thus it could be suggested that 
the anticancer mechanism of DAS involves induction of p53 dependent apoptosis in 
tumor cells mediated through p21/waf1 induction. Since chemoprevention aims to kill 
or eliminate cancerous cells at an early stage, the ability of DAS to modulate the levels 
of p21/ras as early as after the 24hrs of single application of initiating dose of DMBA 
indicates its chemopreventive potential at early stages of tumor development. 
Moreover, the modulatory effect of DAS on p21/ras in DMBA induced skin tumors 
suggest that DAS can suppress the growth of tumors harboring ras mutations. The 
DAS administration was also able to reverse the MDR in drug resistant human K562 
leukemic cells and in mouse liver, further contributing to its beneficial health effects. 
The study thus demonstrates a causal link between nutrition and improved 
cancer chemotherapy suggesting that DAS can act as a nontoxic anticancer agent of 
dietary origin. Furthermore, its ability to modulate MDR would find its usefulness in the 
improvement of the conventional chemotherapy by cytotoxic drugs. The 
characterization of the chemopreventive activity of food constituents and related 
compounds along with their mechanism of action will ultimately help formulate dietary 
advice for the general population and/or prophylactic drug strategies for individuals at 
particular risk of developing cancer. Such research has the potential to improve, in a 
fundamental way in reducing the global cancer burden. 
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